Crohn's, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, Crohn's

Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E. Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 22: 655-664 (1987).
Aamodt G, Bukholm G, Jahnsen J, Moum B, Vatn MH; the IBSEN Study Group. The association between water supply and inflammatory bowel disease based on a 1990-1993 cohort study in Southeastern Norway. Am. J. Epidemiol. 168: 1065-1072 (2008). *
Aamodt G, Jahnsen J, Bengtson MB, Moum B, Vatn MH; the IBSEN Study Group. Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993. Inflamm. Bowel Dis. 14: 984-991 (2008).
Aase S, Koppang HS, Solheim T, Kjaerheim A, Axell T, Storhaug K, Refsum S. Crohn disease of the oral cavity, illustrated by some cases. Tidsskr. Nor. Laegeforen. 121: 2489-2491 (2001).
Abad C, Gomariz RP, Waschek JA. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr. Top. Med. Chem. 6: 151-163 (2006).
Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, Garcia-Gomez M, Leceta J, Gomariz RP. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm. Bowel Dis. 11: 674-684 (2005). *
Abad E, Tural C, Mirapeix E, Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J. Autoimmun. 10: 175-180 (1997). *
Abadia-Molina AC, Ji H, Faubion WA, Julien A, Latchman Y, Yagita H, Sharpe A, Bhan AK, Terhorst C. CD48 controls T cell and antigen-presenting cell functions in experimental colitis. Gastroenterology 130: 424-434 (2006). *
Abakar-Mahamat A, Filippi J, Pradier C, Dozol A, Hebuterne X. Incidence of inflammatory bowel disease in Corsica from 2002 to 2003. Gastroenterol. Clin. Biol. 31: 1098-1103 (2007).
Abbas Z, Khan R, Abid S, Hamid S, Shah H, Jafri W. Is Crohn's disease in Pakistan less severe than in the West? Trop. Doct. 34: 39-41 (2004).
Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr. Biol. 14: 2217-2227 (2004). *
Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC. Coordinate regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol. Cell. Biol. 27: 6012-6025 (2007). *
Abd El-Atti S, Wasicek K, Mark S, Hegazi R. Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. JPEN J. Parenter. Enteral Nutr. May 7 [Epub ahead of print] (2009).
Abdelli MN, Ben Abdallah H, Houissa F, Bouali MR, Khediri MF. Azathioprine for prevention of postoperative recurrence in Crohn's disease. Tunis. Med. 85: 569-572 (2007).
Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am. J. Gastroenterol. 102: 1333-1334 (2007).
Abdul-Baki H, Elhajj I, El-Zahabi LM, Azar C, Aoun E, Zantout H, Nasreddine W, Ayyach B, Mourad FH, Soweid A, Barada KA, Sharara AI. Clinical epidemiology of inflammatory bowel disease in Lebanon. Inflamm. Bowel Dis. 13: 475-480 (2007). *
Abe Y, Yoshikawa T, Kamada H, Shibata H, Nomura T, Minowa K, Kayamuro H, Katayama K, Miyoshi H, Mukai Y, Yoshioka Y, Nakagawa S, Tsunoda SI, Tsutsumi Y. Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. J. Immunol. Methods 335: 71-78 (2008). *
Abedin M, Scheurich D, Reimold SC, Reimold AM. Acute coronary syndrome after infliximab infusion. Cardiol. Rev. 14: 50-52 (2006).
Aberra FN. Omega-3 fatty acids for maintenance of remission of Crohn's disease. Gastroenterology 135: 1005-1006 (2008). *
Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, Lewis JD. Antibiotic use and the risk of flare of inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 3: 459-465 (2005). *
Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment. Pharmacol. Ther. 21: 307-319 (2005). *
Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for active tuberculosis in inflammatory bowel disease patients. Clin. Gastroenterol. Hepatol. 5: 1070-1075 (2007).
Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 108: 417-422 (1995). *
Ablassmaier B, Hartmann J. A case of severe gangrenous ischemic colitis following nonsteroidal anti-inflammatory drug intake. Zentralbl. Chir. 129: 510-512 (2004).
Abo T, Kawamura T, Kawamura H, Tomiyama-Miyaji C, Kanda Y. Relationship between diseases accompanied by tissue destruction and granulocytes with surface adrenergic receptors. Immunol. Res. 37: 201-210 (2007).
Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel Dis. 15: 1090-1100 (2009). *
Abraham C, Cho JH. Functional consequences of NOD2 (CARD15) mutations. Inflamm. Bowel Dis. 12: 641-650 (2006). *
Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 60: 97-110 (2009). *
Abreu MT. Immunologic regulation of Toll-like receptors in gut epithelium. Curr. Opin. Gastroenterol. 19: 559-564 (2003).
Abreu MT. Serologies in Crohn's disease: can we change the gray zone to black and white? Gastroenterology 131: 664-667 (2006). *
Abreu MT. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 210-211 (2005). *
Abreu MT. Crohn's disease in patients who fail infliximab therapy: what does the future hold? Rev. Gastroenterol. Disord. 7 Suppl. 1: S20-S26 (2007).
Abreu MT. Certolizumab pegol in Crohn's disease: a viewpoint by Maria T. Abreu. BioDrugs 21: 202-203 (2007).
Abreu MT. Choosing therapy on the basis of disease classifications in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 7: 169-179 (2004).
Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr. Gastroenterol. Rep. 4: 481-489 (2002).
Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J. Clin. Gastroenterol. 40: 55-63 (2006).
Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, Chen S, Zehnder D, Lin YC, Yang H, Hewison M, Adams JS. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 53: 1129-1136 (2004). *
Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41: 874-888 (2007).
Abreu MT, Sparrow MP. Translational research in inflammatory bowel disease. Mt. Sinai J. Med. 73: 1067-1073 (2006). *
Abreu MT, Sparrow MP. The role of translational research in inflammatory bowel disease. Rev. Gastroenterol. Mex. 72: 146-153 (2007).
Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123: 679-688 (2002). *
Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W; Crohn's Disease Photopheresis Study Group. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm. Bowel Dis. 15: 829-836 (2009).
Abreu MT, Yang H. Is genetic testing in IBD ready for prime time? Am. J. Gastroenterol. 99: 316-318 (2004). *
Abu-Suboh Abadia M, Casellas F, Vilaseca J, Malagelada J. Response of first attack of inflammatory bowel disease requiring hospital admission to steroid therapy. Rev. Esp. Enferm. Dig. 96: 539-547 (2004).
Abubakar I, Myhill D, Aliyu SH, Hunter PR. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. Inflamm. Bowel Dis. 14: 401-410 (2008). *
Abubakar I, Myhill DJ, Hart AR, Lake IR, Harvey I, Rhodes JM, Robinson R, Lobo AJ, Probert CS, Hunter PR. A case-control study of drinking water and dairy products in Crohn's disease - further investigation of the possible role of Mycobacterium avium paratuberculosis. Am. J. Epidemiol. 165: 776-783 (2007). *
Abuzakouk M, Feighery C, Jackson J. Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br. J. Biomed. Sci. 59: 173-179 (2002).
Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment. Pharmacol. Ther. 10: 321-326 (1996). *
Achkar JP, Dassopoulos T, Silverberg MS, Tuvlin JA, Duerr RH, Brant SR, Siminovitch K, Reddy D, Datta LW, Bayless TM, Zhang L, Barmada MM, Rioux JD, Steinhart AH, McLeod RS, Griffiths AM, Cohen Z, Yang H, Bromfield GP, Schumm P, Hanauer SB, Cho JH, et al. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am. J. Gastroenterol. 101: 572-580 (2006). *
Achkar JP, Duerr R. The expanding universe of inflammatory bowel disease genetics. Curr. Opin. Gastroenterol. 24: 429-434 (2008). *
Achkar JP, Fiocchi C. Gene-gene interactions in inflammatory bowel disease: biological and clinical implications. Am. J. Gastroenterol. May 12 [Epub ahead of print] (2009). *
Achneck HE, Pradhan SK, Kavic SM, Longo WE. Primary signet-ring cell carcinoma mimicking segmental Crohn's colitis. Dig. Liver Dis. 37: 537-541 (2005).
Achneck HE, Wong IY, Kim PJ, Fernandes MA, Walther Z, Seymour NE, Jain D. Ileostomy adenocarcinomas in the setting of ulcerative colitis. J. Clin. Gastroenterol. 39: 396-400 (2005).
Achord JL, Gunn CH Jr, Jackson JF. Regional enteritis and HLA concordance in multiple siblings. Dig. Dis. Sci. 27: 330-332 (1982).
Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets 11: 1369-1384 (2007).
Actis GC, Pellicano R, Bugianesi E, Lagget M, Rizzetto M. Use of corticosteroids, immunomodulators, and Infliximab at a third-level day-hospital service of gastro-hepatology. Minerva Gastroenterol. Dietol. 54: 239-242 (2008).
Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm. Bowel Dis. 5: 200-211 (1999).
Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Curr. Pharm. Des. 14: 1217-1224 (2008).
Adam SJ, Counter CM. A method to generate genetically defined tumors in pigs. Methods Enzymol. 439: 39-51 (2008).
Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *
Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J. Am. Acad. Dermatol. 51: 660-662 (2004).
Adams R, McGuckin M, Florin T. Dietary antigens in Crohn's disease. Am. J. Gastroenterol. 104: 526 (2009). *
Adams RJ, Heazlewood SP, Gilshenan KS, O'Brien M, McGuckin MA, Florin TH. IgG antibodies against common gut bacteria are more diagnostic for Crohn's disease than IgG against mannan or flagellin. Am. J. Gastroenterol. 103: 386-396 (2008). *
Adamska I, Czerwionka-Szaflarska M, Kulwas A, Mierzwa G, Bala G, Rosc D. Value of E-selectin and L-selectin determination in children and youth with inflammatory bowel disease. Med. Wieku. Rozwoj. 11: 413-418 (2007).
Adamska I, Czerwionka-Szaflarska M, Kulwas A, Mierzwa G, Bala G, Rosc D. Adhesion molecules of immunoglobin super family in children and youth with inflammatory bowel disease. Pol. Merkur. Lekarski. 26: 101-104 (2009).
Adani GL, Baccarani U, Risaliti A, Donini A, Aoki T, Avital I. Appendicectomy and Crohn's disease: clinical and genetic associations. Gastroenterology 125: 1562-1563 (2003). *
Addo A, Le J, Li W, Aksentijevich I, Balow J Jr, Lee A, Gregersen PK, Kastner DL, Remmers EF. Analysis of CARD15/NOD2 haplotypes fails to identify common variants associated with rheumatoid arthritis susceptibility. Scand. J. Rheumatol. 34: 198-203 (2005). *
Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand. J. Gastroenterol. 32: 1013-1021 (1997).
Adhiah AH, Jasim HA, Fadhil AM. HLA antigens and inflammatory bowel disease in a sample of Iraqi patients. East. Mediterr. Health J. 14: 1155-1163 (2008).
Adibi SA. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G779-G788 (2003). *
Adler J, Raju S, Beveridge AS, Wang S, Zhu J, Zimmermann EM. College adjustment in University of Michigan students with Crohn's and colitis. Inflamm. Bowel Dis. 14: 1281-1286 (2008).
Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig. Dis. Sci. 36: 449-453 (1991).
Afzal MA, Armitage E, Ghosh S, Williams LC, Minor PD. Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease. J. Med. Virol. 62: 377-382 (2000). *
Afzal MA, Minor PD, Armitage E, Ghosh S. Measles virus and Crohn's disease. Gut 44: 896-897 (1999). *
Afzal MA, Minor PD, Schild GC. Clinical safety issues of measles, mumps and rubella vaccines. Bull. World Health Organ. 78: 199-204 (2000).
Afzal NA, Davies S, Paintin M, Arnaud-Battandier F, Walker-Smith JA, Murch S, Heuschkel R, Fell J. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig. Dis. Sci. 50: 1471-1475 (2005). *
Afzal NA, Ozzard A, Keady S, Thomson M, Murch S, Heuschkel R. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease. Dig. Dis. Sci. 52: 3329-3333 (2007). *
Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, Davies S, Murch S, Derkx B, Heuschkel R, Fell JM. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment. Pharmacol. Ther. 20: 167-172 (2004). *
Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 5: 289-293 (2004). *
Agapov M. Balantidiasis in a patient with suspected Crohn's disease. Endoscopy 38: 655 (2006). *
Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci. 1030: 434-441 (2004). *
Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H. TNF blockade: an inflammatory issue. Ernst Schering Res. Found. Workshop 56: 161-186 (2006).
Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J. Gastroenterol. Hepatol. 20: 1691-1695 (2005). *
Aghdassi E, Wendland BE, Stapleton M, Raman M, Allard JP. Adequacy of nutritional intake in a Canadian population of patients with Crohn's disease. J. Am. Diet. Assoc. 107: 1575-1580 (2007). *
Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial. Am. J. Gastroenterol. 98: 348-353 (2003). *
Agius LM. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis. J. Theor. Biol. 227: 219-228 (2004). *
Agnholt J. Biological therapy as treatment of inflammatory bowel diseases. Ugeskr. Laeger. 170: 2152-2156 (2008).
Agnholt J, Dahlerup JF, Buntzen S, Tottrup A, Nielsen SL, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment. Pharmacol. Ther. 17: 703-710 (2003). *
Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23: 76-85 (2003). *
Agnholt J, Kaltoft K, Jakobsen NO, Dahlerup JF. T-cell vaccination in Crohn's disease: principles and presentation of the first two cases. Cytokines Cell Mol. Ther. 7: 117-123 (2002).
Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease - a possible target for infliximab treatment. Eur. J. Gastroenterol. Hepatol. 16: 649-655 (2004).
Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sorensen ES. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn's disease. Scand. J. Immunol. 65: 453-460 (2007). *
Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease. Clin. Gastroenterol. Hepatol. 3: 1215-1220 (2005).
Agrawal D, Rukkannagari S, Kethu S. Pathogenesis and clinical approach to extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol. Dietol. 53: 233-248 (2007).
Agret F, Cosnes J, Hassani Z, Gornet JM, Gendre JP, Lemann M, Beaugerie L. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment. Pharmacol. Ther. 21: 509-513 (2005). *
Aguas M, Bastida G, Nos P, Beltran B, Grueso JL, Ponce J. Septic thrombophlebitis of the superior mesenteric vein and multiple liver abscesses in a patient with Crohn's disease at onset. BMC Gastroenterol. 7: 22 (2007). *
Aguilera-Montilla N, Perez-Blas M, Valeri AP, Lopez-Santalla M, Rodriguez-Juan C, Mencia A, Castellano G, Manzano ML, Casis B, Sanchez F, Martin-Villa JM. Higher proliferative capacity of T lymphocytes from patients with Crohn disease than from ulcerative colitis is disclosed by use of Herpesvirus saimiri-transformed T-cell lines. Scand. J. Gastroenterol. 39: 1236-1242 (2004). *
Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M. New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies. Rev. Med. Chil. 131: 1445-1453 (2003).
Aharoni R, Kayhan B, Arnon R. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm. Bowel Dis. 11: 106-115 (2005). *
Ahern PP, Izcue A, Maloy KJ, Powrie F. The interleukin-23 axis in intestinal inflammation. Immunol. Rev. 226: 147-159 (2008). *
Ahmad K, Rogers S. Development of Crohn disease in a patient on etanercept for psoriasis. Br. J. Dermatol. 157: 396 (2007).
Ahmad NM, Ahmad KM, Younus F. Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease. J. Infect. 54: e29-e32 (2007).
Ahmad S, Tester RF, Corbett A, Karkalas J. Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. Carbohydr. Res. 341: 2694-2701 (2006). *
Ahmad T. Phenotype-determining genes in inflammatory bowel disease. Novartis Found. Symp. 263: 17-29 (2004).
Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, de Silva A, Cook JT, Barnardo M, Cullen S, Welsh KI, Jewell DP. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122: 854-866 (2002). *
Ahmad T, Marshall S, Jewell D. Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease. Curr. Opin. Gastroenterol. 19: 327-335 (2003).
Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. World J. Gastroenterol. 12: 3628-3635 (2006). *
Ahmad T, Marshall SE, Mulcahy-Hawes K, Orchard T, Crawshaw J, Armuzzi A, Neville M, van Heel D, Barnardo M, Welsh KI, Jewell DP, Bunce M. High resolution MIC genotyping: design and application to the investigation of inflammatory bowel disease susceptibility. Tissue Antigens 60: 164-179 (2002). *
Ahmad T, Pesi Tamboli C, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126: 1533-1549 (2004). *
Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP. Review article: the genetics of inflammatory bowel disease. Aliment. Pharmacol. Ther. 15: 731-748 (2001). *
Ahmad T, Zhang L, Gogus F, Verity D, Wallace G, Madanat W, Fayyad F, James T, Neville M, Kanawati C, Fortune F, Celik A, Stanford M, Jewell DP, Marshall SE. CARD15 polymorphisms in Behcet's disease. Scand. J. Rheumatol. 34: 233-237 (2005).
Ahmadi AA, Polyak S. Endoscopy/surveillance in inflammatory bowel disease. Surg. Clin. North Am. 87: 743-762 (2007).
Ahman T. Molecular classification of IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 27. May 7-8 (2004). *
Ahmed FE. Role of genes, the environment and their interactions in the etiology of inflammatory bowel diseases. Expert Rev. Mol. Diagn. 6: 345-363 (2006).
Ahmed I, Boulter MK, Lobo DN. The SLAPPA (significance of lower abdominal/periumbilical piercing as a predictor of acute appendicitis) audit. Sex Health 3: 195-196 (2006).
Ahmed KA, Thompson JW, Joyner RE, Stocks RM. Airway obstruction secondary to tracheobronchial involvement of asymptomatic undiagnosed Crohn's disease in a pediatric patient. Int. J. Pediatr. Otorhinolaryngol. 69: 1003-1005 (2005).
Ahmed M, Jenkins HR. Vitamin B-12 in Crohn's disease patients with small bowel surgery. Arch. Dis. Child. 89: 293 (2004). *
Ahmed M, Kosgallana A, Soon D, O'Donovan D, Chaudhuri A. Respiratory muscle weakness in a patient with quiescent Crohn's disease and pneumonia. QJM 101: 245-247 (2008).
Ahmed SF, Horrocks IA, Patterson T, Zaidi S, Ling SC, McGrogan P, Weaver LT. Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. J. Pediatr. Gastroenterol. Nutr. 38: 276-280 (2004). *
Ahn HS, Lee SK, Kim HJ, Jang JY, Joo KR, Dong SH, Kim BH, Lee JI, Chang YW, Chang R. Risk of postoperative infection in patients with inflammatory bowel disease. Korean J. Gastroenterol. 48: 306-312 (2006).
Ahn LB, Huang CS, Forse RA, Hess DT, Andrews C, Farraye FA. Crohn's disease after gastric bypass surgery for morbid obesity: is there an association? Inflamm. Bowel Dis. 11: 622-624 (2005). *
Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, Yim S, Lambert G, Kurotani R, Nagashima K, Gonzalez FJ, Inoue Y. Hepatocyte nuclear factor 4 in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm. Bowel Dis. 14: 908-920 (2008).
Ahrens R, Waddell A, Seidu L, Blanchard C, Carey R, Forbes E, Lampinen M, Wilson T, Cohen E, Stringer K, Ballard E, Munitz A, Xu H, Lee N, Lee JJ, Rothenberg ME, Denson L, Hogan SP. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J. Immunol. 181: 7390-7399 (2008).
Ahuja V. Crohn's disease and mycobacteria: 'the Thomson brothers' or 'back to the future'. Trop. Gastroenterol. 25: 151-155 (2004).
Aihara H, Hiwatashi N. Salazosulfapyridine and 5-aminosalicylic acid agents for the treatment of ulcerative colitis. Nippon Rinsho 57: 2476-2480 (1999).
Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am. J. Gastroenterol. 103: 944-948 (2008). *
Ainsworth MA, Brynskov J. Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis. Ugeskr. Laeger. 169: 789-791 (2007).
Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Ellozy SH, Hegazi RAF, Yager J, Bodian C, Gorfine SR, Bauer JJ, Plevy SE, Sachar DB. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am. J. Gastroenterol. 99: 432-441 (2004). *
Aisenberg J, Wagreich J, Shim J, Almer S, Peen E, Heimann T, Gelernt IM, Greenstein A, Rubin P, Harpaz N, et al. Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study. Dig. Dis. Sci. 40: 1866-1872 (1995).
Aithal GP, Craggs A, Day CP, Welfare M, Daly AK, Mansfield JC, Hudson M. Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. Dig. Dis. Sci. 46: 1520-1525 (2001). *
Aithal GP, Day CP, Leathart J, Daly AK, Hudson M. Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. Genes Immun. 2: 44-47 (2001). *
Aizawa Y, Sutoh S, Matsuoka M, Negishi M, Torii A, Miyakawa Y, Sugisaka H, Nakamura M, Toda G. Association of interleukin-18 gene single-nucleotide polymorphisms with susceptibility to inflammatory bowel disease. Tissue Antigens 65: 88-92 (2005). *
Ajaj W, Goyen M, Langhorst J, Ruehm SG, Gerken G, Lauenstein TC. MR colonography for the assessment of colonic anastomoses. J. Magn. Reson. Imaging 24: 101-107 (2006).
Ajaj W, Lauenstein TC, Langhorst J, Kuehle C, Goyen M, Zoepf T, Ruehm SG, Gerken G, Debatin JF, Goehde SC. Small bowel hydro-MR imaging for optimized ileocecal distension in Crohn's disease: should an additional rectal enema filling be performed? J. Magn. Reson. Imaging 22: 92-100 (2005).
Ajlouni Y, Iser JH, Gibson PR. Endoscopic balloon dilatation of intestinal strictures in Crohn's disease: safe alternative to surgery. J. Gastroenterol. Hepatol. 22: 486-490 (2007). *
Akagi S, Hiyama E, Imamura Y, Takesue Y, Matsuura Y, Yokoyama T. Interleukin-10 expression in intestine of Crohn disease. Int. J. Mol. Med. 5: 389-395 (2000).
Akahoshi M, Ishihara M, Namba K, Kitaichi N, Ando Y, Takenaka S, Ishida T, Ohno S, Mizuki N, Nakashima H, Shirakawa T. Mutation screening of the CARD15 gene in sarcoidosis. Tissue Antigens 71: 564-567 (2008). *
Akay N, Boyvat A, Heper AO, Soykan I, Arica IE, Bektas M, Ensari A, Cokca F. Behcet's disease-like presentation of bullous pyoderma gangrenosum associated with Crohn's disease. Clin. Exp. Dermatol. 31: 384-386 (2006). *
Akazawa A, Sakaida I, Higaki S, Kubo Y, Uchida K, Okita K. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J. Gastroenterol. 37: 345-353 (2002). *
Akbayir N, Calis AB, Alkim C, Sokmen HM, Erdem L, Ozbal A, Bolukbas F, Akbayir N. Sensorineural hearing loss in patients with inflammatory bowel disease: a subclinical extraintestinal manifestation. Dig. Dis. Sci. 50: 1938-1945 (2005). *
Akbulut S, Yavuz B, Koseoglu T, Gokoz A, Saritas U. Crohn's disease with isolated esophagus and gastric involvement. Turk. J. Gastroenterol. 15: 196-200 (2004). *
Akcam M, Artan R, Yilmaz A, Cig H, Aksoy NH. Abdominal tuberculosis in adolescents. Difficulties in diagnosis. Saudi Med. J. 26: 122-126 (2005).
Akhavan A, Jackman SV, Costa G, Davies B, Wu T, Bond G, Abu-Elmagd K. Urogenital disorders associated with gut failure and intestinal transplantation. J. Urol. 178: 2067-2072 (2007).
Akhtar RY, Lewis BS, Ullman T. Mucosal healing of Crohn's disease demonstrated by capsule endoscopy in a woman with obscure gastrointestinal bleeding. Am. J. Gastroenterol. 104: 1065-1066 (2009).
Akiho H, Lovato P, Deng Y, Ceponis PJ, Blennerhassett P, Collins SM. Interleukin-4 and -13-induced hypercontractility of human intestinal muscle cells: implication for motility changes in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G609-G615 (2005). *
Akman SA, Arikan C, Sozen G, Ozturk C, Yagci RV. Infliximab treatment of pediatric refractory Crohn's disease: a case report. Turk. J. Gastroenterol. 17: 133-136 (2006). *
Akobeng A, Thomas A. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD005984 (2007). *
Akobeng A, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD003574 (2004). *
Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment. Pharmacol. Ther. 27: 11-18 (2008). *
Akobeng AK. Crohn's disease: current treatment options. Arch. Dis. Child. 93: 787-792 (2008).
Akobeng AK. Anti-mycobacterials and Crohn's disease: author's reply. Aliment. Pharmacol. Ther. 28: 374-375 (2008). *
Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease Cochrane Database Syst. Rev. 1: CD003715 (2004). *
Akobeng AK, Richmond K, Miller V, Thomas AG. Effect of exclusive enteral nutritional treatment on plasma antioxidant concentrations in childhood Crohn's disease. Clin. Nutr. 26: 51-56 (2007).
Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 2: CD007351 (2009). *
Akolkar PN, Gulwani-Akolkar B, Heresbach D, Lin XY, Fisher S, Katz S, Silver J. Differences in risk of Crohn's disease in offspring of mothers and fathers with inflammatory bowel disease. Am. J. Gastroenterol. 92: 2241-224 (1997).
Akolkar PN, Gulwani-Akolkar B, Lin XY, Zhou Z, Daly M, Katz S, Levine J, Present D, Gelb B, Desnick R, Mayer L, Silver J. The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset disease. Am. J. Gastroenterol. 96: 1127-1132 (2001). *
Aktas H, Mensink PB. Therapeutic balloon-assisted enteroscopy. Dig. Dis. 26: 309-313 (2008).
Al-Ghamdi AS, Al-Mofleh IA, Al-Rashed RS, Al-Amri SM, Aljebreen AM, Isnani AC, El-Badawi R. Epidemiology and outcome of Crohn's disease in a teaching hospital in Riyadh. World J. Gastroenterol. 10: 1341-1344 (2004). *
Al-Haddad S, Riddell RH. The role of eosinophils in inflammatory bowel disease. Gut 54: 1674-1675 (2005). *
Al-Jarallah A, Oriowo MA, Khan I. Mechanism of reduced colonic contractility in experimental colitis: role of sarcoplasmic reticulum pump isoform-2. Mol. Cell. Biochem. 298: 169-178 (2007). *
Al-Mubarak L, Al-Khenaizan S, Al Goufi T. Cutaneous presentation of kwashiorkor due to infantile Crohn's disease. Eur. J. Pediatr. Apr 8 [Epub ahead of print] (2009).
Al-Ratrout JT, Ansari NA. Epidermolysis bullosa acquisita and Crohn's disease. Saudi Med. J. 25: 1736-1738 (2004).
Al-Sadi R, Ye D, Dokladny K, Ma TY. Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J. Immunol. 180: 5653-5661 (2008). *
Al-Shamali M, Khan I, Al-Nakib B, Al-Hassan F, Mustafa AS. A multiplex polymerase chain reaction assay for the detection of Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Scand. J. Gastroenterol. 32: 819-823 (1997).
Al-Toma A, Mulder CJ. Review article: stem cell transplantation for the treatment of gastrointestinal diseases - current applications and future perspectives. Aliment. Pharmacol. Ther. 26 Suppl. 2: 77-89 (2007). *
Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC. Eruptive tufted angiomas in a patient with Crohn's disease. J. Clin. Pathol. 58: 214-216 (2005). *
Alam I, Nolan N, Geoghegan J. Isolated Crohn's disease of the appendix. Ir. J. Med. Sci. 173: 114 (2004).
Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. Curr. Pharm. Des. 10: 3505-3524 (2004).
Albert JG, Gittinger FS, Hainz M, Lubbert C, Spiller R. In disguise as an acute flare: an unusual differential diagnosis of Crohn's disease. Gut 58: 742 (2009).
Albert JG, Kotsch J, Kostler W, Behl S, Kaltz B, Bokemeyer B, Dollinger MM, Haerting J, Fleig WE. Course of Crohn's disease prior to establishment of the diagnosis. Z. Gastroenterol. 46: 187-192 (2008).
Albert JG, Martiny F, Krummenerl A, Stock K, Lesske J, Gobel CM, Lotterer E, Nietsch HH, Behrmann C, Fleig WE. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut 54: 1721-1727 (2005). *
Albert JG, Wiedbrauck F, Keuchel M. Small bowel endoscopy. Dtsch. Med. Wochenschr. 133: 1136-1141 (2008).
Albrecht K, Schumann R, Peitgen K, Walz MK. Laparoscopic therapy of appendicovesical fistula - two case reports. Zentralbl. Chir. 129: 396-398 (2004).
Alcala MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm. Bowel Dis. 10: 383-391 (2004). *
Aldebert D, Masy E, Reumaux D, Lion G, Colombel JF, Duthilleul P. Immunoglobulin G subclass distribution of anti-endothelial cell antibodies (AECA) in patients with ulcerative colitis or Crohn's disease. Dig. Dis. Sci. 42: 2350-2355 (1997). *
Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J. Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am. J. Gastroenterol. 102: 577-588 (2007). *
Aldhous MC, Prescott RJ, Roberts S, Samuel K, Waterfall M, Satsangi J. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease? Inflamm. Bowel Dis. 14: 1469-1482 (2008). *
Aleksandra Nielsen A, Nederby Nielsen J, Schmedes A, Brandslund I, Hey H. Saliva interleukin-6 in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 40: 1444-1448 (2005). *
Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, Beaugerie L, Gallot D, Malafosse M, Barritault D, Kern P. Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents. Gut 53: 85-90 (2004). *
Alexander F. Complications of ileal pouch anal anastomosis. Semin. Pediatr. Surg. 16: 200-204 (2007).
Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol. 158: 527-535 (2001). *
Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF. Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease. Dig. Dis. Sci. 40: 485-494 (1995).
Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF. Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease. Dig. Dis. Sci. 41: 660-669 (1996).
Alexandridis E, Zisimopoulos A, Liratzopoulos N, Katsos I, Manolas K, Kouklakis G. Obestatin/ghrelin ratio: a new activity index in inflammatory bowel diseases. Inflamm. Bowel Dis. Apr 30 [Epub ahead of print] (2009).
Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J. Cutan. Med. Surg. 9: 296-302 (2005).
Alexopoulou E, Roma E, Loggitsi D, Economopoulos N, Papakonstantinou O, Panagiotou I, Pahoula I, Kelekis NL. Magnetic resonance imaging of the small bowel in children with idiopathic inflammatory bowel disease: evaluation of disease activity. Pediatr. Radiol. May 19 [Epub ahead of print] (2009).
Alfadhli A, McDonald J, Feagan B. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459 (2005). *
Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459 (2003). *
Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Jarvinen HJ, Karhu A, Aaltonen LA. NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res. 64: 7245-7247 (2004). *
Alic M. Epidemiology supports oral contraceptives as a risk factor in Crohn's disease. Gut 46: 140 (2000). *
Alic M. Crohn's disease epidemiology at the turn of the century-solving the puzzle. Am. J. Gastroenterol. 95: 321-323 (2000). *
Alic M. Is exposure to a patient with Crohn's disease an environmental factor for developing the disease. Gut 45: 631-632 (1999). *
Alison M, Kheniche A, Azoulay R, Roche S, Sebag G, Belarbi N. Ultrasonography of Crohn disease in children. Pediatr. Radiol. 37: 1071-1082 (2007).
Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm. Bowel Dis. 15: 803-806 (2008).
Alkim C, Balci M, Alkim H, Dagli U, Parlak E, Tezel A, Ulker A. The importance of peripheral immune cells in inflammatory bowel disease. Turk. J. Gastroenterol. 18: 82-88 (2007). *
Alkim C, Savas B, Ensari A, Alkim H, Dagli U, Parlak E, Ulker A, Sahin B. Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease. Dig. Dis. Sci. Nov 26 [Epub ahead of print] (2008). *
Allen AS, Satten GA. Statistical models for haplotype sharing in case-parent trio data. Hum. Hered. 64: 35-44 (2007). *
Allen CA, Niesel DW, Torres AG. The effects of low-shear stress on adherent-invasive Escherichia coli. Environ. Microbiol. 10: 1512-1525 (2008).
Allez M, Modigliani R. Clinical features of inflammatory bowel disease. Curr. Opin. Gastroenterol. 16: 329-336 (2000).
Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, Caillat-Zucman S, Paul P, Gornet JM, Douay C, Ravet S, Tamouza R, Charron D, Lemann M, Mayer L, Toubert A. CD4(+)NKG2D(+) T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 132: 2346-2358 (2007). *
Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol. Clin. North Am. 21: 643-658 (1992).
Allgayer H, Holtmeier W, Dietrich CF. Crohn's disease and cancer risk. Incidence/prevalence, clinical characteristics, and potential prevention strategies. Med. Klin. (Munich) 102: 727-733 (2007).
Allgayer H, Kruis W. Recent knowledge of the pathophysiology of inflammation in Crohn disease and ulcerative colitis: possible sequelae for future treatment concepts. Z. Gastroenterol. 28: 117-120 (1990).
Allgayer H, Roisch U, Zehnter E, Ziegenhagen DJ, Dienes HP, Kruis W. Colonic ornithine decarboxylase in inflammatory bowel disease: ileorectal activity gradient, guanosine triphosphate stimulation, and association with epithelial regeneration but not the degree of inflammation and clinical features. Dig. Dis. Sci. 52: 25-30 (2007). *
Allison MC, Poulter LW. Changes in phenotypically distinct mucosal macrophage populations may be a prerequisite for the development of inflammatory bowel disease. Clin. Exp. Immunol. 85: 504-509 (1991). *
Allison SP, Williams L, Sandhar B, Swaffield G, Newman GH, Bastow MD, Fox JE, Hardcastle JH. Supplementation of nutritional fluid and electrolyte balance by perfusion of an isolated small bowel loop in a patient with Crohn's disease. Clin. Nutr. 2: 107-111 (1983).
Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54: 565 (2005). *
Alluwaimi AM. The etiology of Mycobacterium avium subspecies paratuberculosis in Crohn's disease. Saudi Med. J. 28: 1479-1484 (2007).
Ally MR, Veerappan GR, Koff JM. Treatment of recurrent Crohn's uveitis with infliximab. Am. J. Gastroenterol. 103: 2150-2151 (2008). *
Almadi MA, Ghosh S, Aljebreen AM. Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge. Am. J. Gastroenterol. 104: 1003-1012 (2009).
Almeida N, Portela F, Oliveira P, Duarte A, Gregorio C, Gomes D, Gouveia H, Leitao MC. Meningitis in a patient with previously undiagnosed Crohn's disease. Inflamm. Bowel Dis. 15: 643-645 (2009).
Almer S, Granerus G, Strom M, Olaison G, Bonnet J, Lemann M, Smedh K, Franzen L, Bertheau P, Cattan P, Rain JD, Modigliani R. Leukocyte scintigraphy compared to intraoperative small bowel enteroscopy and laparotomy findings in Crohn's disease. Inflamm. Bowel Dis. 13: 164-174 (2007). *
Almer SH, Hjortswang H, Hindorf U. 6-Thioguanine therapy in Crohn's disease - observational data in Swedish patients. Dig. Liver Dis. 41: 194-200 (2009).
Aloi M, Cucchiara S. Extradigestive manifestations of IBD in pediatrics. Eur. Rev. Med. Pharmacol. Sci. 13 Suppl. 1: 23-32 (2009).
Alonso-Hearn M, Molina E, Geijo M, Vazquez P, Sevilla I, Garrido JM, Juste RA. Isolation of Mycobacterium avium subsp. paratuberculosis from muscle tissue of naturally infected cattle. Foodborne Pathog. Dis. 6: 513-518 (2009).
Alos R, Hinojosa J. Timing of surgery in Crohn's disease: a key issue in the management. World J. Gastroenterol. 14: 5532-5539 (2008). *
Alos R, Solana A. Inflammatory bowel disease. Is laparotomy an obsolete technique in the elective surgery of Crohn's disease? Should laparoscopy always be performed in these patients? Gastroenterol. Hepatol. 32: 122-123 (2009).
Alpers DH. The role of nutritional deficiency in the osteopenia and osteoporosis of gastrointestinal diseases. Curr. Opin. Gastroenterol. 18: 203-208 (2002).
Alqahtani S, Coffin CS, Burak K, Chen F, Macgregor J, Beck P. Hepatic portal venous gas: a report of two cases and a review of the epidemiology, pathogenesis, diagnosis and approach to management. Can. J. Gastroenterol. 21: 309-313 (2007).
Alrefai WA, Saksena S, Tyagi S, Gill RK, Ramaswamy K, Dudeja PK. Taurodeoxycholate modulates apical Cl(-)/OH(-) exchange activity in Caco2 cells. Dig. Dis. Sci. 52: 1270-1278 (2007). *
Alsaadi G, Quirynen M, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J. Clin. Periodontol. 34: 610-617 (2007).
Alsaadi G, Quirynen M, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of late oral implant loss. Clin. Oral Implants Res. 19: 670-676 (2008).
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. J. Clin. Periodontol. 35: 51-57 (2008).
Alstead EM. The pill: safe sex and Crohn's disease? Gut 45: 165-166 (1999). *
Alstead EM. Inflammatory bowel disease in pregnancy. Postgrad. Med. J. 78: 23-26 (2002). *
Altarescu G, Elstein D. Coexistence of Fabry disease and Crohn's disease: a case report. Inflamm. Bowel Dis. 11: 87-88 (2005). *
Altschuler EL. Mycophenolate mofetil, Crohn's disease, measles? Am. J. Gastroenterol. 95: 550-551 (2000). *
Altschuler EL, Kast RE. Bupropion for Blau syndrome. Med. Hypotheses 62: 297-298 (2004).
Alva E, Vasquez J, Frisancho O, Mantilla L, Yabar A, Morales D. Refractary corticosteroids colonic Crohn disease with successful remission with infliximab. Rev. Gastroenterol. Peru 29: 51-54 (2009).
Alvarez Beltran M, Infante Pina D, Tormo Carnice R, Segarra Canton O, Redecillas Ferreiro S. Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites. An. Pediatr. (Barc.) 70: 120-125 (2009).
Alvarez-Blanco M, Fernandez-Mere LA, Martinez-Rodriguez E. Crohns disease of the appendix. Cir. Esp. 78: 333-335 (2005).
Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Piu J, Reverter JC, Pique JM, Yague J, Panes J. Combined type-1 plasminogen activator inhibitor and NOD2/CARD15 genotyping predicts complicated Crohn's disease behaviour. Aliment. Pharmacol. Ther. 25: 429-440 (2007). *
Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, Lacy AM, Pique JM, Yague J, Panes J. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann. Surg. 242: 693-700 (2005). *
Alves A, Panis Y, Bouhnik Y, Marceau C, Rouach Y, Lavergne-Slove A, Vicaut E, Valleur P. Factors that predict conversion in 69 consecutive patients undergoing laparoscopic ileocecal resection for Crohn's disease: a prospective study. Dis. Colon Rectum 48: 2302-2308 (2005). *
Alves A, Panis Y, Joly F, Pocard M, Lavergne-Slove A, Bouhnik Y, Valleur P. Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn disease? Inflamm. Bowel Dis. 10: 491-495 (2004). *
Alves C, Vieira N, Toralles MB, Lyra A. Human histocompatibility system association with gastrointestinal diseases. Acta Gastroenterol. Latinoam. 36: 86-93 (2006).
Alzoghaibi MA, Al-Mofleh IA, Al-Jebreen AM. Neutrophil chemokines GCP-2 and GRO-alpha in patients with inflammatory bowel disease. J. Dig. Dis. 9: 144-148 (2008). *
Alzoghaibi MA, Walsh SW, Willey A, Fowler Iii AA, Graham MF. Linoleic acid, but not oleic acid, upregulates the production of interleukin-8 by human intestinal smooth muscle cells isolated from patients with Crohn's disease. Clin. Nutr. 22: 529-535 (2003). *
Alzoghaibi MA, Walsh SW, Willey A, Yager DR, Fowler AA 3rd, Graham MF. Linoleic acid induces interleukin-8 production by Crohn's human intestinal smooth muscle cells via arachidonic acid metabolites. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G528-G537 (2004). *
Amarapurkar DN, Patel ND, Amarapurkar AD, Agal S, Baigal R, Gupte P. Tissue polymerase chain reaction in diagnosis of intestinal tuberculosis and Crohn's disease. J. Assoc. Physicians India 52: 863-867 (2004).
Amarapurkar DN, Patel ND, Rane PS. Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent. World J. Gastroenterol. 14: 741-746 (2008). *
Amati L, Caradonna L, Jirillo E, Caccavo D. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications. Ital. J. Gastroenterol. Hepatol. 31: 313-325 (1999).
Amati L, Caradonna L, Leandro G, Magrone T, Minenna M, Faleo G, Pellegrino NM, Jirillo E, Caccavo D. Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects. Curr. Pharm. Design 9: 1937-1945 (2003).
Amati L, Passeri ME, Selicato F, Mastronardi ML, Penna A, Jirillo E, Covelli V. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease. Immunopharmacol. Immunotoxicol. 28: 665-681 (2006).
Ambrosini R, Barchiesi A, Di Mizio V, Di Terlizzi M, Leo L, Filippone A, Canalis L, Fossaceca R, Carriero A. Inflammatory chronic disease of the colon: how to image. Eur. J. Radiol. 61: 442-448 (2007).
Amemori S, Iwakiri R, Endo H, Ootani A, Ogata S, Noda T, Tsunada S, Sakata H, Matsunaga H, Mizuguchi M, Ikeda Y, Fujimoto K. Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. J. Gastroenterol. 41: 444-449 (2006). *
Ament ME, Berquist W, Vargas J. Advances in ulcerative colitis. Pediatrician 15: 45-57 (1988).
American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 125: 1503-1507 (2003). *
Amin J, Wong M. Measles-Mumps-Rubella immunisation, autism and inflammatory bowel disease: update. CDI: Current Issues in Immunisation 23: 222 [http://www.cda.gov.au/pubs/cdi/1999/cdi2308/pdf/cdi2308e.pdf] (1999). *
Amitai MM, Arazi-Kleinman T, Avidan B, Apter S, Konen E, Biegon A, Hertz M. Fat halo sign in the bowel wall of patients with Crohn's disease. Clin. Radiol. 62: 994-997 (2007).
Amitai MM, Arazi-Kleinman T, Hertz M, Apter S, Portnoy O, Guranda L, Chowers Y, Avidan B. Multislice CT compared to small bowel follow-through in the evaluation of patients with Crohn disease. Clin. Imaging 32: 355-361 (2008).
Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 72: 1100-1116 (2006).
Amonkar SJ, Hughes T, Browell DA. Crohn's disease discovered by an obstructing chick pea. Br. J. Hosp. Med. (Lond.) 68: 445 (2007).
Amoudruz P, Holmlund U, Schollin J, Sverremark-Ekstrom E, Montgomery SM. Maternal country of birth and previous pregnancies are associated with breast milk characteristics. Pediatr. Allergy Immunol. 20: 19-29 (2009).
Amre DK, D'Souza S, Morgan K, Seidman G, Lambrette P, Grimard G, Israel D, Mack D, Ghadirian P, Deslandres C, Chotard V, Budai B, Law L, Levy E, Seidman EG. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am. J. Gastroenterol. 102: 2016-2025 (2007). *
Amre DK, Lambrette P, Law L, Krupoves A, Chotard V, Costea F, Grimard G, Israel D, Mack D, Seidman EG. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn's disease: a case-control study. Am. J. Gastroenterol. 101: 1005-1011 (2006). *
Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am. J. Gastroenterol. 101: 645-652 (2006). *
Amre DK, Mack D, Israel D, Morgan K, Lambrette P, Law L, Grimard G, Deslandres C, Krupoves A, Bucionis V, Costea I, Bissonauth V, Feguery H, D'Souza S, Levy E, Seidman EG. Association between genetic variants in the IL-23R gene and early-onset Crohn's disease: results from a case-control and family-based study among Canadian children. Am. J. Gastroenterol. 103: 615-620 (2008). *
Amre DK, Mack DR, Israel D, Morgan K, Krupoves A, Costea I, Lambrette P, Grimard G, Deslandres C, Levy E, Seidman EG. Investigation of associations between the pregnane X receptor gene (NR1I2) and Crohn's disease in Canadian children using a gene-wide haplotype-based approach. Inflamm. Bowel Dis. 14: 1214-1218 (2008). *
Amre DK, Mack DR, Morgan K, Israel D, Lambrette P, Costea I, Krupoves A, Fegury H, Dong J, Grimard G, Deslandres C, Levy E, Seidman EG. Interleukin 10 (IL-10) gene variants and susceptibility for pediatric onset Crohn's disease. Aliment. Pharmacol. Ther. 29: 1025-1031 (2009). *
Amre DK, Mack DR, Morgan K, Krupoves A, Costea I, Lambrette P, Grimard G, Dong J, Feguery H, Bucionis V, Deslandres C, Levy E, Seidman EG. Autophagy gene ATG16L1 but not IRGM is associated with Crohn's disease in Canadian children. Inflamm. Bowel Dis. 15: 501-507 (2009). *
Amre DK, Seidman EG. DNA variants in cytokine and NOD2 genes, exposures to infections and risk for Crohn's disease. Paediatr. Perinat. Epidemiol. 17: 302-312 (2003).
Amu J, Phadnis S, Sanusi A. Bartholin's gland carcinoma from Crohn's disease. J. Obstet. Gynaecol. 27: 98-99 (2007).
Amundsen SS, Vatn M; the IBSEN study group; Wijmenga C, Sollid LM, Lie BA. Association analysis of MYO9B gene polymorphisms and inflammatory bowel disease in a Norwegian cohort. Tissue Antigens 68: 249-252 (2006). *
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4: 807-818 (2007). *
Anand V, Russell AS, Tsuyuki R, Fedorak R. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can. J. Gastroenterol. 22: 33-36 (2008).
Anandasabapathy S. Endoscopic imaging: emerging optical techniques for the detection of colorectal neoplasia. Curr. Opin. Gastroenterol. 24: 64-69 (2008). *
Ananthakrishnan AN, Attila T, Otterson MF, Lipchik RJ, Massey BT, Komorowski RA, Binion DG. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41: 682-688 (2007).
Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57: 205-210 (2008).
Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am. J. Gastroenterol. 103: 2789-2798 (2008). *
Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm. Bowel Dis. 15: 182-189 (2009).
Ananthakrishnan AN, Weber LR, Knox JF, Skaros S, Emmons J, Lundeen S, Issa M, Otterson MF, Binion DG. Permanent work disability in Crohn's disease. Am. J. Gastroenterol. 103: 154-161 (2008). *
Anastasopoulos G, Marinis A, Konstantinidis C, Theodosopoulos T, Fragulidis G, Vassiliou I. Adenocarcinoma of the third portion of the duodenum in a man with CREST syndrome. World J. Surg. Oncol. 6: 106 (2008). *
Andersen J, Kehlet H. Fast track open ileo-colic resections for Crohn's disease. Colorectal Dis. 7: 394-397 (2005). *
Andersen K, Vogt C, Blondin D, Beck A, Heinen W, Aurich V, Haussinger D, Modder U, Cohnen M. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur. J. Radiol. 58: 140-146 (2006).
Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, Gwilliam R, Jacob J, Nimmo ER, Drummond H, Lees CW, Onnie CM, Hanson C, Blaszczyk K, Ravindrarajah R, Hunt S, Varma D, Hammond N, Lewis G, Attlesey H, Watkins N, et al. Investigation of Crohn�s disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 136: 523-529.e3 (2009). *
Anderson DW. Cytokines as drug targets. IDrugs 4: 375-377 (2001).
Andersson P, Olaison G, Hallbook O, Boeryd B, Sjodahl R. Increased anal resting pressure and rectal sensitivity in Crohn's disease. Dis. Colon Rectum 46: 1685-1689 (2003).
Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 124: 40-46 (2003). *
Andersson UG, Tracey KJ. HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J. Intern. Med. 255: 318-319 (2004). *
Ando T, Nobata K, Watanabe O, Ina K, Kusugami K, Maeda O, Ishiguro K, Ohmiya N, Niwa Y, Goto H. Abnormalities in the upper gastrointestinal tract in inflammatory bowel disease. Inflammopharmacology Apr 28 [Epub ahead of print] (2007).
Ando T, Watanabe O, Ishiguro K, Maeda O, Ishikawa D, Minami M, Hasegawa M, Kondo S, Goto Y, Ohmiya N, Niwa Y, Goto H. Relationships between Helicobacter pylori infection status, endoscopic, histopathological findings, and cytokine production in the duodenum of Crohn's disease patients. J. Gastroenterol. Hepatol. 23 Suppl. 2: S193-S197 (2008).
Ando T, Watanabe O, Nobata K, Ishiguro K, Maeda O, Ishikawa D, Hasegawa M, Kondo S, Kato T, Ohmiya N, Niwa Y, Goto H. Immunological status of the stomach in inflammatory bowel disease - comparison between ulcerative colitis and Crohn's disease. Digestion 77: 145-149 (2008). *
Ando Y, Matsushita M, Kawamata S, Shimatani M, Fujii T, Okazaki K. Infliximab for severe gastrointestinal bleeding in Crohn's disease. Inflamm. Bowel Dis. 15: 483-484 (2009).
Andoh A, Bamba T. Treatment of Crohn's disease by anti-cytokine monoclonal antibodies. Nippon Rinsho 60: 117-122 (2002).
Andoh A, Benno Y, Kanauchi O, Fujiyama Y. Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. Curr. Pharm. Des. 15: 2066-2073 (2009).
Andoh A, Deguchi Y, Inatomi O, Yagi Y, Bamba S, Tsujikawa T, Fujiyama Y. Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease. Oncol. Rep. 16: 103-107 (2006). *
Andoh A, Endo Y, Kushima R, Hata K, Tsujikawa T, Sasaki M, Mekata E, Tani T, Fujiyama Y. A case of Crohn's disease involving the gallbladder. World J. Gastroenterol. 12: 977-978 (2006). *
Andoh A, Fujino S, Hirai Y, Fujiyama Y. Epimorphin expression in human colonic myofibroblasts. Int. J. Mol. Med. 13: 57-61 (2004).
Andoh A, Fujino S, Okuno T, Fujiyama Y, Bamba T. Intestinal subepithelial myofibroblasts in inflammatory bowel diseases. J. Gastroenterol. 37 Suppl. 14: 33-37 (2002).
Andoh A, Fujiyama Y. Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World J. Gastroenterol. 12: 4452-4460 (2006). *
Andoh A, Hirashima M, Maeda H, Hata K, Inatomi O, Tsujikawa T, Sasaki M, Takahashi K, Fujiyama Y. Serum selenoprotein-P levels in patients with inflammatory bowel disease. Nutrition 21: 574-579 (2005). *
Andoh A, Saotome T, Sato H, Tsujikawa T, Araki Y, Fujiyama Y, Bamba T. Epithelial expression of caveolin-2, but not caveolin-1, is enhanced in the inflamed mucosa of patients with ulcerative colitis. Inflamm. Bowel Dis. 7: 210-214 (2001). *
Andoh A, Shioya M, Nishida A, Bamba S, Tsujikawa T, Kim-Mitsuyama S, Fujiyama Y. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J. Immunol. Jun 17 [Epub ahead of print] (2009).
Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 23: 1373-1377 (2008).
Andoh A, Tsujikawa T, Hata K, Araki Y, Kitoh K, Sasaki M, Yoshida T, Fujiyama Y. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am. J. Gastroenterol. 100: 2042-2048 (2005). *
Andoh A, Tsujikawa T, Sasaki M, Mitsuyama K, Suzuki Y, Matsui T, Matsumoto T, Benno Y, Fujiyama Y. Fecal microbiota profile of Crohn's disease determined by terminal restriction fragment length polymorphism analysis. Aliment. Pharmacol. Ther. 29: 75-82 (2009). *
Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J. Gastroenterol. 14: 5154-5161 (2008). *
Andoh A, Yoshida T, Yagi Y, Bamba S, Hata K, Tsujikawa T, Kitoh K, Sasaki M, Fujiyama Y. Increased aggregation response of platelets in patients with inflammatory bowel disease. J. Gastroenterol. 41: 47-54 (2006). *
Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129: 969-984 (2005). *
Andou A, Hisamatsu T, Okamoto S, Chinen H, Kamada N, Kobayashi T, Hashimoto M, Okutsu T, Shimbo K, Takeda T, Matsumoto H, Sato A, Ohtsu H, Suzuki M, Hibi T. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 136: 564-574.e2 (2009). *
Andrabi SI, Ahmad J, Rathore MA, El-Hakeem AA. Gallbladder perforation in a patient on steroid therapy. N. Z. Med. J. 120: U2686 (2007).
Andre MF, Aumaitre O, Piette JC, Grateau G, Cardoso MC, Ouchchane L, Kemeny JL, Dastugue B, Delpech M, Creveaux I. Analysis of the NOD2/CARD15 gene in patients affected with the aseptic abscesses syndrome with or without inflammatory bowel disease. Dig. Dis. Sci. 53: 490-499 (2008). *
Andre MF, Kemeny JL, Aumaitre O. Aseptic abscesses: entity already described in Crohn's disease: comment on the case report by Holstein et al. J. Gastroenterol. Hepatol. 22: 765 (2007). *
Andreakos E. Common and uncommon features of rheumatoid arthritis and chronic obstructive pulmonary disease: clues to a future therapy. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4: 85-92 (2004).
Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol. Rev. 202: 250-265 (2004). *
Andreani ML, Frasca G, Brusco G, Borgnino L, Biagi F, Gasbarrini G, Corazza GR. Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: diagnostic tool or research procedure?. Ann. Ital. Med. Int. 11: 254-257 (1996).
Andreani SM, Dang HH, Edwards DP, Baig MK, Khan M, Payne JG. Ovarian Crohn's disease: contiguous or metastatic? Inflamm. Bowel Dis. 12: 1091-1092 (2006). *
Andreani SM, Dang HH, Grondona P, Khan AZ, Edwards DP. Rectovaginal fistula in Crohn's disease. Dis. Colon Rectum 50: 2215-2222 (2007). *
Andreassen H, Rix M, Brot C, Eskildsen P. Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. Scand. J. Gastroenterol. 33: 1087-1093 (1998). *
Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand. J. Gastroenterol. 32: 1247-1255 (1997).
Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol. Clin. North Am. 28: 255-281, vii (1999).
Andrews JM, Travis SP, Gibson PR, Gasche C. Does concurrent therapy with 5-ASA and immunomodulator(s) in inflammatory bowel disease improve outcomes? Aliment. Pharmacol. Ther. 29: 459-469 (2009). *
Andus T, Daig R, Vogl D, Aschenbrenner E, Lock G, Hollerbach S, Kollinger M, Scholmerich J, Gross V. Imbalance of the interleukin 1 system in colonic mucosa - association with intestinal inflammation and interleukin 1 receptor antagonist genotype 2. Gut 41: 651-657 (1997). *
Andus T, Gross V. Etiology and pathophysiology of inflammatory bowel disease - environmental factors. Hepatogastroenterology 47: 29-43 (2000).
Andus T, Gross V, Caesar I, Schulz HJ, Lochs H, Strohm WD, Gierend M, Weber A, Ewe K, Scholmerich J; German/Austrian Budesonide Study Group. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial. Dig. Dis. Sci. 48: 373-378 (2003). *
Andus T, Klebl F, Rogler G, Bregenzer N, Scholmerich J, Straub RH. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment. Pharmacol. Ther. 17: 409-414 (2003). *
Andus T, Stange EF, Hoffler D, Keller-Stanislawski B. Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med. Klin. (Munich) 98: 429-436 (2003).
Ang TL, Fock KM, Ng TM, Teo EK, Tan YL. Clinical utility, safety and tolerability of capsule endoscopy in urban Southeast Asian population. World J. Gastroenterol. 9: 2313-2316 (2003). *
Angelberger S, Fink KG, Schima W, Szlauer R, Vogelsang H, Reinisch W, Gangl A, Novacek G. Complications in Crohn's disease: right-sided ureteric stenosis and hydronephrosis. Inflamm. Bowel Dis. 13: 1056-1057 (2007). *
Angelberger S, Reinisch W, Dejaco C, Miehsler W, Waldhoer T, Wehkamp J, Lichtenberger C, Schaeffeler E, Vogelsang H, Schwab M, Teml A. NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. Am. J. Gastroenterol. 103: 1197-1202 (2008). *
Angeloni G, Latteri M, Manna R, Rumi C, Gasbarrini G, Navarra P. Circulating levels of cyclosporin A in inflammatory bowel disease: relationships with lymphocyte inhibition and the age of patients. Eur. J. Clin. Pharmacol. 60: 161-164 (2004). *
Angelucci E, Cocco A, Cesarini M, Crudeli A, Necozione S, Caprilli R, Latella G. Monthly and seasonal birth patterns and the occurrence of Crohn's disease. Am. J. Gastroenterol. 104: 1608-1609 (2009).
Angelucci E, Cocco A, Latella G, Caprilli R. Clinical course of late-onset Crohn's disease. Inflamm. Bowel Dis. Nov 4 [Epub ahead of print] (2008).
Angelucci E, Cocco A, Viscido A, Caprilli R. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. Inflamm. Bowel Dis. 14: 435-436 (2008). *
Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli R. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm. Bowel Dis. 13: 1059-1061 (2007). *
Angelucci E, Malesci A, Danese S. Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment. Curr. Med. Chem. 15: 2527-2535 (2008).
Angriman I, Scarpa M, D'Inca R, Basso D, Ruffolo C, Polese L, Sturniolo GC, D'Amico DF, Plebani M. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin. Chim. Acta 381: 63-68 (2007). *
Angriman I, Scarpa M, Ruffolo C, Pomerri F, Filosa T, Polese L, Pagano D, Norberto L, D'Amico DF. Double contrast small-bowel radiography in the preoperative assessment of Crohn's disease: is it still useful? Surg. Today 38: 700-704 (2008).
Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570 (1999). *
Annese V. Digging out Crohn's disease genes. Inflamm. Bowel Dis. Feb 23 [Epub ahead of print] (2009). *
Annese V, Andreoli A, Andriulli A, Dinca R, Gionchetti P, Latiano A, Lombardi G, Piepoli A, Poulain D, Sendid B, Colombel JF. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am. J. Gastroenterol. 96: 2407-2412 (2001). *
Annese V, Andreoli A, Astegiano M, Campieri M, Caprilli R, Cucchiara S, D'Inca R, Giaccari S, Iaquinto G, Lombardi G, Napolitano G, Pera A, Riegler G, Valpiani D, Andriulli A; Italian Study Group for the Disease of Colon and Rectum. Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Am. J. Gastroenterol. 96: 2939-2945 (2001). *
Annese V, Latiano A, Andriulli A. Genetics of inflammatory bowel disease: the beginning of the end or the end of the beginning? Dig. Liver Dis. 35: 442-449 (2003).
Annese V, Latiano A, Bovio P, Forabosco P, Piepoli A, Lombardi G, Andreoli A, Astegiano M, Gionchetti P, Riegler G, Sturniolo GC, Clementi M, Rappaport E, Fortina P, Devoto M, Gasparini P, Andriulli A. Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus - a GISC study. Eur. J. Hum. Genet. 7: 567-573 (1999). *
Annese V, Latiano A, Palmieri O, Lombardi G, Andriulli A; Italian Group of Inflammatory Bowel Disease. NOD2/CARD15 in healthy relatives of IBD patients. Eur. Rev. Med. Pharmacol. Sci. 10: 33-36 (2006).
Annese V, Latiano A, Rossi L, Bossa F, Damonte G, Dallapiccola B, Serafini S, Pierige F, Andriulli A, Magnani M. The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 10: 27-31 (2006).
Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - a pilot uncontrolled study. Am. J. Gastroenterol. 100: 1370-1375 (2005). *
Annese V, Lombardi G, Perri F, D'Inca R, Ardizzone S, Riegler G, Giaccari S, Vecchi M, Castiglione F, Gionchetti P, Cocchiara E, Vigneri S, Latiano A, Palmieri O, Andriulli A. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease - an IG-IBD study. Am. J. Gastroenterol. 100: 84-92 (2005). *
Annese V, Palmieri O, Latiano A, Ardizzone S, Castiglione F, Cottone M, D'Inca R, Gionchetti P, Papi C, Riegler G, Vecchi M, Andriulli A; Italian Group for Inflammatory Bowel Disease. Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease Study. Dig. Liver Dis. 36: 121-124 (2004).
Annese V, Piepoli A, Andriulli A, Latiano A, Napolitano G, Li HH, Forabosco P, Devoto M. Association of Crohn's disease and ulcerative colitis with haplotypes of the MLH1 gene in Italian inflammatory bowel disease patients. J. Med. Genet. 39: 332-334 (2002). *
Annese V, Piepoli A, Andriulli A, Napolitano G, Bisceglia L, Zelante L, Gasparini P. Polymorphism of motilin gene in patients with Crohn's disease. Dig. Dis. Sci. 43: 715-719 (1998). *
Annese V, Piepoli A, Latiano A, Lombardi G, Napolitano G, Caruso N, Cocchiara E, Accadia L, Perri F, Andriulli A. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis. Colon Rectum 48: 57-64 (2005).
Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Aliment Pharmacol. Ther. 20: 1143-1152 (2004). *
Annibale B, Capurso G, Baccini F, Lahner E, D'Ambra G, Di Giulio E, Delle Fave G. Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract. Dig. Liver Dis. 35: 784-787 (2003).
Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fil� L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204: 1849-1861 (2007). *
Ansaldo GL, Varaldo E, Assalino M, Borgonovo G. Artificial nutrition in inflammatory bowel disease. Ann. Ital. Chir. 75: 629-634 (2004).
Ansari A, Aslam Z, DE Sica A, Smith M, Gilshenan K, Fairbanks L, Marinaki A, Sanderson J, Duley J. The influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment. Pharmacol. Ther. 28: 749-757 (2008). *
Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28: 734-741 (2008). *
Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28: 734-741 (2008). *
Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm. Bowel Dis. 14: 1399-1405 (2008).
Ansari N, Abdulla J, Zayyani N, Brahmi U, Taha S, Abdel Satir A. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis? J. Clin. Pathol. 59: 1066-1072 (2006). *
Anthony A, Dhillon AP, Pounder RE, Wakefield AJ. The colonic mesenteric margin is most susceptible to injury in an experimental model of colonic ulceration. Aliment. Pharmacol. Ther. 13: 531-535 (1999). *
Anthony A, Dhillon AP, Pounder RE, Wakefield AJ. Ulceration of the ileum in Crohn's disease: correlation with vascular anatomy. J. Clin. Pathol. 50: 1013-1017 (1997). *
Anthony A, Pounder RE, Dhillon AP, Wakefield AJ. Similarities between ileal Crohn's disease and indomethacin experimental jejunal ulcers in the rat. Aliment. Pharmacol. Ther. 14: 241-245 (2000). *
Antoniu SA. Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? Expert Opin. Investig. Drugs 15: 181-184 (2006).
Antunes DM, da Costa JP, Campos SM, Paschoal PO, Garrido V, Siqueira M, Teixeira GA, Cardoso GP. The serum D-xylose test as a useful tool to identify malabsorption in rats with antigen specific gut inflammatory reaction. Int. J. Exp. Pathol. 90: 141-147 (2009).
Anumakonda V, Hayee B, Chung-Faye G. Remission and relapse of Crohn's disease following autologous haematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Gut 56: 1325 (2007). *
Aparicio-Pages MN, Verspaget HW, Pena AS, Weterman IT, de Bruin PA, Mieremet-Ooms MA, van der Zon JM, van Tol EA, Lamers CB. In vitro cellular cytotoxicity in Crohn's disease and ulcerative colitis: relation with disease activity and treatment, and the effect of recombinant gamma-interferon. J. Clin. Lab. Immunol. 29: 119-124 (1989).
Aparicio-Pages MN, Verspaget HW, Pena AS, Weterman IT, Mieremet-Ooms MA, van der Zon JM, de Bruin PA, Lamers CB. Natural, lectin- and phorbol ester-induced cellular cytotoxicity in Crohn's disease and ulcerative colitis. J. Clin. Lab. Immunol. 27: 109-113 (1988).
APDW2004 Chinese IBD Working Group. Retrospective analysis of 515 cases of Crohn's disease hospitalization in China: nationwide study from 1990 to 2003. J. Gastroenterol. Hepatol. 21: 1009-1015 (2006). *
Apgar JT. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin. Dermatol. 10: 138-147 (1991).
Apostolaki M, Manoloukos M, Roulis M, Wurbel MA, Muller W, Papadakis KA, Kontoyiannis DL, Malissen B, Kollias G. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 134: 2025-2035 (2008). *
Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, Brzezinski A, Strong SA, Hammel J, Kiran RP. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J. Gastrointest. Surg. 12: 1738-1744 (2008). *
Appleyard CB, Hernandez G, Rios-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm. Bowel Dis. 10: 106-111 (2004). *
Aquilina P, Savage NW, Lynham A. Crohn's disease with oral presenting signs masquerading as chronic osteomyelitis. Aust. Dent. J. 48: 134-137 (2003).
Arai F, Takahashi T, Furukawa K, Matsushima K, Asakura H. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease. Dig. Dis. Sci. 43: 2071-2079 (1998). *
Arai T, Esaki Y, Sawabe M, Honma N, Nakamura KI, Takubo K. Hypermethylation of the hMLH1 promoter with absent hMLH1 expression in medullary-type poorly differentiated colorectal adenocarcinoma in the elderly. Mod. Pathol. 17: 172-179 (2004). *
Araki Y, Sugihara H, Hattori T. The free radical scavengers edaravone and tempol suppress experimental dextran sulfate sodium-induced colitis in mice. Int. J. Mol. Med. 17: 331-334 (2006). *
Aranda R, Horgan K. Immunosuppressive drugs in the treatment of inflammatory bowel disease. Semin. Gastrointest. Dis. 9: 2-9 (1998).
Aratari A, Caprilli R. Seasonality in onset of symptoms in Crohn's disease. Dig. Liver Dis. 38: 356 (2006).
Aratari A, Papi C, Galletti B, Angelucci E, Viscido A, D'Ovidio V, Ciaco A, Abdullahi M, Caprilli R. Seasonal variations in onset of symptoms in Crohn's disease. Dig. Liver Dis. 38: 319-323 (2006).
Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn's disease. Aliment. Pharmacol. Ther. 26: 1303-1312 (2007). *
Arber N, Berliner S, Hallak A, Bujanover Y, Dotan I, Liberman E, Santo M, Moshkowitz M, Ratan J, Dotan G, et al. Increased leucocyte adhesiveness/aggregation is a most useful indicator of disease activity in patients with inflammatory bowel disease. Gut 37: 77-80 (1995). *
Ardizzone S. Ulcerative colitis. Orphanet encyclopedia [http://www.orpha.net/data/patho/GB/uk-UC.pdf] (2003). *
Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286 (2005).
Ardizzone S, Bianchi Porro G. Perianal Crohn's disease: overview. Dig. Liver Dis. 39: 957-958 (2007).
Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J. Intern. Med. 247: 63-70 (2000). *
Ardizzone S, Bollani S, Manzionna G, Colombo E, Maconi G, Imbesi V, Bianchi Porro G. Efficacy of medical therapy in preventing the post-surgical recurrence in Crohn's disease. Ann. Ital. Chir. 74: 621-625 (2003).
Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig. Liver Dis. 35: 619-627 (2003).
Ardizzone S, Cassinotti A, Trabattoni D, Manzionna G, Rainone V, Bevilacqua M, Massari A, Manes G, Maconi G, Clerici M, Bianchi Porro G. Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int. J. Immunopathol. Pharmacol. 22: 63-71 (2009).
Ardizzone S, Colombo E, Maconi G, Bollani S, Manzionna G, Petrone MC, Bianchi Porro G. Infliximab in treatment of Crohn's disease: the Milan experience. Dig. Liver Dis. 34: 411-418 (2002).
Ardizzone S, Maconi G, Bianchi V, Russo A, Colombo E, Cassinotti A, Penati C, Tenchini ML, Bianchi Porro G. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm. Bowel Dis. 13: 516-523 (2007). *
Ardizzone S, Maconi G, Cassinotti A, Massari A, Bianchi Porro G. Imaging of perianal Crohn's disease. Dig. Liver Dis. 39: 970-978 (2007).
Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Porro GB. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm. Bowel Dis. 10: 91-96 (2004). *
Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, Imbesi V, Molteni M, Danelli PG, Taschieri AM, Bianchi Porro G. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127: 730-740 (2004). *
Ardizzone S, Porro GB. Should azathioprine be withdrawn in patients with Crohn's disease who are in long-term remission? Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 348-349 (2005). *
Ardizzone S, Porro GB. Is it possible to modify the clinical course of Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 428-429 (2008).
Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig. Liver Dis. 40 Suppl. 2: S253-S259 (2008).
Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap. Neth. J. Med. 61: 111-119 (2003). *
Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor- alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin. Infect. Dis. 45: 1470-1475 (2007). *
Arents NL, Thijs JC, Van Zwet AA, Kleibeuker JH. Does the declining prevalence of Helicobacter pylori unmask patients with idiopathic peptic ulcer disease? Trends over an 8 year period. Eur. J. Gastroenterol. Hepatol. 16: 779-783 (2004).
Arfaoui D, Elloumi H, Debbebi W, Bel Hadj Ali N, Ajmi S. Psychological disorder associated to inflammatory bowel disease. Tunis. Med. 85: 189-191 (2007).
Arfaoui D, Elloumi H, Salah A, Ajmi S. Predictive factors of recurrence in Crohn's disease. Tunis. Med. 83: 83-86 (2005).
Argov S, Sahu RK, Bernshtain E, Salman A, Shohat G, Zelig U, Mordechai S. Inflamatory bowel diseases as an intermediate stage between normal and cancer: a FTIR-microspectroscopy approach. Biopolymers 75: 384-392 (2004). *
Arguelles Arias F, Arguelles Martin F, Caunedo Alvarez A, Rodriguez-Tellez M, Herrerias Gutierrez JM. Utility of capsule endoscopy in pediatric gastroenterology. An. Pediatr. (Barc.) 59: 586-589 (2003).
Arguelles-Arias F, Arguelles Martin F, Caunedo Alvarez A, Sanchez Yague A, Romero Vazquez J, Garcia Montes MJ, Rodriguez-Tellez M, Pellicer Bautista FJ, Herrerias Gutierrez JM. Is capsule endoscopy useful in children with chronic abdominal pain? An. Pediatr. (Barc.) 67: 385-389 (2007).
Arguelles-Arias F, Caunedo A, Romero J, Sanchez A, Rodriguez-Tellez M, Pellicer FJ, Arguelles-Martin F, Herrerias JM. The value of capsule endoscopy in pediatric patients with a suspicion of Crohn's disease. Endoscopy 36: 869-873 (2004).
Arihiro S, Ohtani H, Suzuki M, Murata M, Ejima C, Oki M, Kinouchi Y, Fukushima K, Sasaki I, Nakamura S, Matsumoto T, Torii A, Toda G, Nagura H. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol. Int. 52: 367-374 (2002). *
Arin Letamendia A, Borda Celaya F, Burusco Paternain MJ, Prieto Martinez C, Martinez Echeverria A, Elizalde Apestegui I, Laiglesia Izquierdo M, Macias Mendizabal E, Tamburri Moso P, Sanchez Valverde F. High incidence rates of inflammatory bowel disease in Navarra (Spain). Results of a prospective, population-based study. Gastroenterol. Hepatol. 31: 111-116 (2008).
Arluk GM, Pickhardt PJ. Images in clinical medicine. Inflammatory pseudopolyposis in Crohn's disease. N. Engl. J. Med. 350: 923 (2004). *
Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med. 205: 331-337 (2008). *
Armitage EL, Aldhous MC, Anderson N, Drummond HE, Riemersma RA, Ghosh S, Satsangi J. Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology 127: 1051-1057 (2004). *
Armuzzi A, Ahmad T, Ling KL, De Silva A, Cullen S, van Heel D, Orchard TR, Welsh KI, Marshall SE, Jewell DP. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 52: 1133-1139 (2003). *
Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Dig. Liver Dis. 40 Suppl. 2: S271-S279 (2008).
Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel Dis. 8: 10-15 (2002). *
Arnold J, Sangwaiya A, Bhatkal B, Geoghegan F, Busbridge M. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis. Eur. J. Gastroenterol. Hepatol. 21: 425-429 (2009).
Arnott ID, Drummond HE, Ghosh S. Frequency of continuing mucosal inflammation in clinically inactive Crohn's disease. Scott. Med. J. 46: 136-139 (2001).
Arnott ID, Ho GT, Nimmo ER, Satsangi J, Franchimont D, Vermeire S, Deviere J, Rutgeerts PJ. Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe (Author's reply). Gut 54: 308-309 (2005). *
Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand. J. Gastroenterol. 35: 1163-1169 (2000). *
Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol. 99: 2376-2384 (2004). *
Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment. Pharmacol. Ther. 15: 1639-1646 (2001). *
Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 17: 1451-1457 (2003). *
Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, MacKinlay E, Morecroft J, Anderson N, Kelleher D, O'Sullivan M, McManus R, Satsangi J. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun. 5: 417-425 (2004). *
Arnott ID, Satsangi J. Crohn's disease or Crohn's diseases? Gut 52: 460-461 (2003). *
Arnott ID, Shand A, Ghosh S. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4. Am. J. Gastroenterol. 95: 3326-3327 (2000). *
Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol. Res. 47: 1-10 (2003). *
Aronoff JS, Korelitz BI, Sohn N, Ky A, Rajapakse R, Weinstein MA, Cohen FS. Anorectal Crohn's disease: surgical and medical management. BioDrugs 13: 95-105 (2000).
Arranz A, Abad C, Juarranz Y, Leceta J, Martinez C, Gomariz RP. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 15: 46-53 (2008).
Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J, Gomariz RP, Martinez C. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann. N. Y. Acad. Sci. 1070: 129-134 (2006). *
Arranz A, Juarranz Y, Leceta J, Gomariz RP, Martinez C. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 29: 948-956 (2008). *
Arseneau KO, Stukenborg GJ, Connors AF Jr, Cominelli F. The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm. Bowel Dis. 7: 106-112 (2001). *
Arseneau KO, Tamagawa H, Pizarro TT, Cominelli F. Innate and adaptive immune responses related to IBD pathogenesis. Curr. Gastroenterol. Rep. 9: 508-512 (2007).
Arsenescu R, Bruno ME, Rogier EW, Stefka AT, McMahan AE, Wright TB, Nasser MS, de Villiers WJ, Kaetzel CS. Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol. 1: 399-411 (2008).
Arslan G, Brunborg LA, Froyland L, Brun JG, Valen M, Berstad A. Effects of duodenal seal oil administration in patients with inflammatory bowel disease. Lipids 37: 935-940 (2002).
Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tozun N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dokmeci A. Clinical outcome of Crohn's disease treated with infliximab. Hepatogastroenterology 50: 952-956 (2003).
Asakura H. Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody. Nippon Rinsho 60: 531-538 (2002).
Asakura H, Sugimura K. Present states of development in new drugs and treatment of inflammatory bowel disease. Nippon Rinsho 57: 2490-2495 (1999).
Asakura H, Suzuki K, Kitahora T, Morizane T. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? J. Gastroenterol. Hepatol. 23: 1794-1801 (2008). *
Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J. Gastroenterol. Hepatol. 16: 763-769 (2001). *
Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn's disease in Japan. J. Gastroenterol. May 8 [Epub ahead of print] (2009). *
Aschoff AJ. MDCT of the abdomen. Eur. Radiol. 16 Suppl. 7: M54-M57 (2006).
Asheim P, Uggen PE, Aasarod K, Aadahl P. Intraperitoneal fluid therapy: an alternative to intravenous treatment in a patient with limited vascular access. Anaesthesia 61: 502-504 (2006). *
Ashley MJ. Smoking and diseases of the gastrointestinal system: an epidemiological review with special reference to sex differences. Can. J. Gastroenterol. 11: 345-352 (1997).
Ashok D, Kiely P. Bowel associated dermatosis - arthritis syndrome: a case report. J. Med. Case Reports 1: 81 (2007). *
Ashorn S, Honkanen T, Kolho KL, Ashorn M, Valineva T, Wei B, Braun J, Rantala I, Luukkaala T, Iltanen S. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm. Bowel Dis. 15: 199-205 (2009).
Ashorn S, Raukola H, Valineva T, Ashorn M, Wei B, Braun J, Rantala I, Kaukinen K, Luukkaala T, Collin P, M�ki M, Iltanen S. Elevated serum anti-Saccharomyces cerevisiae, anti-I2 and anti-OmpW antibody levels in patients with suspicion of celiac disease. J. Clin. Immunol. 28: 486-494 (2008). *
Ashwood P, Anthony A, Torrente F, Wakefield AJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J. Clin. Immunol. 24: 664-673 (2004). *
Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3(+) lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J. Neuroimmunol. 173: 126-134 (2006).
Asimakopoulos G. Pregnancy and inflammatory bowel disease. Rev. Med. Chir. Soc. Med. Nat. Iasi. 108: 46-50 (2004).
Askling J, Brandt L, Lapidus A, Karlen P, Bjorkholm M, Lofberg R, Ekbom A. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54: 617-622 (2005). *
Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120: 1356-1362 (2001). *
Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 357: 262-266 (2001). *
Asma SD, Soumaya Y, Kahena J, Raouf DM, Nejib D. Perianal Crohn disease. Dermatol. Online J. 12: 18 (2006).
Aspberg S, Dahlquist G, Kahan T, Kallen B. Fetal and perinatal risk factors for inflammatory bowel disease. Acta Paediatr. 95: 1001-1004 (2006). *
Aspinall RJ. Are adherent Escherichia coli in Crohn's disease and colon cancer truly pathogenic? Gastroenterology 127: 1649-1650 (2004). *
Asplund S, Gramlich T, Fazio V, Petras R. Histologic changes in defunctioned rectums in patients with inflammatory bowel disease: a clinicopathologic study of 82 patients with long-term follow-up. Dis. Colon Rectum 45: 1206-1213 (2002).
Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 246-251 (2007). *
Asquith P, Thompson RA, Cooke WT. Oral manifestations of Crohn's disease. Gut 16: 1249-1254 (1975). *
Assche GV, Rutgeerts P. Medical management of postoperative recurrence in Crohn's disease. Gastroenterol. Clin. North Am. 33: 347-360 (2004).
Astegiano M, Bresso F, Demarchi B, Sapone N, Novero D, Palestro G, Resegotti A, Pellicano R, Rizzetto M. Association between Crohn's disease and Conn's syndrome. A report of two cases. Panminerva Med. 47: 61-64 (2005).
Astegiano M, Cammarota T, Bresso F, Sapone N, Demarchi B, Bertolusso L, Sarno A, Bruno M, Pellicano R, Rizzetto M. Abdominal pain and bowel dysfunction: diagnostic flow-chart could be semplified? Minerva Gastroenterol. Dietol. 47: 53-60 (2001).
Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: retrospective study. Biomed. Pharmacother. 61: 370-376 (2007).
Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand. J. Gastroenterol. 41: 1064-1072 (2006). *
Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig. Dis. Sci. 53: 2215-2221 (2008). *
Athanasiadis S, Yazigi R, Kohler A, Helmes C. Recovery rates and functional results after repair for rectovaginal fistula in Crohn's disease: a comparison of different techniques. Int. J. Colorectal Dis. 22: 1051-1060 (2007). *
Atienza P. Refractory perineal fistulas in Crohn's disease. Gastroenterol. Clin. Biol. 31: 404-411 (2007).
Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J. Intern. Med. 263: 591-596 (2008). *
Atreya R, Atreya I, Neurath MF. Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1072: 98-113 (2006). *
Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6: 583-588 (2000). *
Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin. Rev. Allergy Immunol. 28: 187-196 (2005).
Atreya R, Neurath MF. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr. Drug Targets 9: 369-374 (2008).
Attar A, Bon C, Sebbagh V, Bejou B, Benamouzig R. Endoscopic argon plasma coagulation for the treatment of hemorrhagic pseudopolyps in colonic Crohn's disease. Endoscopy 39: E249 (2007).
Attard TM, Horton KM, DeVito K, Darbari A, Oliva-Hemker M, Thompson R, Cuffari C. Pediatric jejunoileitis: a severe Crohn's disease phenotype that requires intensive nutritional management. Inflamm. Bowel Dis. 10: 357-360 (2004). *
Attvall E, Frigyesi A, Sternby B. What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease? Int. J. Colorectal Dis. 21: 705-710 (2006). *
Attwood SE, Lamb CA. Eosinophilic oesophagitis and other non-reflux inflammatory conditions of the oesophagus: Diagnostic imaging and management. Best Pract. Res. Clin. Gastroenterol. 22: 639-660 (2008).
Atug O, Hamzaoglu H, Tahan V, Alican I, Kurtkaya O, Elbuken E, Ozdogan O, Tozun N. Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis. Dig. Dis. Sci. 53: 481-485 (2008). *
Atug O, Tahan V, Eren F, Tiftikci A, Imeryuz N, Hamzaoglu HO, Tozun N. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease. J. Gastrointestin. Liver Dis. 17: 433-437 (2008). *
Atzeni F, Ardizzone S, Bertani L, Antivalle M, Batticciotto A, Sarzi-Puttini P. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. World J. Gastroenterol. 15: 2469-2471 (2009). *
Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, DE Portu S, Carrabba M, Bianchi Porro G. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment. Pharmacol. Ther. 22: 453-461 (2005). *
Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun. Rev. 6: 529-536 (2007).
Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 4: 144-152 (2005).
Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann. N. Y. Acad. Sci. 1051: 559-569 (2005). *
Audrain MA, Gourbil A, Muller JY, Esnault LM. Anti-lactoferrin autoantibodies: relation between epitopes and iron-binding domain. J. Autoimmun. 9: 569-574 (1996).
Auer IO. Immunologic aspects of chronic inflammatory intestinal diseases. Klin. Padiatr. 195: 337-341 (1983).
Auer IO, Buschmann C, Ziemer E. Immune status in Crohn's disease. 2. Originally unimpaired primary cell mediated immunity in vitro. Gut 19: 618-626 (1978). *
Auer IO, Gotz S, Ziemer E, Malchow H, Ehms H. Immune status in Crohn's disease. 3. Peripheral blood B lymphocytes, enumerated by means of F(ab)2-antibody fragments, Null and T lymphocytes. Gut 20: 261-268 (1979). *
Auer IO, Roder A, Wensinck F, van de Merwe JP, Schmidt H. Selected bacterial antibodies in Crohn's disease and ulcerative colitis. Scand. J. Gastroenterol. 18: 217-223 (1983).
Auer IO, Ziemer E, Sommer H. Immune status in Crohn's disease. V. Decreased in vitro natural killer cell activity in peripheral blood. Clin. Exp. Immunol. 42: 41-49 (1980). *
Auernhammer CJ, Zitzmann K, Schnitzler F, Seiderer J, Lohse P, Vlotides G, Engelhardt D, Sackmann M, Goke B, Ochsenkuhn T. Role of the intracellular receptor domain of gp130 (exon 17) in human inflammatory bowel disease. World J. Gastroenterol. 11: 1196-1199 (2005). *
Augoustides JG, Pochettino A, Pyeritz RE. Successful surgical management of acute type A aortic dissection associated with Crohn disease. J. Thorac. Cardiovasc. Surg. 134: 1048-1049 (2007).
Aurello P, Dente M, D'Angelo F, Nigri G, Cescon M, Ramacciato G. Intestinal occlusion resulting from a small bowel adenocarcinoma as first onset of Crohn's disease in a healthy patient. Am. Surg. 75: 189-190 (2009).
Auslander JN, Lieberman DA, Sonnenberg A. Lack of seasonal variation in the endoscopic diagnoses of Crohn's disease and ulcerative colitis. Am. J. Gastroenterol. 100: 2233-2238 (2005). *
Austin GL, Shaheen NJ, Sandler RS. Positive and negative predictive values: use of inflammatory bowel disease serologic markers. Am. J. Gastroenterol. 101: 413-416 (2006). *
Autret-Leca E, Bensouda-Grimaldi L, Jonville-Bera AP, Beau-Salinas F. Pharmacovigilance of vaccines. Arch. Pediatr. 13: 175-180 (2006).
Autret-Leca E, Jonville-Bera AP, Beau-Salinas F. Vaccines pharmacovigilance. Rev. Prat. 54: 526-531 (2004).
Autschbach F, Braunstein J, Helmke B, Zuna I, Schurmann G, Niemir ZI, Wallich R, Otto HF, Meuer SC. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am. J. Pathol. 153: 121-130 (1998). *
Autschbach F, Eisold S, Hinz U, Zinser S, Linnebacher M, Giese T, Loffler T, Buchler MW, Schmidt J. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut 54: 944-949 (2005). *
Autschbach F, Funke B, Katzenmeier M, Gassler N. Expression of chemokine receptors in normal and inflamed human intestine, tonsil, and liver - an immunohistochemical analysis with new monoclonal antibodies from the 8th international workshop and conference on human leucocyte differentiation antigens. Cell. Immunol. 236: 110-114 (2005). *
Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U, Zuna I, Schulz P, Weckauf H, Berger I, Otto HF, Meuer SC. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch. 441: 500-513 (2002). *
Auvin S, Molinie F, Gower-Rousseau C, Brazier F, Merle V, Grandbastien B, Marti R, Lerebours E, Dupas JL, Colombel JF, Salomez JL, Cortot A, Turck D. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in Northern France (1988-1999). J. Pediatr. Gastroenterol. Nutr. 41: 49-55 (2005). *
Avidan B, Sakhnini E, Lahat A, Lang A, Koler M, Zmora O, Bar-Meir S, Chowers Y. Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion 72: 248-253 (2005).
Avila Alvarez A, Garc�a-Alonso L, Solar Boga A, Garcia-Silva J. Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease. An. Pediatr. (Barc.) 70: 278-281 (2009).
Avital S, Hermon H, Greenberg R, Karin E, Skornick Y. Learning curve in laparoscopic colorectal surgery: our first 100 patients. Isr. Med. Assoc. J. 8: 683-686 (2006). *
Awad J, Farah R, Reshef R, Cohen H, Horn I. Pyloric stenosis as a presenting symptom of Crohn's disease. J. Gastrointestin. Liver Dis. 15: 175-177 (2006). *
Awotesu O, Missotten T, Pitcher MC, Lynn WA, Lightman S. Uveitis in a patient receiving rifabutin for Crohn's disease. J. R. Soc. Med. 97: 440-441 (2004). *
Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 47: 142-144 (2008). *
Aylett P. Digestive Disease Week 2006. Therapies for Crohn's disease and ulcerative colitis. IDrugs 9: 452-454 (2006).
Ayrizono Mde L, Meirelles LR, Leal RF, Coy CS, Fagundes JJ, Goes JR. Long-term outcomes of ileal pouch after secondary diagnosis of Crohn's disease. Arq. Gastroenterol. 45: 204-207 (2008).
Ba'ath ME, Mahmalat M, Smith NP, Dalzell M, Casson DH, Lamont GL, Baillie CT. Surgical management of inflammatory bowel disease. Arch. Dis. Child. 92: 312-316 (2007).
Baars JE, Siegel CA, Kuipers EJ, van der Woude CJ. Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion 79: 30-35 (2009).
Babb RR. The use of metronidazole (Flagyl) in Crohn's disease. J. Clin. Gastroenterol. 10: 479-481 (1988).
Babu TG, Boctor D, Davey A, Bond MC, Jacobson K. Cytomegalovirus-associated hemophagocytic syndrome in a child with Crohn disease receiving azathioprine. J. Pediatr. Gastroenterol. Nutr. 39: 418-421 (2004). *
Baburajan B, Parkes M. The genetics of inflammatory bowel disease. Hosp. Med. 64: 599-602 (2003).
Babusukumar U, Wang T, McGuire E, Broeckel U, Kugathasan S. Contribution of OCTN variants within the IBD5 locus to pediatric onset Crohn's disease. Am. J. Gastroenterol. 101: 1354-1361 (2006). *
Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975-984 (1996). *
Baca B, Hamzaoglu I, Karahasanoglu T, Hamzaoglu HO. Laparoscopic treatment of pyogenic liver abscess complicating Crohn's disease: a case report. Turk. J. Gastroenterol. 18: 58-61 (2007). *
Bacher S, Schmitz ML. The NF-kappa B pathway as a potential target for autoimmune disease therapy. Curr. Pharm. Des. 10: 2827-2837 (2004).
Bachmann C, Klibanov AL, Olson TS, Sonnenschein JR, Rivera-Nieves J, Cominelli F, Ley KF, Lindner JR, Pizarro TT. Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. Gastroenterology 130: 8-16 (2006). *
Bachmann O, Baus S, Hoffmann MW, Manns MP, Gebel M. Incarcerated Spieghel-Hernie mimicking an acute exacerbation of Crohn's disease. Z. Gastroenterol. 43: 1309-1312 (2005).
Bachmeyer C, Leclerc-Landgraf N, Laurette F, Coutarel P, Cadranel JF, Medioni J, Dhote R, Mougeot-Martin M. Acute autoimmune sensorineural hearing loss associated with Crohn's disease. Am. J. Gastroenterol. 93: 2565-2567 (1998). *
Bachvarov DR, Landry M, Houle S, Pare P, Marceau F. Altered frequency of a promoter polymorphic allele of the kinin B1 receptor gene in inflammatory bowel disease. Gastroenterology 115: 1045-1048 (1998). *
Bachwich DR, Lichtenstein GR, Traber PG. Cancer in inflammatory bowel disease. Med. Clin. North Am. 78: 1399-1412 (1994).
Bacon PA. Vasculitic syndromes associated with other rheumatic conditions and unclassified systemic vasculitis. Curr. Opin. Rheumatol. 3: 56-61 (1991).
Badina L, Taddio A, Ventura A. Early combined immunosuppression in Crohn's disease. Lancet 371: 1995 (2008).
Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease: top-down or step-up? Dig. Dis. 25: 260-266 (2007).
Baert F, De Vos M, Louis E, Vermeire S; Belgian IBD Research Group. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol. Belg. 70: 163-170 (2007).
Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348: 601-608 (2003). *
Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P. Management of ulcerative colitis and Crohn's disease. Acta Clin. Belg. 59: 304-314 (2004).
Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22-28 (1999). *
Baert FJ, Rutgeerts PJ. Medical therapies for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 2: 446-450 (2000).
Baert FJ, Rutgeerts PR. Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int. J. Colorectal Dis. 14: 47-51 (1999). *
Bagnoli S, Putignano AL, Melean G, Baglioni S, Sestini R, Milla M, d'Albasio G, Genuardi M, Pacini F, Trallori G, Papi L. Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene. Inflamm. Bowel Dis. 10: 705-708 (2004). *
Bahadursingh AM, Longo WE. Malignant transformation of chronic perianal Crohn's fistula. Am. J. Surg. 189: 61-62 (2005). *
Bai A, Hu P, Chen J, Song X, Chen W, Peng W, Zeng Z, Gao X. Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis. Int. J. Colorectal Dis. 22: 625-635 (2007). *
Bai AP, Ouyang Q, Hu RW. Basic research on inflammatory bowel disease in China. J. Dig. Dis. 8: 194-197 (2007).
Bai M, Katsanos KH, Economou M, Kamina S, Balli C, Briasoulis E, Kappas AM, Agnantis N, Tsianos EV. Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature. Scand. J. Gastroenterol. 41: 866-869 (2006). *
Baichi MM, Arifuddin RM, Mantry PS. What we have learned from 5 cases of permanent capsule retention. Gastrointest. Endosc. 64: 283-287 (2006).
Baidoo L, Lichtenstein GR. What next after infliximab? Am. J. Gastroenterol. 100: 80-83 (2005). *
Baidoo L, Regueiro M. Radiologic testing in Crohn's disease. Inflamm. Bowel Dis. 14: S181-S182 (2008).
Baier PK, Arampatzis G, Imdahl A, Hopt UT. The iliopsoas abscess: aetiology, therapy, and outcome. Langenbecks Arch. Surg. 391: 411-417 (2006). *
Bailen LS. Bones and Crohn's: should we treat Crohn's disease patients with alendronate? Inflamm. Bowel Dis. 7: 175-176 (2001). *
Bailon E, Camuesco D, Nieto A, Concha A, Arriba AF, Roman J, Ramis I, Merlos M, Zarzuelo A, Galvez J, Comalada M. The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition. Biochem. Pharmacol. 74: 1496-1506 (2007). *
Bairead E, Harmon DL, Curtis AM, Kelly Y, O'Leary C, Gardner M, Leahy DT, Vaughan P, Keegan D, O'Morain C, O'Donoghue D, Shanahan F, Parfrey NA, Quane KA. Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur. J. Hum. Genet. 11: 237-244 (2003). *
Baisse B, Fontolliet C, Bian YS, Vuilleumier H, Benhattar J. Synchronous ileal and colonic adenocarcinomas associated with Crohn's disease: report of a case with a focus on genetic alterations and carcinogenesis. J. Clin. Pathol. 57: 885-887 (2004). *
Baixauli J, Delaney CP, Wu JS, Remzi FH, Lavery IC, Fazio VW. Functional outcome and quality of life after repeat ileal pouch-anal anastomosis for complications of ileoanal surgery. Dis. Colon Rectum 47: 2-11 (2004). *
Bajaj JS, Saeian K, Varma RR, Franco J, Knox J F, Podoll J, Emmons J, Levy M, Binion DG. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am. J. Gastroenterol. 100: 1121-1125 (2005). *
Bajaj-Elliott M, Breese E, Poulsom R, Fairclough PD, MacDonald TT. Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal myofibroblasts. Am. J. Pathol. 151: 1469-1476 (1997). *
Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev. Gastroenterol. Disord. 5: 19-30 (2005).
Baker DE. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev. Gastroenterol. Disord. 4: 196-210 (2004). *
Baker DE. MMX Mesalamine. Rev. Gastroenterol. Disord. 6: 146-152 (2006).
Baker DE. Natalizumab: overview of its pharmacology and safety. Rev. Gastroenterol. Disord. 7: 38-46 (2007).
Baker DE. Certolizumab pegol: a polyethylene glycolated fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease. Rev. Gastroenterol. Disord. 8: 240-253 (2008).
Baker K, Jewell DP. Cyclosporin for the treatment of severe inflammatory bowel disease. Aliment. Pharmacol. Ther. 3: 143-149 (1989).
Baker ME, Walter J, Obuchowski NA, Achkar JP, Einstein D, Veniero JC, Vogel J, Stocchi L. Mural attenuation in normal small bowel and active inflammatory Crohn's disease on CT enterography: location, absolute attenuation, relative attenuation, and the effect of wall thickness. AJR Am. J. Roentgenol. 192: 417-423 (2009).
Baker SJ, Jacob E, Bowden GH. Crohn disease arthropathy: antigens in synovial fluid share epitopes with strains of two species of Viridans streptococci. Scand. J. Gastroenterol. 35: 287-292 (2000). *
Bakker D, Willemsen PT, van Zijderveld FG. Paratuberculosis recognized as a problem at last: a review. Vet. Q. 22: 200-204 (2000).
Baksh FK, Finkelstein SD, Ariyanayagam-Baksh SM, Swalsky PA, Klein EC, Dunn JC. Absence of Mycobacterium avium subsp. paratuberculosis in the microdissected granulomas of Crohn's disease. Mod. Pathol. 17: 1289-1294 (2004). *
Bala G, Swincow G, Rytarowska A, Czerwionka-Szaflarska M. Non-specific inflammatory bowel disease or allergic colitis in small children - what is the final diagnosis? Med. Wieku. Rozwoj. X: 475-482 (2006).
Balasubramanian K, Kumar S, Singh RR, Sharma U, Ahuja V, Makharia GK, Jagannathan NR. Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study. Magn. Reson. Imaging 27: 79-86 (2009). *
Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. 98: 833-838 (2003). *
Baldassano RN. Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's disease: pro. Why use steroids if safer therapies are available? Inflamm. Bowel Dis. 7: 338-341 (2001). *
Baldassano RN, Bradfield JP, Monos DS, Kim CE, Glessner JT, Casalunovo T, Frackelton EC, Otieno FG, Kanterakis S, Shaner JL, Smith RM, Eckert AW, Robinson LJ, Onyiah CC, Abrams DJ, Chiavacci RM, Skraban R, Devoto M, Grant SF, Hakonarson H. Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease. Clin. Gastroenterol. Hepatol. 5: 972-976 (2007).
Baldassano RN, Bradfield JP, Monos DS, Kim CE, Glessner JT, Casalunovo T, Frackelton EC, Otieno FG, Kanterakis S, Shaner JL, Smith RM, Eckert AW, Robinson LJ, Onyiah CC, Abrams DJ, Chiavacci RM, Skraban R, Devoto M, Grant SF, Hakonarson H. Association of the T300A non-synonymous variant of the ATG16L1 gene with susceptibility to paediatric Crohn's disease. Gut 56: 1171-1173 (2007). *
Baldassano RN, Schreiber S, Johnston RB Jr, Fu RD, Muraki T, MacDermott RP. Crohn's disease monocytes are primed for accentuated release of toxic oxygen metabolites. Gastroenterology 105: 60-66 (1993).
Balding J, Livingstone WJ, Conroy J, Mynett-Johnson L, Weir DG, Mahmud N, Smith OP. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm.13: 181-187 (2004). *
Balfour Sartor R. Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications. J. Clin. Gastroenterol. 41 Suppl. 1: S37-S43 (2007).
Ballinger A. Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm. Res. 58 Suppl. 1: 7-10 (2002).
Balog A, Klausz G, Gal J, Molnar T, Nagy F, Ocsovszky I, Gyulai Z, Mandi Y. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 71: 274-280 (2004).
Balsara KP, Shah CR, Maru S, Sehgal R. Laparoscopic-assisted ileo-colectomy for tuberculosis. Surg. Endosc. 19: 986-989 (2005). *
Balzola FA, Khan K, Pera A, Bonino F, Pounder RE, Wakefield AJ. Measles IgM immunoreactivity in patients with inflammatory bowel disease. Ital. J. Gastroenterol. Hepatol. 30: 378-382 (1998).
Bamba S, Lee CY, Brittan M, Preston S, Direkze N, Poulsom R, Alison M, Wright N, Otto W. Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice. J. Pathol. 209: 265-273 (2006). *
Bamias G, Cominelli F. Novel strategies to attenuate immune activation in Crohn's disease. Curr. Opin. Pharmacol. 6: 401-407 (2006).
Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr. Opin. Gastroenterol. 23: 365-369 (2007).
Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG, Rivera-Nieves J, Cominelli F. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J. Immunol. 169: 5308-5314 (2002). *
Bamias G, Martin C 3rd, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P, Cominelli F. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J. Immunol. 171: 4868-4874 (2003). *
Bamias G, Martin C, Mishina M, Ross WG, Rivera-Nieves J, Marini M, Cominelli F. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 128: 654-666 (2005). *
Bamias G, Mishina M, Nyce M, Ross WG, Kollias G, Rivera-Nieves J, Pizarro TT, Cominelli F. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc. Natl. Acad. Sci. U.S.A. 103: 8441-8446 (2006). *
Bamias G, Okazawa A, Rivera-Nieves J, Arseneau KO, De La Rue SA, Pizarro TT, Cominelli F. Commensal bacteria exacerbate intestinal inflammation but are not essential for the development of murine ileitis. J. Immunol. 178: 1809-1818 (2007). *
Bamias G, Sugawara K, Pagnini C, Cominelli F. The Th1 immune pathway as a therapeutic target in Crohn's disease. Curr. Opin. Investig. Drugs 4: 1279-1286 (2003).
Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc. Natl. Acad. Sci. U.S.A. 105: 13644-13649 (2008). *
Ban Y, Tozaki T, Taniyama M, Nakano Y, Yoneyama KI, Ban Y, Hirano T. Association studies of the IL-23R gene in autoimmune thyroid disease in the Japanese population. Autoimmunity 42: 126-130 (2009).
Banerjee R, Bhargav P, Reddy P, Gupta R, Lakhtakia S, Tandan M, Rao VG, Reddy ND. Safety and efficacy of the M2A patency capsule for diagnosis of critical intestinal patency: results of a prospective clinical trial. J. Gastroenterol. Hepatol. 22: 2060-2063 (2007). *
Banerjee S, Peppercorn MA. Inflammatory bowel disease. Medical therapy of specific clinical presentations. Gastroenterol. Clin. North Am. 31: 185-202, x (2002).
Bang UC, Nielsen AM. The use of adalimumab in severe fistulising Crohn's disease - three cases. Ugeskr. Laeger. 170: 2256 (2008).
Bank I, Busari JO. Crohn's disease, autoimmune thyroiditis, and beta-thalassemia trait in an adolescent: an unusual combination of diseases. Eur. J. Pediatr. 167: 1343-1346 (2008). *
Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J. Pathol. 199: 28-35 (2003). *
Bannantine JP, Barletta RG, Stabel JR, Paustian ML, Kapur V. Application of the genome sequence to address concerns that Mycobacterium avium subspecies paratuberculosis might be a foodborne pathogen. Foodborne Pathog. Dis. 1: 3-15 (2004).
Banner KH, Cattaneo C, Net JL, Popovic A, Collins D, Gale JD. Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br. J. Pharmacol.143: 590-598 (2004). *
Bannerjee K, Camacho-Hubner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, Sanderson IR, Croft NM. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J. Pediatr. Gastroenterol. Nutr. 38: 270-275 (2004). *
Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNFalpha) in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem. 279: 32633-32642 (2004). *
Banos Madrid R, Salama Benerroch H, Moran Sanchez S, Gallardo Sanchez F, Albadalejo Merono A, Mercader Martinez J. Lactose malabsorption in patients with inflammatory bowel disease without activity: it would be necessary to exclude the lactose products in their diet to all the patients? An. Med. Interna 21: 212-214 (2004).
Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am. J. Gastroenterol. 91: 44-48 (1996).
Bansi DS, Chapman RW, Fleming KA. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 8: 881-885 (1996).
Banville N, Broderick A, Fitzgerald R, Drumm B, McDermott M. Giant inflammatory polyposis coli as a manifestation of Crohn's disease in patients with coexistent cystic fibrosis. Pediatr. Dev. Pathol. 9: 25-30 (2006).
Baptista ML, Amarante H, Picheth G, Sdepanian VL, Peterson N, Babasukumar U, Lima HC, Kugathasan S. CARD15 and IL23R influences Crohn's disease susceptibility but not disease phenotype in a Brazilian population. Inflamm. Bowel Dis. 14: 674-679 (2008). *
Baqir M, Usman MH, Adenwalla HN, Aziz S, Noor F, Islam TU, Ahmed M, Hotiana M. Takayasu's arteritis with skin manifestations in a patient with inflammatory bowel disease: coincidence or concurrence? Clin. Rheumatol. 26: 996-998 (2007). *
Bar-Meir S. Review article: capsule endoscopy - are all small intestinal lesions Crohn's disease? Aliment. Pharmacol. Ther. 24 Suppl. 3: 19-21 (2006). *
Baratti C, De Simone A, Grassi C, Righi I, Massara PP, Pizzi M, Ferla F, Sposato J, Ardizzone S, Trabucchi E. Inflammatory colitis: classification and surgical treatment. Ann. Ital. Chir. 77: 313-317 (2006).
Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF, Cherbut C, Galmiche JP. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol. Clin. Biol. 27: 987-991 (2003). *
Barbieri D. Inflammatory bowel diseases. J. Pediatr. (Rio. J.) 76: S173-S180 (2000). *
Barbuscia M, Pratico C, Di Pietro N, Rizzo AG, Melita G, De Luca M, Castriciano G, Vita F, Sano M, Gorgone S. Diagnosis and treatment of Crohn's disease. G. Chir. 24: 428-434 (2003).
Barclay AR, Russell RK, Wilson ML, Gilmour WH, Satsangi J, Wilson DC. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J. Pediatr. May 21 [Epub ahead of print] (2009).
Bardel C, Danjean V, Hugot JP, Darlu P, Genin E. On the use of haplotype phylogeny to detect disease susceptibility loci. BMC Genet. 6: 24 (2005). *
Bardella MT, Elli L, De Matteis S, Floriani I, Torri V, Piodi L. Autoimmune disorders in patients affected by celiac sprue and inflammatory bowel disease. Ann. Med. 41: 139-143 (2009).
Barden L, Lipson A, Pert P, Walker-Smith JA. Mesalazine in childhood inflammatory bowel disease. Aliment. Pharmacol. Ther. 3: 597-603 (1989).
Bardin N, Reumaux D, Geboes K, Colombel JF, Blot-Chabaud M, Sampol J, Duthilleul P, Dignat-George F. Increased expression of CD146, a new marker of the endothelial junction in active inflammatory bowel disease. Inflamm. Bowel Dis. 12: 16-21 (2006). *
Baretton GB, Aust DE. Intraepithelial neoplasia/dysplasia - histopathology in ulcerative colitis. Pathologe. 29 Suppl. 2: 280-285 (2008).
Baricevic I, Jones DR, Nikolic JA, Nedic O. Gastrointestinal inflammation and the circulating IGF system in humans. Horm. Metab. Res. 38: 22-27 (2006).
Barish CF. Alicaforsen therapy in inflammatory bowel disease. Expert Opin. Biol. Ther. 5: 1387-1391 (2005).
Barisic GI, Krivokapic ZV, Adzic TN, Pavlovic AR, Popovic MA, Gojnic M. Fecopneumothorax and colopleural fistula - uncommon complications of Crohn's disease. BMC Gastroenterol. 6: 17 (2006). *
Barkay O, Moshkowitz M, Reif S. Crohn's disease diagnosed by wireless capsule endoscopy in adolescents with abdominal pain, protein-losing enteropathy, anemia and negative endoscopic and radiologic findings. Isr. Med. Assoc. J. 7: 216-218 (2005). *
Barkholt L, Lofberg R. Resetting the immune system in refractory Crohn's disease: is autologous hematopoietic stem cell transplantation the way forward? Gastroenterology 128: 786-799 (2005). *
Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin. Exp. Immunol. 149: 217-225 (2007). *
Barmada MM, Brant SR, Nicolae DL, Achkar JP, Panhuysen CI, Bayless TM, Cho JH, Duerr RH. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm. Bowel Dis. 10: 513-520 (2004). *
Barnes BH, Borowitz SM, Saulsbury FT, Hellems M, Sutphen JL. Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. J. Pediatr. Gastroenterol. Nutr. 38: 509-512 (2004). *
Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *
Barnes SL, Vidrich A, Wang ML, Wu GD, Cominelli F, Rivera-Nieves J, Bamias G, Cohn SM. Resistin-like molecule beta (RELMbeta/FIZZ2) is highly expressed in the ileum of SAMP1/YitFc mice and is associated with initiation of ileitis. J. Immunol. 179: 7012-7020 (2007). *
Barnich N, Aguirre JE, Reinecker HC, Xavier R, Podolsky DK. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-kappaB activation in muramyl dipeptide recognition. J. Cell. Biol. 170: 21-26 (2005). *
Barnich N, Bringer MA, Claret L, Darfeuille-Michaud A. Involvement of lipoprotein NlpI in the virulence of adherent invasive Escherichia coli strain LF82 isolated from a patient with Crohn's disease. Infect. Immun. 72: 2484-2493 (2004). *
Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel JF, Darfeuille-Michaud A. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J. Clin. Invest. 117: 1566-1574 (2007). *
Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr. Opin. Gastroenterol. 23: 16-20 (2007).
Barnich N, Darfeuille-Michaud A. Role of bacteria in the etiopathogenesis of inflammatory bowel disease. World J. Gastroenterol. 13: 5571-5576 (2007). *
Barnich N, Hisamatsu T, Aguirre JE, Xavier R, Reinecker HC, Podolsky DK. GRIM-19 interacts with NOD2 and serves as down-stream effector of anti-bacterial function in intestinal epithelial cells. J. Biol. Chem. 280: 19021-19026 (2005). *
Baron FA, Hermanne JP, Dowlati A, Weber T, Thiry A, Fassotte MF, Fillet G, Beguin Y. Bronchiolitis obliterans organizing pneumonia and ulcerative colitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 21: 951-954 (1998).
Baron S, Turck D, Leplat C, Merle V, Gower-Rousseau C, Marti R, Yzet T, Lerebours E, Dupas JL, Debeugny S, Salomez JL, Cortot A, Colombel JF. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 54: 357-363 (2005). *
Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig. Dis. Sci. 38: 1851-1856 (1993).
Barratt HS, Kalantzis C, Polymeros D, Forbes A. Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status. Aliment. Pharmacol. Ther. 21: 141-147 (2005). *
Barrau V. What can be expected from digestive tract MRI? J. Chir. (Paris) 144: 398-402 (2007).
Barreau F, Meinzer U, Chareyre F, Berrebi D, Niwa-Kawakita M, Dussaillant M, Foligne B, Ollendorff V, Heyman M, Bonacorsi S, Lesuffleur T, Sterkers G, Giovannini M, Hugot JP. CARD15/NOD2 is required for Peyer's patches homeostasis in mice. PLoS ONE 2: e523 (2007). *
Barreiro de Acosta M, Seijo Rios S, Dominguez Munoz J. Life-threatenig acute lower gastrointestinal bleeding in patients with Crohn's disease. Rev. Esp. Enferm. Dig. 99: 388-391 (2007).
Barreiro-de Acosta M, Enrique Dominguez-Munoz J, Concepcion Nunez-Pardo de Vera M, Lozano-Leon A, Lorenzo A, Pena S. Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations. Eur. J. Gastroenterol. Hepatol. 19: 73-78 (2007).
Barreiro-de Acosta M, Pena AS. Clinical applications of NOD2/CARD15 mutations in Crohn's disease. Acta Gastroenterol. Latinoam. 37: 49-54 (2007).
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40: 955-962 (2008). *
Barrett JS, Irving PM, Shepherd SJ, Muir JG, Gibson PR. Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. Aliment. Pharmacol. Ther. Apr 16 [Epub ahead of print] (2009). *
Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 13: 1424-1429 (2007). *
Barrie III AM, Plevy SE. The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation. Clin. Appl. Immunol. Rev. 5: 225-240 (2005). *
Barta Z, Csipo I, Antal-Szalmas P, Sipka S, Szabo G, Szegedi G. Anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease. Orv. Hetil. 142: 2303-2307 (2001).
Barta Z, Csipo I, Mekkel G, Zeher M, Majoros L, Bernstein CN, Collins MT. Seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease. J. Clin. Microbiol. 42: 5432-5433 (2004). *
Barta Z, Csipo I, Szabo GG, Szegedi G. Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease. World J. Gastroenterol. 9: 2308-2312 (2003). *
Barta Z, Toth L, Szabo GG, Szegedi G, Zeher M. Intravenous pulse cyclophosphamide therapy in Crohn's disease and ulcerative colitis. Gut 53: 1058 (2004). *
Barta Z, Toth L, Zeher M. Pulse cyclophosphamide therapy for inflammatory bowel disease. World J. Gastroenterol. 12: 1278-1280 (2006). *
Bartel G, Weiss I, Turetschek K, Schima W, Puspok A, Waldhoer T, Gasche C. Ingested matter affects intestinal lesions in Crohn's disease. Inflamm. Bowel Dis. 14: 374-382 (2008). *
Bartels LE, Jorgensen SP, Agnholt J, Kelsen J, Hvas CL, Dahlerup JF. 1,25-Dihydroxyvitamin D3 and dexamethasone increase interleukin-10 production in CD4+ T cells from patients with Crohn's disease. Int. Immunopharmacol. 7: 1755-1764 (2007).
Barthel HR, Gille T, Halbsguth A, Kramer M. Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J. Gastroenterol. Hepatol. 20: 1464-1465 (2005). *
Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, Mambrini P, Saint-Paul MC, Delmont JP, Salducci J, Grimaud JC, Sahel J. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am. J. Gastroenterol. 94: 2141-2148 (1999). *
Barthet M, Juhan V, Gasmi M, Grimaud JC. Imaging of perianal Crohn's disease. Gastroenterol. Clin. Biol. 28: S52-S60 (2004).
Bartholo RM, Zaltman C, Elia C, Cardoso AP, Flores V, Lago P, Cassabian L, Carvalho Dorileo F, Lapa-E-Silva JR. Bronchial hyperresponsiveness and analysis of induced sputum cells in Crohn's disease. Braz. J. Med. Biol. Res. 38: 197-203 (2005). *
Bartnik W. Inflammatory bowel disease - Polish contribution. J. Physiol. Pharmacol. 54 Suppl. 3: 205-210 (2003). *
Barton A, Eyre S, Bowes J, Ho P, John S, Worthington J. Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. Arthritis Rheum. 52: 752-758 (2005). *
Barton SG, Rampton DS, Winrow VR, Domizio P, Feakins RM. Expression of heat shock protein 32 (hemoxygenase-1) in the normal and inflamed human stomach and colon: an immunohistochemical study. Cell Stress Chaperones 8: 329-334 (2003). *
Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment. Pharmacol. Ther. 18: 1121-1127 (2003). *
Bartram SA, Peaston RT, Rawlings DJ, Walshaw D, Francis RM, Thompson NP. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J. Gastroenterol. 12: 5680-5686 (2006). *
Bartsch H, Nair J. Accumulation of lipid peroxidation-derived DNA lesions: potential lead markers for chemoprevention of inflammation-driven malignancies. Mutat. Res. 591: 34-44 (2005).
Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch. Surg. 391: 499-510 (2006). *
Bartt RE. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 19: 341-349 (2006).
Bartunkova J, Kolarova I, Sediva A, Holzelova E. Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. Clin. Immunol. 102: 162-168 (2002). *
Basile G, Chiarenza S, Di Mari P, Leanza S, Boscarelli G, Buffone A. Crohn's disease in the elderly. Ann. Ital. Chir. 77: 247-251 (2006).
Basili G, Lorenzetti L, Celona G, Biondi G, Preziuso E, Angrisano C, Goletti O, Belcari C, Venturini G. Gallstone ileus in patient with Crohn's disease: report of a clinical observation. Surg. Endosc. 20: 703-704 (2006).
Basit AW. Advances in colonic drug delivery. Drugs 65: 1991-2007 (2005).
Basler T, Geffers R, Weiss S, Valentin-Weigand P, Goethe R. Mycobacterium avium subspecies induce differential expression of pro-inflammatory mediators in a murine macrophage model: Evidence for enhanced pathogenicity of Mycobacterium avium subspecies paratuberculosis. Immunobiology 213: 879-888 (2008).
Basler T, Jeckstadt S, Valentin-Weigand P, Goethe R. Mycobacterium paratuberculosis, Mycobacterium smegmatis, and lipopolysaccharide induce different transcriptional and post-transcriptional regulation of the IRG1 gene in murine macrophages. J. Leukoc. Biol. 79: 628-638 (2006). *
Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 53: 1471-1478 (2004). *
Bastida Pa G, Nos Mate P, Aguas Peri M, Beltran Niclas B, Rodriguez Sole M, Ponce Garcia J. Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease. Gastroenterol. Hepatol. 30: 511-516 (2007).
Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. Am. J. Gastroenterol. 100: 2254-2261 (2005). *
Basu SK, Govardhan CP, Jung CW, Margolin AL. Protein crystals for the delivery of biopharmaceuticals. Expert Opin. Biol. Ther. 4: 301-317 (2004).
Bat B, Lodowska J, Orchel A, Parfiniewicz B, Weglarz L, Dzierzewicz Z, Wilczok T. Evaluation of biotransformation of sulphasalazine in the colon epithelial Caco-2 cells. Acta Pol. Pharm. 61 Suppl.: 8-10 (2004).
Bataille F, Klebl F, Rummele P, Schroeder J, Farkas S, Wild PJ, Furst A, Hofstadter F, Scholmerich J, Herfarth H, Rogler G. Morphological characterisation of Crohn's disease fistulae. Gut 53: 1314-1321 (2004). *
Bataille F, Rohrmeier C, Bates R, Weber A, Rieder F, Brenmoehl J, Strauch U, Farkas S, Furst A, Hofstadter F, Scholmerich J, Herfarth H, Rogler G. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm. Bowel Dis. 14: 1514-1527 (2008).
Bateson MC. Advances in gastroenterology and hepatology. Postgrad. Med. J. 76: 328-332 (2000). *
Batra A, Zeitz M, Siegmund B. Adipokine signaling in inflammatory bowel disease. Inflamm. Bowel Dis. Apr 30 [Epub ahead of print] (2009).
Batra AK, Levey JM, Trister J, Patwardhan R. Pyoderma gangrenosum in a patient with collagenous colitis. J. Am. Acad. Dermatol. 49: 277-279 (2003).
Batta AK, Tint GS, Xu G, Shefer S, Salen G. Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid. J. Lipid Res. 39: 1641-1646 (1998). *
Battaglia E, Biancone L, Resegotti A, Emanuelli G, Fronda GR, Camussi G. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am. J. Gastroenterol. 94: 3279-3284 (1999).
Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 40: 470-474 (1997). *
Bauditz J, Lochs H, Schreiber S. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N. Engl. J. Med. 338: 334 (1998).
Bauditz J, Ruckert Y, Raedler A, Nikolaus S, Lochs H, Schreiber S. Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease. Lancet 345: 1445 (1995).
Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 53: 609-612 (2004). *
Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196-200 (2002). *
Bauerfeind P, Beglinger C, Beltinger J, Braegger C, Eigenmann F, Fried M, Guyot J, Hurlimann R, Michetti P, Seibold F, Straumann A. Infliximab - practical guidelines for the treatment of Crohn's disease. Rev. Med. Suisse. 2: 1807-1815 (2006).
Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int. J. Clin. Pharmacol. Ther. 43: 7-11 (2005).
Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17: 425-431 (2003).
Baum CL, Selhub J, Rosenberg IH. Antifolate actions of sulfasalazine on intact lymphocytes. J. Lab. Clin. Med. 97: 779-784 (1981).
Baumgart DC. What's new in inflammatory bowel disease in 2008? World J. Gastroenterol. 14: 329-330 (2008). *
Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, Gentz E, Molnar T, Nagy F, Lonovics J, Lochs H, Wiedenmann B, Nickel R, Witt H, Dignass A. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of Toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion 76: 196-202 (2007). *
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640 (2007). *
Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB. Transient cytokine-Induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am. J. Gastroenterol. 104: 868-876 (2009).
Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, Dignass AU. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut 54: 228-236 (2005). *
Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am. J. Gastroenterol. 101: 1048-1056 (2006). *
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657 (2007). *
Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, Lehnardt S, Dorffel Y, Sturm A, Scheffold A, Schmitz J, Radbruch A. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin. Exp. Immunol. [In Press] (2009). *
Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 1: 403-418 (2007). *
Baxter PS, Dickson JA, Variend S, Taylor CJ. Intestinal disease in cystic fibrosis. Arch. Dis. Child. 63: 1496-1497 (1988). *
Bayerdorffer E, Bock H. Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease. Leber. Magen. Darm. 18: 104-113 (1988).
Bayle FJ, Bouvard MP. Anorexia nervosa and Crohn's disease dual diagnosis: a case study. Eur. Psychiatry 18: 421-422 (2003).
Bayless TM, Picco MF, LaBuda MC. Genetic anticipation in Crohn's disease. Am. J. Gastroenterol. 93: 2322-2325 (1998). *
Bayraktar Y, Arslan S, Saglam F, Uzunalimoglu B, Kayhan B. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients? Hepatogastroenterology 45: 2064-2072 (1998).
Beattie RM. Enteral nutrition as primary therapy in childhood Crohn's disease: control of intestinal inflammation and anabolic response. JPEN J. Parenter. Enteral Nutr. 29: S151-S159 (2005). *
Beattie RM, Croft NM, Fell JM, Afzal NA, Heuschkel RB. Inflammatory bowel disease. Arch. Dis. Child. 91: 426-432 (2006). *
Beaugerie L. What is an inflammatory bowel disease? Rev. Prat. 55: 943-948 (2005).
Beaugerie L, Lamy P, Ganne N, Carbonnel F, Le Quintrec Y, Cosnes J, Gendre JP. Morbid associations in Crohn's disease. Study of a series of 832 patients. Presse. Med. 26: 892-894 (1997).
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of disabling Crohn�s disease. Gastroenterology 130: 650-656 (2006). *
Beaulieu DB, Ananthakrishnan AN, Issa M, Rosenbaum L, Skaros S, Newcomer JR, Kuhlmann RS, Otterson MF, Emmons J, Knox J, Binion DG. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm. Bowel Dis. 15: 25-28 (2009).
Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr. Opin. Gastroenterol. 20: 318-327 (2004).
Bebb JR, Scott BB. How effective are the usual treatments for Crohn's disease? Aliment. Pharmacol. Ther. 20: 151-159 (2004). *
Becheanu G, Manuc M, Dumbrava M, Herlea V, Hortopan M, Costache M. The evaluation of interstitial Cajal cells distribution in non-tumoral colon disorders. Rom. J. Morphol. Embryol. 49: 351-355 (2008).
Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm. Bowel Dis. 5: 44-60 (1999). *
Beck PL, Wallace JL. Cytokines in inflammatory bowel disease. Mediators Inflamm. 6: 95-103 (1997). *
Beck PL, Xavier R, Wong J, Ezedi I, Mashimo H, Mizoguchi A, Mizoguchi E, Bhan AK, Podolsky DK. Paradoxical roles of different nitric oxide synthase isoforms in colonic injury. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G137-G147 (2004). *
Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, Bechthold O, Frick J, Galle PR, Autenrieth I, Neurath MF. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112: 693-706 (2003). *
Becker E, Horn S, Hussla B, Irle H, Knorr I, Korsukewitz C, Pottins I, Rohwetter M, Schuhknecht P, Timner K. Guidelines for the sociomedical assessment of performance in patients suffering from inflammatory bowel disease. Gesundheitswesen 67: 396-415 (2005).
Becker KG. Comparative genetics of type 1 diabetes and autoimmune disease: common loci, common pathways? Diabetes 48: 1353-1358 (1999). *
Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 95: 9979-9984 (1998). *
Becker ML, Rose CD. Blau syndrome and related genetic disorders causing childhood arthritis. Curr. Rheumatol. Rep. 7: 427-433 (2005).
Becker SA. Perianal Crohn's disease. Isr. Med. Assoc. J. 9: 495 (2007).
Beckler DR, Elwasila S, Ghobrial G, Valentine JF, Naser SA. Correlation between rpoB gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin and rifampicin resistance for treatment of Crohn's disease. World J. Gastroenterol. 14: 2723-2730 (2008). *
Beckly JB, Hancock L, Geremia A, Cummings JR, Morris A, Cooney R, Pathan S, Guo C, Jewell DP. Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease. Inflamm. Bowel Dis. 14: 500-507 (2008). *
Beddy D, Mulsow J, Watson RW, Fitzpatrick JM, O'connell PR. Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. Br. J. Surg. 93: 1290-1296 (2006). *
Beddy D, Watson RW, Fitzpatrick JM, O'Connell PR. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease. Br. J. Surg. 91: 72-77 (2004). *
Beddy DJ, Watson WR, Fitzpatrick JM, O'Connell PR. Critical involvement of stress-activated mitogen-activated protein kinases in the regulation of intracellular adhesion molecule-1 in serosal fibroblasts isolated from patients with Crohn's disease. J. Am. Coll. Surg. 199: 234-242 (2004). *
Bedford PA, Todorovic V, Westcott ED, Windsor AC, English NR, Al-Hassi HO, Raju KS, Mills S, Knight SC. Adipose tissue of human omentum is a major source of dendritic cells, which lose MHC class II and stimulatory function in Crohn's disease. J. Leukoc. Biol. 80: 546-554 (2006). *
Bedioui H, Jouini M, Ksantini R, Fteriche F, Chebbi F, Daghfous A, Ayadi S, Kacem M, Boubaker J, Filali A, Ben Safta Z. A previously unreported late complication of Finney strictureplasty. J. Chir. (Paris) 144: 69-71 (2007).
Bedioui H, Mouelhi L, Jouini M, Nouira K, Najjar T, Bensafta Z. Crohn colitis complicated by a gastrocolic and a colovesical fistula: diagnosis and therapeutic management. Presse. Med. Feb 11 [Epub ahead of print] (2009).
Bedioui H, Nouira K, Chaker Y, Chebbi F, Ksantini R, Daghfous A, Rebai W, Fteriche F, Ammous A, Jouini M, Kacem MJ, Bensafta Z. Radiologic diagnosis of enterosalpingeal fistula complicating Crohn's disease. Gastroenterol. Clin. Biol. 32: 158-161 (2008).
Bednarz W, Czopnik P, Wojtczak B, Olewinski R, Domoslawski P, Spodzieja J. Analysis of results of surgical treatment in Crohn's disease. Hepatogastroenterology 55: 998-1001 (2008).
Beer TW, Edwards CW. Pulmonary nodules due to reactive systemic amyloidosis (AA) in Crohn's disease. Thorax 48: 1287-1288 (1993). *
Befeler AS, Lissoos TW, Schiano TD, Conjeevaram H, Dasgupta KA, Millis JM, Newell KA, Thistlethwaite JR, Baker AL. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 65: 393-396 (1998).
Beglinger Ch. Treatment of Crohn's disease. Ther. Umsch. 60: 159-163 (2003).
Beglinger Ch, Gyr N. Incapacity to work, occupational disability and disability in inflammatory bowel disease. Ther. Umsch. 64: 457-462 (2007).
Begue B, Dumant C, Bambou JC, Beaulieu JF, Chamaillard M, Hugot JP, Goulet O, Schmitz J, Philpott DJ, Cerf-Bensussan N, Ruemmele FM. Microbial induction of CARD15 expression in intestinal epithelial cells via Toll-like receptor 5 triggers an antibacterial response loop. J. Cell. Physiol. 209: 241-252 (2006). *
Behm B, Bickston S. Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD006893 (2008). *
Behm BW, Bickston SJ. Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis. Curr. Treat. Options Gastroenterol. 10: 171-177 (2007).
Behr MA, Bruere P, Oxlade O. Global rates of Crohn's disease. Inflamm. Bowel Dis. 14: 1170-1172 (2008).
Behr MA, Hanley J. Antimycobacterial therapy for Crohn's disease: a reanalysis. Lancet Infect. Dis. 8: 344 (2008).
Behr MA, Kapur V. The evidence for Mycobacterium paratuberculosis in Crohn's disease. Curr. Opin. Gastroenterol. 24: 17-21 (2008). *
Behr MA, Schurr E. Mycobacteria in Crohn's disease: a persistent hypothesis. Inflamm. Bowel Dis. 12: 1000-1004 (2006). *
Behr MA, Semret M, Poon A, Schurr E. Crohn's disease, mycobacteria, and NOD2. Lancet Infect. Dis. 4: 136-137 (2004).
Behrens R, Segerer H, Bowing B, Bender SW. Crohn's disease in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 9: 528-531 (1989).
Beigel F, Jurgens M, Filik L, Bader L, Luck C, Goke B, Ochsenkuhn T, Brand S, Seiderer J. Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease. Inflamm. Bowel Dis. Feb 13 [Epub ahead of print] (2009).
Beil WJ, McEuen AR, Schulz M, Wefelmeyer U, Kraml G, Walls AF, Jensen-Jarolim E, Pabst R, Pammer J. Selective alterations in mast cell subsets and eosinophil infiltration in two complementary types of intestinal inflammation: ascariasis and Crohn's disease. Pathobiology 70: 303-313 (2003).
Beitz JM. Continent diversions: the new gold standards of ileoanal reservoir and neobladder. Ostomy Wound Manage. 50: 26-35 (2004).
Beji S, Kaaroud H, Ben Moussa F, Goucha R, Abderrahim E, El Younsi F, Ben Maiz H. Renal amyloidosis complicating the outcome of chronic inflammatory colitis. Presse. Med. 33: 862-865 (2004).
Bekpen C, Marques-Bonet T, Alkan C, Antonacci F, Leogrande MB, Ventura M, Kidd JM, Siswara P, Howard JC, Eichler EE. Death and resurrection of the human IRGM gene. PLoS Genet. 5: e1000403 (2009). *
Belaiche J, Chapelier N, Wertz S, Louis E. Innovative therapies in inflammatory bowel disease at the CHU. Rev. Med. Liege. 62 Spec. No: 63-67 (2008).
Belaiche J, Louis E. Early obstructive colon after treatment of active refractory Crohn's disease with infliximab. Gastroenterol. Clin. Biol. 27: 1045 (2003).
Belaiche J, Louis E. Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies. Rev. Med. Liege 55: 827-832 (2000).
Belazarian L. New insights and therapies for teenage psoriasis. Curr. Opin. Pediatr. 20: 419-424 (2008).
Belda A, Hinojosa J, Serra B, Garcia L, Merino C, Belda A, Moles JR. Systemic candidiasis and infliximab therapy. Gastroenterol. Hepatol. 27: 365-367 (2004).
Belizon A, Sardinha CT, Sher ME. Converted laparoscopic colectomy: what are the consequences? Surg. Endosc. 20: 947-951 (2006). *
Belkahla N, Maamouri N, Ouerghi H, Ben Ammar A. Role of intestinal flora in inflammatory bowel disease and probiotics place in their management. Tunis. Med. 83: 132-136 (2005).
Bell AJ, Price AB, Forbes A, Ciclitira PJ, Groves C, Nicholls RJ. Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Colorectal Dis. 8: 402-410 (2006). *
Bell SJ, Chisholm SA, Owen RJ, Borriello SP, Kamm MA. Evaluation of Helicobacter species in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18: 481-486 (2003). *
Bell SJ, Rigby R, English N, Mann SD, Knight SC, Kamm MA, Stagg AJ. Migration and maturation of human colonic dendritic cells. J. Immunol. 166: 4958-4967 (2001). *
Belling R, Woods L, McLaren S. Stakeholder perceptions of specialist inflammatory bowel disease nurses' role and personal attributes. Int. J. Nurs. Pract. 14: 67-73 (2008).
Bello C, Goldstein F, Thornton JJ. Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am. J. Gastroenterol. 86: 460-466 (1991).
Bellolio R F, Zuniga A JM, Wagner H P, Pinedo M G, Duarte G I, Zuniga D A. Ileorectal anastomosis in the surgical treatment of ulcerative colitis: long-term results. Rev. Med. Chil. 136: 1121-1126 (2008).
Belloni Fortina A, Piaserico S, Zattra E, Alaibac M. Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn's disease. Melanoma Res. 15: 223-224 (2005).
Belluzzi A. n-3 Fatty acids for the treatment of inflammatory bowel diseases. Proc. Nutr. Soc. 61: 391-395 (2002). *
Belluzzi A. Polyunsaturated fatty acids (n-3 PUFAs) and inflammatory bowel disease (IBD): pathogenesis and treatment. Eur. Rev. Med. Pharmacol. Sci. 8: 225-229 (2004).
Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F. Polyunsaturated fatty acids and inflammatory bowel disease. Am. J. Clin. Nutr. 71: 339S-342S (2000). *
Belluzzi A, Roda G, Tonon F, Soleti A, Caponi A, Tuci A, Roda A, Roda E. A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: a pilot study. World J. Gastroenterol. 13: 1575-1578 (2007). *
Belmiro CL, Souza HS, Elia CC, Castelo-Branco MT, Silva FR, Machado RL, Pavao MS. Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease. Int. J. Colorectal Dis. 20: 295-304 (2005). *
Belniak E, Stelmasiak Z, Papuc E. Multiple sclerosis and other autoimmune diseases. Neurol. Neurochir. Pol. 41: 259-266 (2007).
Belousova E. Epidemiology of inflammatory bowel disease in Russia. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, p. 31 (2006). *
Beltinger J, Froehlich F. Patients with inflammatory bowel disease in specialist gastroenterology practice: a prospective survey. Schweiz. Rundsch. Med. Prax. 94: 459-465 (2005).
Beltran B, Nos P, Bastida G, Iborra M, Hoyos M, Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut 55: 1670-1671 (2006). *
Ben Hamida KS, Serghini M, Ksontini I, Kedadi H, Ben Yaghlene L, Bougassas W, Dougui MH. Bone loss owing to inflammatory bowel disease: prospective study about 50 cases. Tunis. Med. 87: 144-148 (2009).
Ben Temime L, Gherib BS, Daldoul S, Bel Hadj Salah R, Abdesselem Mel M, Zaouche A. Adenocarcinoma at the site of ileo-anal anastomosis in Crohn's disease: report of a case. Tunis. Med. 83: 55-58 (2005).
Ben-Horin S, Avidan B, Yanai H, Lang A, Chowers Y, Bar-Meir S. Familial clustering of Crohn's disease in Israel: prevalence and association with disease severity. Inflamm. Bowel Dis. 15: 171-175 (2009). *
Ben-Horin S, Chowers Y. Neuroimmunology of the gut: physiology, pathology, and pharmacology. Curr. Opin. Pharmacol. 8: 490-495 (2008).
Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, de Miera IS, Chowers Y, Moran GW. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and C. difficile infection. Clin. Gastroenterol. Hepatol. Jun 9 [Epub ahead of print] (2009).
Benchimol E, Seow Ch, Steinhart A, Griffiths A. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2: CD006792 (2008). *
Bendet N, Scapa E, Cohen O, Bloch O, Aharoni D, Ramot Y, Weiss M, Halevi A, Rapoport MJ. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection. Scand. J. Gastroenterol. 39: 650-656 (2004). *
Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand. J. Gastroenterol. Jan 13 [Epub ahead of print] (2009). *
Bene J, Komlosi K, Magyari L, Talian G, Horvath K, Gasztonyi B, Miheller P, Figler M, Mozsik G, Tulassay Z, Melegh B. Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. Br. J. Nutr. 98: 345-350 (2007). *
Bene J, Magyari L, Talian G, Komlosi K, Gasztonyi B, Tari B, Varkonyi A, Mozsik G, Melegh B. Prevalence of SLC22A4, SLC22A5 and CARD15 gene mutations in Hungarian pediatric patients with Crohn's disease. World J. Gastroenterol. 12: 5550-5553 (2006). *
Bene L, Fust G, Huszti Z, Hernadi Z, Fekete B, Meszaros M, Veres A, Kovacs A, Miklos K, Singh M, Romics L, Prohaszka Z. Impaired humoral immune response against mycobacterial 65-kDa heat shock protein (HSP65) in patients with inflammatory bowel disease. Dig. Dis. Sci. 47: 1432-1437 (2002). *
Benes Z. Crohn's disease and infectious agents. Klin. Mikrobiol. Infekc. Lek. 11: 15-19 (2005).
Bengtson MB, Solberg C, Aamodt G, Jahnsen J, Moum B, Sauar J, Vatn MH; Ibsen Study Group. Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease. Inflamm. Bowel Dis. May 11 [Epub ahead of print] (2009).
Bengtson MB, Solberg C, Aamodt G, Sauar J, Jahnsen J, Moum B, Lygren I, Vatn MH; IBSEN study group. Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years. Journal of Crohn's and Colitis 3: 92-99 (2009).
Beniada A, Benoist G, Maurel J, Dreyfus M. Inflammatory bowel disease and pregnancy: report of 76 cases and review of the literature. J. Gynecol. Obstet. Biol. Reprod. (Paris) 34: 581-588 (2005).
Benjamin J, Makharia GK, Ahuja V, Kalaivani M, Joshi YK. Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease. World J. Gastroenterol. 14: 1399-1405 (2008). *
Benjamin J, Makharia GK, Joshi YK. Association between intestinal permeability and anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease. Inflamm. Bowel Dis. 14: 1610-1611 (2008).
Benjamin J, Makharia GK, Kalaivani M, Joshi YK. Nutritional status of patients with Crohn's disease. Indian J. Gastroenterol. 27: 195-200 (2008). *
Benoni C, Nilsson A. Smoking habits in patients with inflammatory bowel disease. A case-control study. Scand. J. Gastroenterol. 22: 1130-1136 (1987).
Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm. Bowel Dis. 14: 7-12 (2008). *
Bensoussan M, Jovenin N, Garcia B, Vandromme L, Jolly D, Bouche O, Thiefin G, Cadiot G. Complementary and alternative medicine use by patients with inflammatory bowel disease. Gastroenterol. Clin. Biol. 30: 14-23 (2006). *
Bentley RW, Keenan JI, Gearry RB, Kennedy MA, Barclay ML, Roberts RL. Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjects. Am. J. Gastroenterol. 103: 1168-1172 (2008). *
Bentsen BS, Moum B, Ekbom A. Incidence of inflammatory bowel disease in children in southeastern Norway: a prospective population-based study 1990-94. Scand. J. Gastroenterol. 37: 540-545 (2002). *
Berger P, Wolf R, Flierman A, den Dunnen WF, Hoekstra HJ. Myositis as the first manifestation of an exacerbation of Crohn's disease. Ned. Tijdschr. Geneeskd. 151: 1295-1298 (2007).
Bergman L, Lindblom JB, Safwenberg J, Krause U. HL-A frequencies in Crohn's disease and ulcerative colitis. Tissue Antigens 7: 145-150 (1976).
Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 23: 841-855 (2006). *
Bergman R, Sloots CE. Diagnostic image (246). A man with faecal production of the umbilicus. Ned. Tijdschr. Geneeskd. 149: 1940 (2005).
Bergquist A, Lindberg G, Saarinen S, Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J. Hepatol. 42: 252-256 (2005). *
Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, Prytz H, Hultcrantz R, Loof LA, Sandberg-Gertzen H, Almer S, Askling J, Ehlin A, Ekbom A. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin. Gastroenterol. Hepatol. 6: 939-943 (2008).
Berkelhammer C, Andrejic J, Mohammed A. Endocarditis in Crohn's disease. Inflamm. Bowel Dis. Dec 9 [Epub ahead of print] (2008).
Berkelhammer C, Debre M, Gutti P. Piriformis muscle abscess complicating Crohn's ileitis. Inflamm. Bowel Dis. 11: 1028-1029 (2005). *
Berkelhammer C, Mohammed A, Zalzaleh G, Grela J, Blumstein A, Stein R. Spontaneous multiperforation in lymphomatous colitis masquerading as Crohn's disease: 2 cases. Inflamm. Bowel Dis. 14: 1172-1173 (2008).
Berlec A, Strukelj B. Novel applications of recombinant lactic acid bacteria in therapy and in metabolic engineering. Recent Pat. Biotechnol. 3: 77-87 (2009).
Bermejo F, Lopez-Sanroman A, Hinojosa J, Castro L, Jurado C, Gomez-Beldal AB. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev. Esp. Enferm. Dig. 96: 94-101 (2004).
Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Perez-Calle JL, Vera I, Menchen L, Martin-Arranz MD, Opio V, Carneros JA, Van-Domselaar M, Mendoza JL, Luna M, Lopez P, Calvo M, Algaba A. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment. Pharmacol. Ther. 28: 623-628 (2008). *
Bermejo F, San Roman AL, Algaba A, Van Domselaar M, Carneros JA, Rivero M, Piqueras B, Paz Valer M. Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab. Gastroenterol. Hepatol. 31: 629-632 (2008).
Bermejo PE, Burgos A. Neurological complications of inflammatory bowel disease. Med. Clin. (Barc.) 130: 666-675 (2008).
Bernal I, Domenech E, Garcia-Planella E, Marin L, Manosa M, Navarro M, Cabre E, Gassull MA. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig. Dis. Sci. 51: 2165-2169 (2006). *
Bernard A, Langille M, Hughes S, Rose C, Leddin D, Veldhuyzen van Zanten S. A systematic review of patient inflammatory bowel disease information resources on the world wide web. Am. J. Gastroenterol. 102: 2070-2077 (2007). *
Bernardes-Silva CF, Damiao AO, Sipahi AM, Laurindo FR, Iriya K, Lopasso FP, Buchpiguel CA, Lordello ML, Agostinho CL, Laudanna AA. Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress. Dig. Dis. Sci. 49: 1569-1574 (2004). *
Berndt U, Bartsch S, Philipsen L, Danese S, Wiedenmann B, Dignass AU, Hammerle M, Sturm A. Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J. Immunol. 179: 295-304 (2007). *
Bernhardt WM, Schefold JC, Weichert W, Rudolph B, Frei U, Groneberg DA, Schindler R. Amelioration of anemia after kidney transplantation in severe secondary oxalosis. Clin. Nephrol. 65: 216-221 (2006).
Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, D'Armiento F, Romeo EF, Cucchiara S. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig. Liver Dis. 38: 381-387 (2006).
Berni Canani R, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig. Liver Dis. 40: 547-553 (2008).
Bernklev T, Jahnsen J, Aadland E, Sauar J, Schulz T, Lygren I, Henriksen M, Stray N, Kjellevold O, Vatn M, Moum B; IBSEN Study Group. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand. J. Gastroenterol. 39: 365-373 (2004). *
Bernklev T, Jahnsen J, Henriksen M, Lygren I, Aadland E, Sauar J, Schulz T, Stray N, Vatn M, Moum B. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 12: 402-412 (2006). *
Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm. Bowel Dis. 11: 909-918 (2005). *
Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold O, Aadland E, Vatn M, Moum B. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur. J. Gastroenterol. Hepatol. 17: 1037-1045 (2005).
Bernstein CN. Challenges in designing a randomized trial of surveillance colonoscopy in IBD. Inflamm. Bowel Dis. 4: 132-141 (1998). *
Bernstein CN. Limiting fracture risk in Crohn's disease: is there anything better than calcium and vitamin D? Clin. Gastroenterol. Hepatol. 3: 110-112 (2005). *
Bernstein CN. Osteoporosis and other complications of inflammatory bowel disease. Curr. Opin. Gastroenterol. 18: 428-434 (2002).
Bernstein CN. Neoplasia in inflammatory bowel disease: surveillance and management strategies. Curr. Gastroenterol. Rep. 8: 513-518 (2006).
Bernstein CN. Inflammatory bowel diseases as secondary causes of osteoporosis. Curr. Osteoporos. Rep. 4: 116-123 (2006).
Bernstein CN. Is hyperhomocysteinemia associated with osteoporosis in patients with Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 550-551 (2007). *
Bernstein CN. Section editor's commentary. Infliximab as first-line therapy for Crohn's disease. Inflamm. Bowel Dis. 8: 63-65 (2002). *
Bernstein CN. Assessing environmental risk factors affecting the inflammatory bowel diseases: a joint workshop of the Crohn's & Colitis Foundations of Canada and the USA. Inflamm. Bowel Dis. 14: 1139-1146 (2008). *
Bernstein CN. Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr. Gastroenterol. Rep. 4: 513-516 (2002).
Bernstein CN, Blanchard JF. Viruses and inflammatory bowel disease: is there evidence for a causal association? Inflamm. Bowel Dis. 6: 34-39 (2000). *
Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 85: 430-434 (2001).
Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854-862 (2001). *
Bernstein CN, Blanchard JF, Rawsthorne P, Collins MT. Population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease and ulcerative colitis. J. Clin. Microbiol. 42: 1129-1135 (2004). *
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am. J. Gastroenterol. 96: 1116-1122 (2001). *
Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm. Bowel Dis. 8: 356-361 (2002). *
Bernstein CN, Greenberg H, Boult I, Chubey S, Leblanc C, Ryner L. A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn's disease. Am. J. Gastroenterol. 100: 2493-2502 (2005). *
Bernstein CN, Leslie WD. Osteoporosis and inflammatory bowel disease. Aliment. Pharmacol. Ther. 19: 941-952 (2004). *
Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am. J. Gastroenterol. 101: 110-118 (2006). *
Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can. J. Gastroenterol. 21: 507-511 (2007).
Bernstein CN, Nayar G, Hamel A, Blanchard JF. Study of animal-borne infections in the mucosas of patients with inflammatory bowel disease and population-based controls. J. Clin. Microbiol. 41: 4986-4990 (2003). *
Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am. J. Gastroenterol. 95: 677-683 (2000). *
Bernstein CN, Pettigrew NM, el-Gabalawy HS, Sargent M, Meu Y, Wilkins J. The differential expression of a novel intestinal epithelial glycoprotein in various forms of inflammatory bowel disease. Am. J. Clin. Pathol. 106: 42-51 (1996).
Bernstein CN, Rawsthorne P, Blanchard JF. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm. Bowel Dis. 13: 759-762 (2007). *
Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. Am. J. Gastroenterol. 101: 993-1002 (2006). *
Bernstein CN, Sargent M, Gallatin WM. Beta2 integrin/ICAM expression in Crohn's disease. Clin. Immunol. Immunopathol. 86: 147-160 (1998).
Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm. Bowel Dis. 11: 325-330 (2005). *
Bernstein CN, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. Am. J. Gastroenterol. 102: 338-343 (2007). *
Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J. Bone Miner. Res. 10: 250-256 (1995).
Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in IBD: a population-based study. Gastroenterology 129: 827-836 (2005). *
Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin. Gastroenterol. Hepatol. 6: 41-45 (2008).
Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am. J. Gastroenterol. 101: 1559-1568 (2006). *
Bernstein CN, Wang MH, Sargent M, Brant SR, Collins MT. Testing the interaction between NOD-2 status and serological response to Mycobacterium paratuberculosis in cases of inflammatory bowel disease. J. Clin. Microbiol. 45: 968-971 (2007). *
Bernstein D, Rogers A. Malignancy in Crohn's disease. Am. J. Gastroenterol. 91: 434-440 (1996).
Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am. J. Gastroenterol. 100: 2031-2035 (2005). *
Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, Yang C, Desreumaux P, Giovannini M, Cezard JP, Zouali H, Emilie D, Peuchmaur M. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut 52: 840-846 (2003). *
Berstad AE, Brandtzaeg P. Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut 42: 522-529 (1998). *
Bertalot G, Villanacci V, Gramegna M, Orvieto E, Negrini R, Saleri A, Terraroli C, Ravelli P, Cestari R, Viale G. Evidence of Epstein-Barr virus infection in ulcerative colitis. Dig. Liver Dis. 33: 551-558 (2001).
Bertrand MJ, Doiron K, Labbe K, Korneluk RG, Barker PA, Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity May 20 [Epub ahead of print] (2009). *
Beslek A, Onen F, Birlik M, Akarsu M, Akar S, Sari I, Gurler O, Akpinar H, Manisali M, Akkoc N. Prevalence of spondyloarthritis in Turkish patients with inflammatory bowel disease. Rheumatol. Int. 29: 955-957 (2009). *
Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw index. Inflamm. Bowel Dis. 12: 304-310 (2006). *
Beutler B. Autoimmunity and apoptosis: the Crohn's connection. Immunity 15: 5-14 (2001). *
Beutler B, Bazzoni F. TNF, apoptosis and autoimmunity: a common thread? Blood Cells Mol. Dis. 24: 216-230 (1998). *
Beutler BA. The role of tumor necrosis factor in health and disease. J. Rheumatol. Suppl. 57: 16-21 (1999).
Bevins CL. The Paneth cell and the innate immune response. Curr. Opin. Gastroenterol. 20: 572-580 (2004).
Bevins CL. Defensins and other antibacterial mediators. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 45 (2005). *
Bevins CL. Events at the host-microbial interface of the gastrointestinal tract V. Paneth cell alpha-defensins in intestinal host defense. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G173-G176 (2005). *
Bevins CL. Paneth cell defensins: key effector molecules of innate immunity. Biochem. Soc. Trans. 34: 263-266 (2006). *
Bevins CL. The role of gut flora and innate immunity in pathogenesis of inflammatory bowel disease. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 58. September 12 - 13 (2003). *
Bevins CL, Stange EF, Wehkamp J. Decreased Paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut 58: 882-883 (2009).
Bewtra M, Lichtenstein GR. Infliximab use in Crohn's disease. Expert Opin. Biol. Ther. 5: 589-599 (2005).
Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin. Gastroenterol. Hepatol. 5: 597-601.e1 (2007).
Beynon V, Cotofana S, Brand S, Lohse P, Mair A, Wagner S, Mussack T, Ochsenkuhn T, Folwaczny M, Folwaczny C, Glas J, Torok HP. NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes. Inflamm. Bowel Dis. 14: 1033-1040 (2008). *
Beyrouti MI, Beyrouti R, Kharrat M, Kchaou I, Abbes M, Affes N, Tafech I, Ghorbel A, Krichene MS, Boudawara T, Sellami A. Intestinal Crohn disease: surgical aspects and predictive factors of risk of relapse. About 26 cases. Tunis. Med. 82: 927-940 (2004).
Bezabeh T, Somorjai RL, Smith IC, Nikulin AE, Dolenko B, Bernstein CN. The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn's disease. Am. J. Gastroenterol. 96: 442-448 (2001). *
Bhaduri S, Jenkinson S, Lewis F. Vulval Crohn's disease - a multi-specialty approach. Int. J. STD AIDS 16: 512-514 (2005).
Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum. Mol. Genet. 7: 1537-1545 (1998). *
Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol. Rev. 169: 195-207 (1999).
Bhat M, Dawson D. Wheezes, blisters, bumps and runs: multisystem manifestations of a Crohn's disease flare-up. CMAJ 177: 715-718 (2007). *
Bhat M, Nguyen GC, Pare P, Lahaie R, Deslandres C, Bernard EJ, Aumais G, Jobin G, Wild G, Cohen A, Langelier D, Brant S, Dassopoulos T, McGovern D, Torres E, Duerr R, Regueiro M, Silverberg MS, Steinhart H, Griffiths AM, Elkadri A, Cho J, et al. Phenotypic and genotypic characteristics of inflammatory bowel disease in French Canadians: comparison with a large North American repository. Am. J. Gastroenterol. Jun 9 [Epub ahead of print] (2009). *
Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, Panagopoulos G, Ofer A, Tamas E, Kotsali P, Vele O. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J. Gastroenterol. 12: 6167-6171 (2006). *
Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, Disanti W, Chun A, Keenan G, Mamun K. A prospective open-label trial of remicade(R) in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J. Clin. Gastroenterol. 41: 677-681 (2007).
Bhuket T, Takami M, Fisher L. The use of wireless capsule endoscopy in clinical diagnostic gastroenterology. Expert Rev. Med. Devices 2: 259-266 (2005).
Biagi F, Rondonotti E, Campanella J, Villa F, Bianchi PI, Klersy C, De Franchis R, Corazza GR. Video capsule endoscopy and histology for small-bowel mucosa evaluation: a comparison performed by blinded observers. Clin. Gastroenterol. Hepatol. 4: 998-1003 (2006).
Biagioni C, Favilli F, Catarzi S, Marcucci T, Fazi M, Tonelli F, Vincenzini MT, Iantomasi T. Redox state and O2*- production in neutrophils of Crohn's disease patients. Exp. Biol. Med. (Maywood) 231: 186-195 (2006). *
Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Juzwiak S, Kurzawski G, Tan EK, Drozdzik M. CARD15 variants in patients with sporadic Parkinson's disease. Neurosci. Res. 57: 473-476 (2007). *
Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population. Eur. J. Gastroenterol. Hepatol. 19: 217-223 (2007).
Biancone L, Calabrese E, Palmieri G, Petruzziello C, Onali S, Sica GS, Cossignani M, Condino G, Das KM, Pallone F. Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: relationship with colonic metaplasia. World J. Gastroenterol. 14: 5290-5300 (2008). *
Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 78-91 (2007). *
Biancone L, Cretella M, Tosti C, Palmieri G, Petruzziello C, Geremia A, Calabrese E, Pallone F. Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest. Endosc. 63: 486-492 (2006).
Biancone L, De Nigris F, Del Vecchio Blanco G, Monteleone I, Vavassori P, Geremia A, Pallone F. Review article: monitoring the activity of Crohn's disease. Aliment. Pharmacol. Ther. 16 Suppl. 4: 29-33 (2002). *
Biancone L, Fiori R, Tosti C, Marinetti A, Catarinacci M, De Nigris F, Simonetti G, Pallone F. Virtual colonoscopy compared with conventional colonoscopy for stricturing postoperative recurrence in Crohn's disease. Inflamm. Bowel Dis. 9: 343-350 (2003). *
Biancone L, Geboes K, Spagnoli LG, Del Vecchio Blanco G, Monteleone I, Vavassori P, Palmieri G, Chimenti S, Pallone F. Metastatic Crohn's disease of the forehead. Inflamm. Bowel Dis. 8: 101-105 (2002). *
Biancone L, Mandal A, Yang H, Dasgupta T, Paoluzi AO, Marcheggiano A, Paoluzi P, Pallone F, Das KM. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology 109: 3-12 (1995). *
Biancone L, Monteleone G, Marasco R, Pallone F. Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives. Clin. Exp. Immunol. 113: 198-205 (1998). *
Biancone L, Onali S, Calabrese E, Petruzziello C, Zorzi F, Condino G, Sica GS, Pallone F. Non-invasive techniques for assessing postoperative recurrence in Crohn's disease. Dig. Liver Dis. 40 Suppl. 2: S265-S270 (2008).
Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benezzato L, Papi C, Meucci G, Riegler G, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched-pair study. Gut 55: 228-233 (2006). *
Biancone L, Pavia M, Del Vecchio Blanco G, D'Inca R, Castiglione F, De Nigris F, Doldo P, Cosco F, Vavassori P, Bresci GP, Arrigoni A, Cadau G, Monteleone I, Rispo A, Fries W, Mallardi B, Sturniolo GC, Pallone F. Hepatitis B and C virus infection in Crohn's disease. Inflamm. Bowel Dis. 7: 287-294 (2001). *
Biancone L, Schillaci O, Capoccetti F, Bozzi RM, Fina D, Petruzziello C, Geremia A, Simonetti G, Pallone F. Technetium-99m-HMPAO labeled leukocyte single photon emission computerized tomography (SPECT) for assessing Crohn's disease extent and intestinal infiltration. Am. J. Gastroenterol. 100: 344-354 (2005). *
Biancone L, Sica GS, Calabrese E, Onali S, Petruzziello C, Pallone F. Frequency and pattern of endoscopic recurrence in Crohn's disease patients with ileocolonic resection using a laparoscopic versus laparotomic approach: a prospective longitudinal study. Am. J. Gastroenterol. 103: 809-811 (2008).
Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F. Review article: maintenance treatment of Crohn's disease. Aliment. Pharmacol. Ther. 17 Suppl. 2: 31-37 (2003).
Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, Pallone F. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment. Pharmacol. Ther. 19: 755-764 (2004). *
Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-glucose breath test. Curr. Med. Res. Opin. 16: 14-20 (2000).
Biank V, Broeckel U, Kugathasan S. Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm. Bowel Dis. 13: 1430-1438 (2007). *
Biank V, Friedrichs F, Babusukumar U, Wang T, Stoll M, Broeckel U, Kugathasan S. DLG5 R30Q variant is a female-specific protective factor in pediatric onset Crohn's disease. Am. J. Gastroenterol. 102: 391-398 (2007). *
Biank VF, Kugathasan S. What are the risk factors for surgery and their implications for management of children with Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 660-661 (2006). *
Biasi F, Mascia C, Poli G. TGFbeta1 expression in colonic mucosa: modulation by dietary lipids. Genes Nutr. 2: 233-243 (2007). *
Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J. Med. Microbiol. 55: 1141-1149 (2006). *
Bibiloni R, Tandon P, Vargas-Voracka F, Barreto-Zuniga R, Lupian-Sanchez A, Rico-Hinojosa MA, Guban J, Fedorak R, Tannock GW. Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent? J. Med. Microbiol. 57: 111-117 (2008). *
Bickston SJ. Keeping the M in mind: recombinant human GMCSF and Crohn's disease. Inflamm. Bowel Dis. 9: 132 (2003). *
Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 518-523 (2003).
Bickston SJ, Foley E, Lawrence C, Rockoff T, Shaffer HA Jr, Yeaton P. Terminal ileal stricture in Crohn's disease: treatment using a metallic enteral endoprosthesis. Dis. Colon Rectum 48: 1081-1085 (2005). *
Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 117: 1433-1437 (1999). *
Biczysko M, Kosciniski T, Biczysko R. Unusual complication after caesarean section in a pregnant women with undiagnosed Crohn's disease. Ginekol. Pol. 79: 635-637 (2008).
Bielecki K, Baczuk L. Anorectal Lesniowski-Crohn's disease. Wiad. Lek. 61: 177-182 (2008).
Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm. Bowel Dis. 15: 778-788 (2009).
Biemond I, Burnham WR, D'Amaro J, Langman MJ. HLA-A and -B antigens in inflammatory bowel disease. Gut 27: 934-941 (1986). *
Biesalski HK, Hafner G, Gross M, Bassler KH. Vitamin A in the serum of healthy probands and clinical groups. Infusionsther. Klin. Ernahr. 12: 109-114 (1985).
Biet F, Boschiroli ML, Thorel MF, Guilloteau LA. Zoonotic aspects of Mycobacterium bovis and Mycobacterium avium-intracellulare complex (MAC). Vet. Res. 36: 411-436 (2005). *
Billich A. Drug evaluation: Apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 10: 53-59 (2007).
Binder B, Ahlgrimm-Siess V, Hofmann-Wellenhof R. Eruptive melanocytic nevi of the palms and soles in a patient with Crohn disease. J. Dtsch. Dermatol. Ges. 4: 486-488 (2006).
Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract. Res. Clin. Gastroenterol. 18: 463-479 (2004).
Binder V. Genetic epidemiology in inflammatory bowel disease. Dig. Dis. 16: 351-355 (1998).
Binder V, Orholm M. Familial occurrence and inheritance studies in inflammatory bowel disease. Neth. J. Med. 48: 53-56 (1996).
Binion DG, Alemzadeh R. Growth of an IBD controversy: growth hormone and Crohn's disease. Inflamm. Bowel Dis. 7: 176-178 (2001). *
Binion DG, Kugathasan S, Dwinell MB. Molecular stratification of Crohn's disease by chemokine receptors: fractalkine receptor polymorphisms define a fibrostenosing ileal subgroup. Am. J. Gastroenterol. 101: 107-109 (2006). *
Binion DG, Theriot KR, Shidham S, Lundeen S, Hatoum O, Lim HJ, Otterson MF. Clinical factors contributing to rapid reoperation for Crohn's disease patients undergoing resection and/or strictureplasty. J. Gastrointest. Surg. 11: 1692-1698 (2007). *
Bioque G, Bouma G, Crusius JB, Koutroubakis I, Kostense PJ, Meuwissen SG, Pena AS. Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 8: 105-110 (1996).
Bioque G, Crusius JB, Koutroubakis I, Bouma G, Kostense PJ, Meuwissen SG, Pena AS. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin. Exp. Immunol. 102: 379-383 (1995). *
Birchard KR, Brown MA, Hyslop WB, Firat Z, Semelka RC. MRI of acute abdominal and pelvic pain in pregnant patients. AJR Am. J. Roentgenol. 184: 452-458 (2005). *
Birnie AJ, Perkins W. A case of linear IgA disease occurring in a patient with colonic Crohn's disease. Br. J. Dermatol. 153: 1050-1052 (2005). *
Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm. Bowel Dis. 10: 848-859 (2004). *
Birtwistle J. The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis. Postgrad. Med. J. 72: 714-718 (1996). *
Bisaccia E, Palangio M, Gonzalez J. Extracorporeal photochemotherapy for the treatment of refractory Crohn's disease. Transfus. Apher. Sci. 37: 171-174 (2007).
Bischoff SC, Herrmann A, Goke M, Manns MP, von zur Muhlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am. J. Gastroenterol. 92: 1157-1163 (1997).
Bischoff SC, Schwengberg S, Lorentz A, Manns MP, Bektas H, Sann H, Levi-Schaffer F, Shanahan F, Schemann M. Substance P and other neuropeptides do not induce mediator release in isolated human intestinal mast cells. Neurogastroenterol. Motil. 16: 185-193 (2004).
Bisping G, Lugering N, Lutke-Brintrup S, Pauels HG, Schurmann G, Domschke W, Kucharzik T. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells. Clin. Exp. Immunol. 123: 15-22 (2001). *
Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, Lopez-Otin C, Saarialho-Kere U. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig. Dis. Sci. 49: 653-661 (2004). *
Bitton A. Preventing postoperative recurrence in Crohn's disease with 6-mercaptopurine and azathioprine: approaching the cutting edge. Inflamm. Bowel Dis. 11: 513-514 (2005). *
Bitton A. Anti-tumor necrosis factor alpha: Crohn's disease guided missile. Inflamm. Bowel Dis. 4: 173-174 (1998). *
Bitton A, Dobkin P, Edwardes MD, Sewitch M, Meddings J, Rawal S, Cohen A, Vermeire S, Dufresne L, Franchimont D, Wild GE. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 57: 1386-1392 (2008).
Bizzaro N. The predictive significance of autoantibodies in organ-specific autoimmune diseases. Clin. Rev. Allergy Immunol. 34: 326-331 (2007).
Bjarnason I. Intestinal permeability. Gut 35: S18-S22 (1994). *
Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 40: 228-233 (1997). *
Bjorkkjaer T, Brunborg LA, Arslan G, Lind RA, Brun JG, Valen M, Klementsen B, Berstad A, Froyland L. Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. Scand. J. Gastroenterol. 39: 1088-1094 (2004). *
Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am. J. Gastroenterol. 102: 1677-1682 (2007). *
Bjornsson E, Chapman RW. Sclerosing cholangitis. Curr. Opin. Gastroenterol. 19: 270-275 (2003).
Bjornsson S. Inflammatory bowel disease in Iceland during a 30-year period, 1950-1979. Scand. J. Gastroenterol. Suppl. 170: 47-49 (1989).
Bjornsson S, Johannsson JH, Oddsson E. Inflammatory bowel disease in Iceland, 1980-89. A retrospective nationwide epidemiologic study. Scand. J. Gastroenterol. 33: 71-77 (1998). *
Blackwell JM, Searle S. Genetic regulation of macrophage activation: understanding the function of Nramp1 (=Ity/Lsh/Bcg). Immunol. Lett. 65: 73-80 (1999).
Blakelock RT, Beasley SW. Infection and the gut. Semin. Pediatr. Surg. 12: 265-274 (2003).
Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am. J. Gastroenterol. 96: 1977-1997 (2001). *
Blanchard JF, Bernstein CN, Wajda A, Rawsthorne P. Small-area variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis. Am. J. Epidemiol. 154: 328-335 (2001). *
Blanchet E, Beau P. Efficacy of hydrostatic balloon dilatation of anastomotic Crohn's disease strictures. Gastroenterol. Clin. Biol. 27: 1105-1109 (2003).
Blanchet E, Beau P, Frat JP. Bone marrow aplasia following dipyrone treatment in a patient with Crohn's disease receiving long-term methotrexate. Gastroenterol. Clin. Biol. 28: 502-503 (2004).
Bland RM, Evans TJ, Raine P, Weaver LT. Inflammatory bowel disease in Scottish children. Health Bull. (Edinb.) 57: 365-373 (1999).
Blaser MJ, Hoverson D, Ely IG, Duncan DJ, Wang WL, Brown WR. Studies of Campylobacter jejuni in patients with inflammatory bowel disease. Gastroenterology 86: 33-38 (1984).
Blaser MJ, Miller RA, Lacher J, Singleton JW. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 87: 888-894 (1984).
Blazovics A. Gallstone disease: free radical reactions and the ambivalent role of bilirubin in the pathomechanism of gallstone formation. Orv. Hetil. 148: 589-596 (2007).
Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis. Colon Rectum 36: 908-912 (1993).
Bleich A, Hopf S, Hedrich HJ, van Lith HA, Li F, Sartor RB, Mahler M. Genetic dissection of granulomatous enterocolitis and arthritis in the intramural peptidoglycan-polysaccharide-treated rat model of IBD. Inflamm. Bowel Dis. Jun 12 [Epub ahead of print] (2009).
Bleiziffer O, Dragu A, Kneser U, Horch RE. Solving acne inversa (hidradenitis suppurativa) in Crohn disease with buried chip skin grafts. J. Cutan. Med. Surg. 13: 164-168 (2009).
Blick SK, Curran MP. Certolizumab pegol in Crohn's disease. BioDrugs 21: 195-201 (2007).
Blokzijl H, van Steenpaal A, Vander Borght S, Bok LI, Libbrecht L, Tamminga M, Geuken M, Roskams TA, Dijkstra G, Moshage H, Jansen PL, Faber KN. Upregulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease. J. Biol. Chem. 283: 35630-35637 (2008). *
Blokzijl H, Vander Borght S, Bok LI, Libbrecht L, Geuken M, van den Heuvel FA, Dijkstra G, Roskams TA, Moshage H, Jansen PL, Faber KN. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm. Bowel Dis. 13: 710-720 (2007). *
Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr. Opin. Gastroenterol. 22: 30-43 (2006).
Blonski W, Lichtenstein GR. Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject-that is the question. Gastrointest. Endosc. 63: 493-496 (2006).
Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 9: 221-233 (2006).
Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm. Bowel Dis. 13: 769-796 (2007). *
Blonski WC, Katzka DA, Lichtenstein GR, Metz DC. Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease. Eur. J. Gastroenterol. Hepatol. 17: 441-444 (2005).
Bloom S, Heryet A, Fleming K, Chapman RW. Inappropriate expression of blood group antigens on biliary and colonic epithelia in primary sclerosing cholangitis. Gut 34: 977-983 (1993). *
Blum E, Katz JA. Postoperative therapy for Crohn's disease. Inflamm. Bowel Dis. 15: 463-472 (2009).
Blumberg RS. Crohn disease. JAMA 300: 439-440 (2008). *
Blumberg RS, Strober W. Prospects for research in inflammatory bowel disease. JAMA 285: 643-647 (2001). *
BMJ Group. Crohn's disease or abdominal tuberculosis? Gut 56: 1757-1758 (2007). *
Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, Castiglione F, Scarpa R, Perna F, Signoriello G, Galati D, Ponticiello A, Sanduzzi A. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur. J. Clin. Microbiol. Infect. Dis. 27: 907-913 (2008). *
Bocker U, Lohr JM, Marx A. Twenty-six-year-old female with assumed Crohn's disease and a gastrointestinal stromal tumor: response. Inflamm. Bowel Dis. 15: 489-490 (2009).
Bodar E, Netea MG, Jong DJ, Kullberg BJ, Joosten LA, Meer JW. NOD2 engagement induces proinflammatory cytokine production, but not apoptosis, in leukocytes isolated from patients with Crohn's disease. Eur. Cytokine Netw. 19: 185-189 (2008).
Bode L, Freeze HH. Applied glycoproteomics-approaches to study genetic-environmental collisions causing protein-losing enteropathy. Biochim. Biophys. Acta 1760: 547-559 (2006). *
Bode M, Eder S, Schurmann G. Perianal fistulas in Crohn's disease - biologicals and surgery: is it worthwhile? Z. Gastroenterol. 46: 1376-1383 (2008).
Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 23: 875-888 (2005).
Bodger K, Halfvarson J, Dodson A, Campbell F, Wilson S, Lee R, Lindberg E, Jarnerot G, Tysk C, Rhodes J. Altered colonic glycoprotein expression in unaffected monozygotic twins of inflammatory bowel disease patients. Gut 55: 973-977 (2006). *
Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment. Pharmacol. Ther. May 5 [Epub ahead of print] (2009). *
Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH, Sandborn WJ, Loftus EV Jr, Harmsen WS, Crownhart BS. Crohn disease: mural attenuation and thickness at contrast-enhanced CT enterography - correlation with endoscopic and histologic findings of inflammation. Radiology 238: 505-516 (2006). *
Boedeker EC. Crohn's mucosa harbors adherent-invasive E. coli. Inflamm. Bowel Dis. 6: 155 (2000). *
Boehm D, Krzystek-Korpacka M, Neubauer K, Matusiewicz M, Berdowska I, Zielinski B, Paradowski L, Gamian A. Paraoxonase-1 status in Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 15: 93-99 (2009).
Boehncke WH, Buerger C, Boehncke S. Co-morbidities in psoriasis vulgaris. Hautarzt. 60: 116-121 (2009).
Bogaard HJ, Erkelens GW, Faber WR, de Vries PJ. Cutaneous nocardiosis as an opportunistic infection. Ned. Tijdschr. Geneeskd. 148: 533-536 (2004).
Bognar M, Blake W, Agudelo C. Chronic recurrent multifocal osteomyelitis associated with Crohn's disease. Am. J. Med. Sci. 315: 133-135 (1998).
Bohm SK, Kruis W. Probiotics: do they help to control intestinal inflammation? Ann. N. Y. Acad. Sci. 1072: 339-350 (2006). *
Bohr UR, Glasbrenner B, Primus A, Zagoura A, Wex T, Malfertheiner P. Identification of enterohepatic Helicobacter species in patients suffering from inflammatory bowel disease. J. Clin. Microbiol. 42: 2766-2768 (2004). *
Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, Strober W. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116: 557-565 (1999).
Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY. Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G590-G598 (2007). *
Bokemeyer B. Asymptomatic elevation of serum lipase and amylase in conjunction with Crohn's disease and ulcerative colitis. Z. Gastroenterol. 40: 5-10 (2002).
Bolukbas FF, Bolukbas C, Horoz M, Baba F, Uzunkoy A. A case of previously undiagnosed Crohn's disease presenting with acute pancreatitis as an extraintestinal manifestation. Ann. Saudi Med. 25: 71-73 (2005).
Bona D, Incarbone R, Chella B, Vecchi M, Bonavina L. Heartburn and multiple-site foregut perforations as primary manifestation of Crohn's disease. Dis. Esophagus 18: 199-201 (2005). *
Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, Belaiche J, Cadiot G, Metman EH, Cortot A, Colombel JF; Getaid. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment. Pharmacol. Ther. 18: 401-408 (2003). *
Bondeson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int. J. Clin. Pract. 55: 211-216 (2001).
Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 124: 521-536 (2003). *
Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, Chen FF, Foster SJ, Duerr RH, Brant SR, Cho JH, Nunez G. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124: 140-146 (2003). *
Boner AL, Peroni D, Bodini A, Delaini G, Piacentini G. Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int. J. Immunopathol. Pharmacol. 20: 847-849 (2007).
Bongiovanni M, Ranieri R, Ferrero S, Casanova F, Monforte AD. Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin. AIDS 20: 1989-1990 (2006).
Bonheur JL, Braunstein J, Korelitz BI, Panagopoulos G. Anal skin tags in inflammatory bowel disease: new observations and a clinical review. Inflamm. Bowel Dis. 14: 1236-1239 (2008).
Bonnard A, Fouquet V, Berrebi D, Hugot JP, Belarbi N, Bruneau B, Aigrain Y, de Lagausie P. Crohn's disease in children. Preliminary experience with a laparoscopic approach. Eur. J. Pediatr. Surg. 16: 90-93 (2006).
Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm. Bowel Dis. 10: 751-757 (2004). *
Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am. J. Gastroenterol. 95: 1946-1948 (2000). *
Booth IW. The nutritional consequences of gastrointestinal disease in adolescence. Acta Paediatr. Scand. Suppl. 373: 91-102 (1991).
Booya F, Akram S, Fletcher JG, Huprich JE, Johnson CD, Fidler JL, Barlow JM, Solem CA, Sandborn WJ, Loftus EV Jr. CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findings. Abdom. Imaging Jun 13 [Epub ahead of print] (2008). *
Booya F, Fletcher JG, Huprich JE, Barlow JM, Johnson CD, Fidler JL, Solem CA, Sandborn WJ, Loftus EV Jr, Harmsen WS. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology 241: 787-795 (2006). *
Bor MV, Nexo E, Hvas AM. Holo-transcobalamin concentrations and transcobalamin saturation reflect recent vitamin B12 absorption better than does serum vitamin B12. Clin. Chem. 50: 1043-1049 (2004). *
Boraschi P, Braccini G, Gigoni R, Cartei F, Perri G. MR enteroclysis using iron oxide particles (ferristene) as an endoluminal contrast agent: an open phase III trial. Magn. Reson. Imaging 22: 1085-1095 (2004). *
Boraska Jelavic T, Barisic M, Drmic Hofman I, Boraska V, Vrdoljak E, Peruzovic M, Hozo I, Puljiz Z, Terzic J. Microsatelite GT polymorphism in the Toll-like receptor 2 is associated with colorectal cancer. Clin. Genet. 70: 156-160 (2006). *
Boraz RA. Oral manifestations of Crohn disease: update of the literature and report of case. ASDC J. Dent. Child. 55: 72-74 (1988).
Borchardt JK. Focus on small molecule inhibitors for treatment of inflammatory and autoimmune diseases. Drug News Perspect. 17: 607-614 (2004).
Borchers R, Heinzlmann M, Zahn R, Witter K, Martin K, Loeschke K, Folwaczny C. K-ras mutations in sera of patients with colorectal neoplasias and long-standing inflammatory bowel disease. Scand. J. Gastroenterol. 37: 715-718 (2002). *
Bordas JM, Llach J, Mata A. Utility of single- and double-balloon enteroscopy. Gastroenterol. Hepatol. Jun 3 [Epub ahead of print] (2009).
Borgaonkar M, MacIntosh D, Fardy J, Simms L. Anti-tuberculous therapy for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev. 2: CD000299 (2000). *
Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am. J. Gastroenterol. 95: 725-729 (2000). *
Borgaonkar MR, Townson G, Donnelly M, Irvine EJ. Providing disease-related information worsens health-related quality of life in inflammatory bowel disease. Inflamm. Bowel Dis. 8: 264-269 (2002). *
Borgiani P, Perricone C, Ciccacci C, Romano S, Novelli G, Biancone L, Petruzziello C, Pallone F. Interleukin-23R Arg381Gln is associated with susceptibility to Crohn's disease but not with phenotype in an Italian population. Gastroenterology 133: 1049-1051 (2007). *
Borgiani P, Vallo L, D'Apice MR, Giardina E, Pucci S, Capon F, Nistico S, Chimenti S, Pallone F, Novelli G. Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population. Eur. J. Dermatol. 12: 540-542 (2002).
Boriskin HS, Devito BS, Hines JJ, Scarmato VJ, Friedman B. CT enterography vs. capsule endoscopy. Abdom. Imaging 34: 149-155 (2009). *
Borley NR, Mortensen NJ, Jewell DP. MRI scanning in perianal Crohn's disease: an important diagnostic adjunct. Inflamm. Bowel Dis. 5: 231-233 (1999).
Borm ME, Bodegraven AA, Mulder CJ, Kraal G, Bouma G. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int. J. Immunogenet. 32: 401-405 (2005). *
Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G. The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype. Genes Immun. 9: 274-278 (2008). *
Borody TJ, Bilkey S, Wettstein AR, Leis S, Pang G, Tye S. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig. Liver Dis. 39: 438-444 (2007).
Borody TJ, Heifets LB. Severe recurrent Crohn's disease of ileocolonic anastomosis and antimicrobial (anti-mycobacterial) therapy. Gut 55: 1211 (2006). *
Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn's disease using antimycobacterial triple therapy - approaching a cure? Dig. Liver Dis. 34: 29-38 (2002).
Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. 36: 342-347 (2004).
Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 4: 744-753 (2006).
Borruel N, Carol M, Casellas F, Antol�n M, de Lara F, Esp�n E, Naval J, Guarner F, Malagelada JR. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51: 659-664 (2002). *
Borthakur A, Bhattacharyya S, Dudeja PK, Tobacman JK. Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G829-G838 (2007). *
Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, Politi P, Ravelli P, Imperiali G, Colombo E, Pera A, Daperno M, Carnovali M, de Franchis R, Vecchi M; the Study Group for Inflammatory Bowel Diseases (GSMII). Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J. Gastroenterol. Hepatol. 22: 542-549 (2007). *
Borum ML, Liu E. Crohn's disease mimicking bulimia nervosa. Prim. Care Companion J. Clin. Psychiatry 8: 311-312 (2006). *
Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F. NOD2-associated diseases: bridging innate immunity and autoinflammation. Clin. Immunol. May 23 [Epub ahead of print] (2009). *
Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP. The pathogenesis of inflammatory dermatoses, especially psoriasis. Ned. Tijdschr. Geneeskd. 150: 179-183 (2006).
Bosca MM, Perez-Baylach CM, Solis MA, Anton R, Mayordomo E, Pons S, Minguez M, Benages A. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 55: 294-295 (2006). *
Bosch ME, Sanchez AJ, Rojas FS, Ojeda CB. Recent advances in analytical determination of thalidomide and its metabolites. J. Pharm. Biomed. Anal. 46: 9-17 (2008).
Bosch X. Hypercalcemia due to endogenous overproduction of 1,25-dihydroxyvitamin D in Crohn's disease. Gastroenterology 114: 1061-1065 (1998). *
Bossuyt X. Serologic markers in inflammatory bowel disease. Clin. Chem. 52: 171-181 (2006). *
Bosworth BP, Sanders A, Maltz C. Common variable immunodeficiency masquerading as Crohn's ileocolitis. Inflamm. Bowel Dis. 12: 151-152 (2006). *
Botoman VA, Bonner GF, Botoman DA. Management of inflammatory bowel disease. Am. Fam. Physician 57: 57-68, 71-72 (1998).
Botti F, Carrara A, Antonelli B, Quadri F, Maino M, Cesana B, Contessini-Avesani E. The minimal bowel resection in Crohn's disease: analysis of prognostic factors on the surgical recurrence. Ann. Ital. Chir. 74: 627-633 (2003).
Bottini N, Gloria-Bottini F, Amante A, Saccucci P, Bottini E. Genetic polymorphism and Th1/Th2 orientation. Int. Arch. Allergy Immunol. 138: 328-333 (2005).
Bottini N, Gloria-Bottini F, Lucarini N, Ronchetti PG, Fontana L. Inflammatory bowel disease: are there gender differences in the genetics of signal transduction? A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase. Dis. Markers 16: 163-166 (2000).
Bottini N, Stefanini L, Lucarelli P, Bottini E. Adaptation to past malarial endemia and susceptibility to common diseases in modern populations: a study of adenosine deaminase and MN blood group genetic polymorphisms. Am. J. Phys. Anthropol. 128: 194-198 (2005). *
Bouali F, Berrah A, Si Ahmed-Bouali D, Harrieche F, Benhalima M, Hamladji RM, Arrada M. Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients). Rev. Med. Interne. 26: 777-783 (2005).
Boubaker J, Feki M, Hsairi M, Fekih M, Kaabachi N, Filali A, Mebazaa A. Osteoporosis and inflammatory bowel disease: prevalence and risk factors in Tunisian patients. Gastroenterol. Clin. Biol. 27: 901-907 (2003).
Boudiaf M, Jaff A, Soyer P, Bouhnik Y, Hamzi L, Rymer R. Small-bowel diseases: prospective evaluation of multi-detector row helical CT enteroclysis in 107 consecutive patients. Radiology 233: 338-344 (2004). *
Bougnoux ME, Diogo D, Francois N, Sendid B, Veirmeire S, Colombel JF, Bouchier C, Van Kruiningen H, d'Enfert C, Poulain D. Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract. J. Clin. Microbiol. 44: 1810-1820 (2006). *
Bouhnik Y. Diagnostic tools in inflammatory bowel diseases. Rev. Prat. 55: 977-983 (2005).
Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment. Pharmacol. Ther. 14: 1561-1565 (2000). *
Bouma G, Kaushiva A, Strober W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology 123: 554-565 (2002). *
Bouma G, Oudkerk Pool M, Crusius JB, Schreuder GM, Hellemans HP, Meijer BU, Kostense PJ, Giphart MJ, Meuwissen SG, Pena AS. Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD). Clin. Exp. Immunol. 109: 175-179 (1997). *
Bouma G, Pena AS. Immunology in medical practice. XXVI. Immunogenetics of chronic inflammatory bowel diseases. Ned. Tijdschr. Geneeskd. 143: 2414-2420 (1999).
Bouma G, Poen AC, Garcia-Gonzalez MA, Schreuder GM, Felt-Bersma RJ, Meuwissen SG, Pena AS. HLA-DRB1*03, but not the TNFA -308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. Immunogenetics 47: 451-455 (1998).
Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521-533 (2003). *
Bouma G, Xia B, Crusius JB, Bioque G, Koutroubakis I, Von Blomberg BM, Meuwissen SG, Pena AS. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin. Exp. Immunol. 103: 391-396 (1996). *
Bourges O, Dorgeret S, Alberti C, Hugot JP, Sebag G, Cezard JP. Low bone mineral density in children with Crohn's disease. Arch. Pediatr. 11: 800-806 (2004).
Bourhis LL, Benko S, Girardin SE. Nod1 and Nod2 in innate immunity and human inflammatory disorders. Biochem. Soc. Trans. 35: 1479-1484 (2007). *
Bourikas LA, Kourbeti IS, Koutsopoulos AV, Koutroubakis IE. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis. Gut 57: 425 (2008).
Bourne PC, Terzyan SS, Cloud G, Landolfi NF, Vasquez M, Edmundson AB. Three-dimensional structures of a humanized anti-IFN-gamma Fab (HuZAF) in two crystal forms. Acta Crystallogr. D. Biol. Crystallogr. 60: 1761-1769 (2004). *
Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 22: 331-337 (2008).
Bourreille A, Doubremelle M, de la Bletiere DR, Segain JP, Toquet C, Buelow R, Galmiche JP. RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease. Scand. J. Gastroenterol. 38: 526-532 (2003). *
Bourreille A, Humbert B, Maugere P, Galmiche JP, Darmaun D. Glutamine metabolism in Crohn's disease: a stable isotope study. Clin. Nutr. 23: 1167-1175 (2004).
Bourreille A, Jarry M, D'Halluin PN, Ben-Soussan E, Maunoury V, Bulois P, Sacher-Huvelin S, Vahedy K, Lerebours E, Heresbach D, Bretagne JF, Colombel JF, Galmiche JP. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of post-operative recurrence of Crohn's disease: a prospective study. Gut 55: 978-983 (2006). *
Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P. Sigma receptor ligands: applications in inflammation and oncology. Curr. Opin. Investig. Drugs 5: 1158-1163 (2004).
Bousvaros A. Mucosal healing in children with Crohn's disease: appropriate therapeutic goal or medical overkill? Inflamm. Bowel Dis. 10: 481-483 (2004). *
Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. 11: 833-839 (2005). *
Bousvaros A, Sylvester F, Kugathasan S, Szigethy E, Fiocchi C, Colletti R, Otley A, Amre D, Ferry G, Czinn SJ, Splawski JB, Oliva-Hemker M, Hyams JS, Faubion WA, Kirschner BS, Dubinsky MC; and the Members of the Challenges in Pediatric IBD Study Groups. Challenges in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 12: 885-913 (2006). *
Bousvaros A, Zurakowski D, Duggan C, Law T, Rifai N, Goldberg NE, Leichtner AM. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J. Pediatr. Gastroenterol. Nutr. 26: 129-135 (1998). *
Bouzaidi S, Ben Salem M, Mnif N, Ben Hammouda I, Ben Yedder J, Trabelsi S, Moussa A, Jemaa Y, Debbech R, Salem M, Najjar T, Hamza R. Bone mineral density in patients with Crohn's disease: about 53 cases. Tunis. Med. 82: 753-759 (2004).
Bovenschen HJ, Tjioe M, Vermaat H, Hoop D, Witteman BM, Janssens RW, Stoof TJ, Kerkhof PC. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br. J. Dermatol. 154: 880-884 (2006). *
Boyanova L, Gergova G, Spassova Z, Koumanova R, Yaneva P, Mitov I, Derejian S, Krastev Z. Campylobacter infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease, and other chronic intestinal diseases. Diagn. Microbiol. Infect. Dis. 49: 71-74 (2004).
Boye B, Jahnsen J, Mokleby K, Leganger S, Jantschek G, Jantschek I, Kunzendorf S, Benninghoven D, Wilhelmsen I, Sharpe M, Blomhoff S, Malt UF, Lundin KE. The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease? Inflamm. Bowel Dis. 14: 680-686 (2008). *
Boye B, Lundin KE, Leganger S, Mokleby K, Jantschek G, Jantschek I, Kunzendorf S, Benninghoven D, Sharpe M, Wilhelmsen I, Blomhoff S, Malt UF, Jahnsen J. The INSPIRE study: do personality traits predict general quality of life (short form-36) in distressed patients with ulcerative colitis and Crohn's disease? Scand. J. Gastroenterol. 43: 1505-1513 (2008). *
Boyer L, Sidpra D, Jevon G, Buchan AM, Jacobson K. Differential responses of VIPergic and nitrergic neurons in paediatric patients with Crohn's disease. Auton. Neurosci. 134: 106-114 (2007).
Boyne MS, Dye KR. Crohn's colitis and idiopathic thrombocytopenic purpura. Postgrad. Med. J. 76: 299-300 (2000). *
Boysen T, Clausen MR. A case of acute liver failure caused by herpes simplex type 2. Scand. J. Infect. Dis. 36: 529-532 (2004).
Braat H, McGuirk P, Kate FT, Huibregtse I, Dunne P, Hommes D, Deventer S, Mills K. Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule. Gut 56: 351-357 (2007). *
Braat H, Peppelenbosch MP, Hommes DW. Immunology of Crohn's disease. Ann. N. Y. Acad. Sci. 1072: 135-154 (2006). *
Braat H, Peppelenbosch MP, Hommes DW. Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin. Biol. Ther. 3: 725-731 (2003).
Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4: 754-759 (2006).
Braat H, Stokkers P, Hommes T, Cohn D, Vogels E, Pronk I, Spek A, van Kampen A, van Deventer S, Peppelenbosch M, Hommes D. Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn's disease patients. J. Mol. Med. 83: 601-609 (2005). *
Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am. J. Clin. Nutr. 80: 1618-1625 (2004). *
Brackmann S, Andersen SN, Aamodt G, Langmark F, Clausen OP, Aadland E, Fausa O, Rydning A, Vatn MH. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand. J. Gastroenterol. 44: 46-55 (2009). *
Bradley PJ, Ferlito A, Devaney KO, Rinaldo A. Crohn's disease manifesting in the head and neck. Acta Otolaryngol. 124: 237-241 (2004).
Bradley RJ, Rosen MP. Subfertility and gastrointestinal disease: 'Unexplained' is often undiagnosed. Obstet. Gynecol. Surv. 59: 108-117 (2004).
Braegger CP, MacDonald TT. Immune mechanisms in chronic inflammatory bowel disease. Ann. Allergy 72: 135-141 (1994).
Bragagni G, Brogna R, Franceschetti P, Zoli G. Cardiac involvement in Crohn's disease: echocardiographic study. J. Gastroenterol. Hepatol. 22: 18-22 (2007). *
Branagan G, Thompson MR, Senapati A. Cleft closure for the treatment of unhealed perineal sinus. Colorectal Dis. 8: 314-317 (2006). *
Branco BC, Harpaz N, Sachar DB, Greenstein AJ, Tabrizian P, Bauer JJ, Greenstein AJ. Colorectal carcinoma in indeterminate colitis. Inflamm. Bowel Dis. 15: 1076-1081 (2009).
Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, Jagla W, Popp A, Leclair S, Herrmann K, Seiderer J, Ochsenkuhn T, Goke B, Auernhammer CJ, Dambacher J. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G827-G838 (2006). *
Brand S, Crispin A. C-reactive protein polymorphism and Crohn's disease: authors' reply. Aliment. Pharmacol. Ther. 25: 520-521 (2007).
Brand S, Hofbauer K, Dambacher J, Schnitzler F, Staudinger T, Pfennig S, Seiderer J, Tillack C, Konrad A, Goke B, Ochsenkuhn T, Lohse P. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype. Am. J. Gastroenterol. 101: 99-106 (2006). *
Brand S, Olszak T, Beigel F, Diebold J, Otte JM, Eichhorst ST, Goke B, Dambacher J. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J. Cell. Biochem. 97: 709-723 (2006). *
Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, Seiderer J, Tillack C, Konrad A, Crispin A, Goke B, Lohse P, Ochsenkuhn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm. Bowel Dis. 11: 645-652 (2005). *
Brandtzaeg P. The changing immunological paradigm in coeliac disease. Immunol. Lett. 105: 127-139 (2006).
Brandtzaeg P. Immunopathology of Crohn's disease. Ann. Gastroenterol. Hepatol. (Paris) 21: 202-220 (1985).
Brandtzaeg P. Inflammatory bowel disease: clinics and pathology. Do inflammatory bowel disease and periodontal disease have similar immunopathogeneses? Acta Odontol. Scand. 59: 235-243 (2001). *
Brandtzaeg P, Baklien K. Immunohistochemical studies of the immunoglobulin-producing cell systems of the human intestinal mucosa. Acta Histochem. Suppl. 21: 105-119 (1980).
Brandwein SL, McCabe RP, Cong Y, Waites KB, Ridwan BU, Dean PA, Ohkusa T, Birkenmeier EH, Sundberg JP, Elson CO. Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J. Immunol. 159: 44-52 (1997).
Brannigan AE, Watson RW, Beddy D, Hurley H, Fitzpatrick JM, O'Connell PR. Increased adhesion molecule expression in serosal fibroblasts isolated from patients with inflammatory bowel disease is secondary to inflammation. Ann. Surg. 235: 507-511 (2002). *
Brant SR. Exposed: the genetic underpinnings of ulcerative colitis relative to Crohn's disease. Gastroenterology 136: 396-399 (2009). *
Brant SR. IBD5: the second Crohn's disease gene? Inflamm. Bowel Dis. 8: 371-372 (2002). *
Brant SR, Fu Y, Fields CT, Baltazar R, Ravenhill G, Pickles MR, Rohal PM, Mann J, Kirschner BS, Jabs EW, Bayless TM, Hanauer SB, Cho JH. American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology 115: 1056-1061 (1998). *
Brant SR, Nguyen GC. Is there a gender difference in the prevalence of Crohn's disease or ulcerative colitis? Inflamm. Bowel Dis. 14: S2-S3 (2008).
Brant SR, Panhuysen CI, Bailey-Wilson JE, Rohal PM, Lee S, Mann J, Ravenhill G, Kirschner BS, Hanauer SB, Cho JH, Bayless TM. Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology 119: 1483-1490 (2000). *
Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet.73: 1282-1292 (2003). *
Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty TH, Hanauer SB, Duerr RH, Cho JH. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm. Bowel Dis. 9: 281-289 (2003). *
Brant SR, Shugart YY. Inflammatory bowel disease gene hunting by linkage analysis - rationale, methodology, and present status of the field. Inflamm. Bowel Dis. 10: 300-311 (2004). *
Brant SR, Wang MH, Rawsthorne P, Sargent M, Datta LW, Nouvet F, Shugart YY, Bernstein CN. A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am. J. Gastroenterol. 102: 313-323 (2007). *
Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin. Drug Saf. 5: 9-16 (2006).
Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann WD, Fuellekrug J, Stremmel W, Ehehalt R. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm. Bowel Dis. Jun 5 [Epub ahead of print] (2009).
Braun C, Zahn R, Martin K, Albert E, Folwaczny C. Polymorphisms of the ICAM-1 gene are associated with inflammatory bowel disease, regardless of the p-ANCA status. Clin. Immunol. 101: 357-360 (2001). *
Braun J. Primativism, siderophilic bacteria, and Crohn's disease. Inflamm. Bowel Dis. 10: 884-885 (2004). *
Braun J. In search of desire: mimicry, MAP, and Crohn's disease. Gastroenterology 131: 312-314 (2006). *
Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 57: 639-647 (2007). *
Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr. Opin. Rheumatol. 13: 245-249 (2001).
Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin. Biol. Ther. 3: 141-168 (2003).
Braun J, Targan SR. Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease. Adv. Exp. Med. Biol. 579: 209-218 (2006).
Braus NA, Elliott DE. Advances in the pathogenesis and treatment of IBD. Clin. Immunol. Mar 23 [Epub ahead of print] (2009). *
Braveman JM, Schoetz DJ Jr, Marcello PW, Roberts PL, Coller JA, Murray JJ, Rusin LC. The fate of the ileal pouch in patients developing Crohn's disease. Dis. Colon Rectum 47: 1613-1619 (2004).
Breban M, Said-Nahal R, Hugot JP, Miceli-Richard C. Familial and genetic aspects of spondyloarthropathy. Rheum. Dis. Clin. North Am. 29: 575-594 (2003).
Brechmann T, Heyer C, Schmiegel W. Methotrexate-induced pneumonitis in a woman with Crohn's disease. Dtsch. Med. Wochenschr. 132: 1759-1762 (2007).
Breedveld FC. Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept. Ned. Tijdschr. Geneeskd. 149: 2273-2277 (2005).
Breen EM, Ashley SW. Laparoscopic surgery for Crohn's disease? - a conditional yes. Inflamm. Bowel Dis. 6: 43-45 (2000). *
Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78: 127-131 (1993). *
Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, MacDonald TT. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466 (1994).
Bregenzer N, Hartmann A, Strauch U, Scholmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm. Bowel Dis. 12: 53-56 (2006). *
Bregenzer N, Schaffler A, Gelbmann CM, Steinkamp M, Reinshagen M, Scholmerich J, Andus T. Lack of correlation between the vitamin D receptor Fokl start codon polymorphism and bone mineral density in patients with Crohn's disease. Exp. Clin. Endocrinol. Diabetes 114: 1-5 (2006).
Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 94: 1855-1858 (2005). *
Bremner AR, Beattie RM. Recent advances in the medical therapy of Crohn's disease in childhood. Expert Opin. Pharmacother. 8: 2553-2568 (2007).
Bremner AR, Griffiths M, Argent JD, Fairhurst JJ, Beattie RM. Sonographic evaluation of inflammatory bowel disease: a prospective, blinded, comparative study. Pediatr. Radiol. 36: 947-953 (2006). *
Bremner AR, Pridgeon J, Fairhurst J, Beattie RM. Ultrasound scanning may reduce the need for barium radiology in the assessment of small-bowel Crohn's disease. Acta Paediatr. 93: 479-481 (2004).
Brenmoehl J, Falk W, Goke M, Scholmerich J, Rogler G. Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). Int. J. Colorectal Dis. 23: 947-955 (2008). *
Brenmoehl J, Herfarth H, Gl�ck T, Audebert F, Barlage S, Schmitz G, Froehlich D, Schreiber S, Hampe J, Scholmerich J, Holler E, Rogler G. Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med. 33: 1541-1548 (2007).
Brenmoehl J, Holler E, Rogler G. Polymorphisms within epithelial receptors: NOD2/CARD15. Methods Mol. Med. 134: 115-122 (2007).
Brenmoehl J, Lang M, Hausmann M, Leeb SN, Falk W, Scholmerich J, Goke M, Rogler G. Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa. Int. J. Colorectal Dis. 22: 611-623 (2007). *
Brenner DA. Gastrointestinal basic science 2002-2003: the year in review. Clin. Gastroenterol. Hepatol. 2: 9-13 (2004). *
Brenner DJ. Should computed tomography be the modality of choice for imaging Crohn's disease in children? The radiation risk perspective. Gut 57: 1489-1490 (2008).
Brentnall TA. Ursodiol: good drug makes good. Gastroenterology 124: 1139-1140 (2003). *
Brescianini S, Trinh T, Stoll M, Schreiber S, Rioux JD, Daly MJ. IBD5 is associated with an extensive complicated Crohn�s disease feature: implications from genotype-phenotype analysis. Gut 56: 149-150 (2007). *
Breslin NP, Nash C, Hilsden RJ, Hershfield NB, Price LM, Meddings JB, Sutherland LR. Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease. Am. J. Gastroenterol. 96: 2934-2938 (2001). *
Breslin NP, Todd A, Kilgallen C, O'Morain C. Monozygotic twins with Crohn's disease and ulcerative colitis: a unique case report. Gut 41: 557-560 (1997). *
Bressler B. The role of endoscopy in the management of postoperative patients with Crohn's disease. Can. J. Gastroenterol. 20: 631-632 (2006). *
Bressler B, Sands BE. Review article: medical therapy for fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 24: 1283-1293 (2006). *
Bresso F, Askling J, Astegiano M, Demarchi B, Sapone N, Rizzetto M, Gionchetti P, Lammers KM, de Leone A, Riegler G, Nimmo ER, Drummond H, Noble C, Torkvist L, Ekbom A, Zucchelli M, Lofberg R, Satsangi J, Pettersson S, D'Amato M. Potential role for the common cystic fibrosis DeltaF508 mutation in Crohn's disease. Inflamm. Bowel Dis. 13: 531-536 (2007). *
Bresson JL, Schmitz J. Malnutrition in Crohn's disease: substrate deficiency or misuse? Horm. Res. 38 Suppl. 1: 76-78 (1992).
Bret J, Lemaire O, Prat C, Zabraniecki L, Fournie B. Aseptic osteomyelitis responding to TNFalpha antagonist therapy in a patient with Crohn's disease. Joint Bone Spine 75: 489-491 (2008). *
Bretagnol F, Alves A, Panis Y. Laparoscopic ileocolectomy for Crohn's disease. J. Chir. (Paris) 144: 522-526 (2007).
Breynaert C, Vermeire S, Rutgeerts P, Van Assche G. Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk? Acta Gastroenterol. Belg. 71: 367-372 (2008).
Breza TS Jr, Magro CM. Lichenoid and granulomatous dermatitis associated with atypical mycobacterium infections. J. Cutan. Pathol. 33: 512-515 (2006). *
Bridger S, Lee JC, Bjarnason I, Jones JE, Macpherson AJ. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Gut 51: 21-25 (2002). *
Brignola C, Belloli C, Ardizzone S, Astegiano M, Cottone M, Trallori G. The relationship between heritability and smoking habits in Crohn's disease. Italian Cooperative Study Group. Am. J. Gastroenterol. 95: 3171-3175 (2000). *
Brignola C, Belloli C, De Simone G, Varesco L, Walger P, Areni A, Calabrese C, Di Febo G, Barbara L. Familial adenomatous polyposis and inflammatory bowel disease associated in two kindreds. Dig. Dis. Sci. 40: 402-405 (1995).
Brihier H, Nion-Larmurier I, Afchain P, Tiret E, Beaugerie L, Gendre JP, Cosnes J. Intestinal perforation in Crohn's disease. Gastroenterol. Clin. Biol. 29: 1105-1111 (2005). *
Brimblecombe R. Mesalazine: a global safety evaluation. Scand. J. Gastroenterol. Suppl. 172: 66 (1990).
Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J. Immunol. 174: 5814-5822 (2005). *
Brinckerhoff CE, Sporn MB. Retinoids and rexinoids for the 21st century: a brave new world for arthritis. J. Rheumatol. 30: 211-213 (2003).
Bringer MA, Barnich N, Glasser AL, Bardot O, Darfeuille-Michaud A. HtrA stress protein is involved in intramacrophagic replication of adherent and invasive Escherichia coli strain LF82 isolated from a patient with Crohn's disease. Infect. Immun. 73: 712-721 (2005). *
Bringer MA, Glasser AL, Tung CH, Meresse S, Darfeuille-Michaud A. The Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages. Cell. Microbiol. 8: 471-484 (2006). *
Bringer MA, Rolhion N, Glasser AL, Darfeuille-Michaud A. The oxidoreductase DsbA plays a key role in the ability of the Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 to resist macrophage killing. J. Bacteriol. 189: 4860-4871 (2007). *
Brinza D, He J, Zelikovsky A. Combinatorial search methods for multi-SNP disease association. Conf. Proc. IEEE Eng. Med. Biol. Soc. 1: 5802-5805 (2006).
Brinza D, Zelikovsky A. Design and validation of methods searching for risk factors in genotype case-control studies. J. Comput. Biol. 15: 81-90 (2008).
Briones T, Salvadalena G. An introduction to genetics and application to Crohn's disease. J. Wound Ostomy Continence Nurs. 34: 80-87 (2007).
Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, McEvoy LM, Butcher EC, Kassam N, Mackay CR, Newman W, Ringler DJ. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. 151: 97-110 (1997). *
Brito F, Barros FC, Zaltman C, Pugas Carvalho AT, de Vasconcellos Carneiro AJ, Fischer RG, Gustafsson A, de Silva Figueredo CM. Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis. J. Clin. Periodontol. 35: 555-560 (2008).
Brittenden J, Hosker HS, Healey C, Porter G. Oesophago-bronchial fistula causing cough and recurrent lower respiratory tract infections in a patient with Crohn's disease. Hosp. Med. 66: 310-311 (2005).
Broedl UC, Schachinger V, Lingenhel A, Lehrke M, Stark R, Seibold F, Goke B, Kronenberg F, Parhofer KG, Konrad-Zerna A. Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13: 391-397 (2007). *
Broekroelofs J, Mulder AH, Nelis GF, Westerveld BD, Tervaert JW, Kallenberg CG. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity. Dig. Dis. Sci. 39: 545-549 (1994).
Brogan PA, Malik M, Shah N, Kilday JP, Ramsay A, Shah V, Murch SH, Thomson MA, Walker-Smith JA, Lindley KJ, Milla PJ, Dillon MJ. Systemic vasculitis: a cause of indeterminate intestinal inflammation. J. Pediatr. Gastroenterol. Nutr. 42: 405-415 (2006). *
Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 38: 500-523 (1989).
Brohee P, Violon P, Mavroudakis N, Pirotte B, Brotchi J, Zegers de Beyl D, Hildebrand J. Central nervous system lesions associated with Crohn's disease. J. Neuroimaging 7: 195-198 (1997).
Bronner MP. Granulomatous appendicitis and the appendix in idiopathic inflammatory bowel disease. Semin. Diagn. Pathol. 21: 98-107 (2004).
Bronowski C, Smith SL, Yokota K, Corkill JE, Martin HM, Campbell BJ, Rhodes JM, Hart CA, Winstanley C. A subset of mucosa-associated Escherichia coli isolates from patients with colon cancer, but not Crohn's disease, share pathogenicity islands with urinary pathogenic E. coli. Microbiology 154: 571-583 (2008). *
Brookes MJ, Green JR. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs 64: 1069-1089 (2004).
Brooklyn T, Probert C. A Crohn's repertoire: T cell receptor gammadelta. Inflamm. Bowel Dis. 9: 213-214 (2003). *
Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther. Drug Monit. 29: 619-625 (2007).
Brooks M. Crohn's disease, a functional deficiency of IgA? Lancet 1: 158 (1981).
Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis. 26: 31-41 (2006). *
Broome U, Glaumann H, Hellers G, Nilsson B, Sorstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 35: 84-89 (1994). *
Broome U, Lofberg R, Lundqvist K, Veress B. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis. Colon Rectum 38: 1301-1305 (1995).
Brosbol-Ravnborg A, Hvas CL, Agnholt J, Dahlerup JF, Vind I, Till A, Rosenstiel P, Hollsberg P. Clinical immunology review series: Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways. Clin. Exp. Immunol. 155: 487-495 (2009). *
Bross DA, Leichtner AM, Zurakowski D, Law T, Bousvaros A. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J. Pediatr. Gastroenterol Nutr. 23: 164-171 (1996).
Brown AC, Valiere A. Probiotics and medical nutrition therapy. Nutr. Clin. Care 7: 56-68 (2004). *
Brown CJ, Jaffer H, Jaffer N, Burul C, McLeod RS. Spinal epidural abscess - a rare complication of inflammatory bowel disease. Can. J. Gastroenterol. 22: 177-180 (2008).
Brown CJ, Maclean AR, Cohen Z, Macrae HM, O'connor BI, McLeod RS. Crohn's disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure. Dis. Colon Rectum 48: 1542-1549 (2005). *
Brown MO. Inflammatory bowel disease. Prim. Care 26: 141-170 (1999).
Brown S, Applegate KE, Sandrasegaran K, Jennings SG, Garrett J, Skantharajah A, Maglinte DT. Fluoroscopic and CT enteroclysis in children: initial experience, technical feasibility, and utility. Pediatr. Radiol. 38: 497-510 (2008). *
Brown SJ, Abreu MT. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr. Opin. Drug Discov. Devel. 8: 160-168 (2005).
Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102: 2058-2069 (2007). *
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46: 3151-3158 (2002). *
Browning BL, Barclay ML, Bingham SA, Brand S, Buning C, Castro M, Cucchiara S, Dallapiccola B, Drummond H, Ferguson LR, Ferraris A, Fisher SA, Gearry RB, Glas J, Henckaerts L, Huebner C, Knafelz D, Lakatos L, Lakatos PL, Latiano A, Liu X, Mathew CG, et al. Gender-stratified analysis of DLG5 R30Q in 4707 Crohn's disease patients and 4973 controls from 12 Caucasian cohorts. J. Med. Genet. 45: 36-42 (2008).
Browning BL, Huebner C, Petermann I, Demmers P, McCulloch A, Gearry RB, Barclay ML, Shelling AN, Ferguson LR. Association of DLG5 variants with inflammatory bowel disease in the New Zealand caucasian population and meta-analysis of the DLG5 R30Q variant. Inflamm. Bowel Dis. 13: 1069-1076 (2007). *
Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, Shelling AN, Ferguson LR. Has Toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am. J. Gastroenterol. 102: 2504-2512 (2007). *
Broxmeyer L. Is mad cow disease caused by a bacteria? Med. Hypotheses 63: 731-739 (2004).
Bruckner HW, Hrehorovich VR, Sawhney HS, Meeus SI, Coopeman AM. Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease. J. Chemother. 18: 545-548 (2006).
Brugere-Picoux J. Crohn disease: uncertainty about the etiologic role of Mycobacterium paratuberculosis. Bull. Acad. Natl. Med. 182: 823-829 (1998).
Bruining DH Jr, Loftus EV Jr. Ultrasound-enteroclysis for Crohn's disease: the best of both worlds? Inflamm. Bowel Dis. 14: 290 (2008).
Bruining DH, Loftus EV. Evolving diagnostic strategies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 8: 478-485 (2006).
Bruining DH, Loftus EV Jr. Crohn's disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know. Abdom. Imaging 34: 297-302 (2009). *
Bruining DH, Siddiki HA, Fletcher JG, Tremaine WJ, Sandborn WJ, Loftus EV Jr. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm. Bowel Dis. 14: 1701-1706 (2008).
Brullet E, Bonfill X, Urrutia G, Ruiz Ochoa V, Cueto M, Clofent J, Martinez Salmeron JF, Riera J, Obrador A. Epidemiological study on the incidence of inflammatory bowel disease in 4 Spanish areas. Spanish Group on the Epidemiological Study of Inflammatory Bowel Disease. Med. Clin. (Barc.) 110: 651-656 (1998).
Brunborg LA, Madland TM, Lind RA, Arslan G, Berstad A, Froyland L. Effects of short-term oral administration of dietary marine oils in patients with inflammatory bowel disease and joint pain: a pilot study comparing seal oil and cod liver oil. Clin. Nutr. 27: 614-622 (2008).
Brunello F, Pera A, Martini S, Marino L, Astegiano M, Barletti C, Gastaldi P, Verme G, Emanuelli G. Antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease. Dig. Dis. Sci. 36: 1741-1745 (1991).
Brunner B, Hirschi C, Weimann R, Seibold F. Treatment-resistant lingual Crohn's disease disappears after infliximab. Scand. J. Gastroenterol. 40: 1255-1259 (2005). *
Brunner B, Scheurer U, Seibold F. Differences in yeast intolerance between patients with Crohn's disease and ulcerative colitis. Dis. Colon Rectum 50: 83-88 (2007). *
Brunner J, Sergi C, Muller T, Gassner I, Prufer F, Zimmerhackl LB. Juvenile sarcoidosis presenting as Crohn's disease. Eur. J. Pediatr. 165: 398-401 (2006). *
Bruno I, Martelossi S, Geatti O, Maggiore G, Guastalla P, Povolato M, Ventura A. Antigranulocyte monoclonal antibody immunoscintigraphy in inflammatory bowel disease in children and young adolescents. Acta Paediatr. 91: 1050-1055 (2002).
Brunser O, Gotteland M, Cruchet S. Functional fermented milk products. Nestle Nutr. Workshop Ser. Pediatr. Program 60: 235-250 (2007).
Brustolim D, Ribeiro-Dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 6: 903-907 (2006).
Bruzzese E, Canani RB, De Marco G, Guarino A. Microflora in inflammatory bowel diseases: a pediatric perspective. J. Clin. Gastroenterol. 38: S91-S93 (2004).
Bruzzese V. Diffused suberitrodermic psoriasis induced by infliximab. Reumatismo 59: 328-331 (2007).
Brynskov J, Feagan BG, Jewell D, McDonald JWD, Stange EF. Cyclosporine for maintenance of remission in Crohn�s disease. Cochrane Database Syst. Rev. 2: CD004377 (2004). *
Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig. Dis. 12: 290-304 (1994).
Brzezinski A, Rankin GB, Seidner DL, Lashner BA. Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Cleve. Clin. J. Med. 62: 317-323 (1995).
Buccino GP, Corrente G, Visintini D. Crohn's disease and multiple sclerosis: a single case report. Ital. J. Neurol. Sci. 15: 303-306 (1994).
Buchanan GN, Owen HA, Torkington J, Lunniss PJ, Nicholls RJ, Cohen CR. Long-term outcome following loose-seton technique for external sphincter preservation in complex anal fistula. Br. J. Surg. 91: 476-480 (2004). *
Buchman AL. Bones and Crohn's: problems and solutions. Inflamm. Bowel Dis. 5: 212-227 (1999).
Buchman AL, Miller FH, Wallin A, Chowdhry AA, Ahn C. Videocapsule endoscopy versus barium contrast studies for the diagnosis of Crohn's disease recurrence involving the small intestine. Am. J. Gastroenterol. 99: 2171-2177 (2004). *
Buchman AL, Paine MF, Wallin A, Ludington SS. A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. Dig. Dis. Sci. 50: 2312-2315 (2005). *
Buckland MS, Mylonaki M, Rampton D, Longhurst HJ. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation. Clin. Diagn. Lab. Immunol. 12: 1328-1330 (2005). *
Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, von Knebel Doeberitz M, Kloor M. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br. J. Cancer 92: 1746-1753 (2005).
Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig. Dis. Sci. 49: 1036-1039 (2004). *
Bueno de Mesquita M, Ferrante M, Henckaerts L, Joossens M, Janssens V, Hlavaty T, Pierik M, Joossens S, Van Schuerbeek N, Van Assche G, Rutgeerts P, Vermeire S, Hoffman I. Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease. Eur. J. Pediatr. 168: 575-583 (2009). *
Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, Kuechler I, Krueger S, Schmidt HH, Lochs H. Genetic basis for increased intestinal permeability in families with Crohn�s disease: role of CARD15 3020insC mutation? Gut 55: 342-347 (2006). *
Buhner S, Nagel E, Korber J, Vogelsang H, Linn T, Pichlmayr R. Ileal and colonic fatty acid profiles in patients with active Crohn's disease. Gut 35: 1424-1428 (1994). *
Buisine MP, Desreumaux P, Debailleul V, Gambiez L, Geboes K, Ectors N, Delescaut MP, Degand P, Aubert JP, Colombel JF, Porchet N. Abnormalities in mucin gene expression in Crohn's disease. Inflamm. Bowel Dis. 5: 24-32 (1999). *
Buisine MP, Desreumaux P, Leteurtre E, Copin MC, Colombel JF, Porchet N, Aubert JP. Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut 49: 544-551 (2001). *
Bulian P, Gaidano G, Poeta GD, Gattei V. CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target. Future Oncol. 4: 355-358 (2008).
Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild P, Rhodes G,. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J. Clin. Microbiol. 41: 2915-2923 (2003). *
Bullen TF, Hershman MJ. Surgery for inflammatory bowel disease. Hosp. Med. 64: 719-723 (2003).
Buller HA. Problems in diagnosis of IBD in children. Neth. J. Med. 50: S8-S11 (1997).
Bulte M, Schonenbrucher H, Abdulmawjood A. From farm to fork - Mycobacterium avium ssp. paratuberculosis (MAP) as zoonotic agent? Berl. Munch. Tierarztl. Wochenschr. 118: 377-385 (2005).
Buning C, Geerdts L, Fiedler T, Gentz E, Pitre G, Reuter W, Luck W, Buhner S, Molnar T, Nagy F, Lonovics J, Dignass A, Landt O, Nickel R, Genschel J, Lochs H, Schmidt HH, Witt H. DLG5 variants in inflammatory bowel disease. Am. J. Gastroenterol. 101: 786-792 (2006). *
Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, Baier P, Bochow B, Ockenga J, Schmidt HH, Lochs H. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment. Pharmacol. Ther. 19: 1073-1078 (2004). *
Buning C, Genschel J, Weltrich R, Lochs H, Schmidt H. The interleukin-25 gene located in the inflammatory bowel disease (IBD) 4 region: no association with inflammatory bowel disease. Eur. J. Immunogenet. 30: 329-333 (2003). *
Buning C, Halangk J, Dignass A, Ockenga J, Deindl P, Nickel R, Genschel J, Landt O, Lochs H, Schmidt H, Witt H. Keratin 8 Y54H and G62C mutations are not associated with inflammatory bowel disease. Dig. Liver Dis. 36: 388-391 (2004).
Buning C, Lochs H. Conventional therapy for Crohn's disease. World J. Gastroenterol. 12: 4794-4806 (2006). *
Buning C, Molnar T, Nagy F, Lonovics J, Weltrich R, Bochow B, Genschel J, Schmidt H, Lochs H. NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease: is Hungary different? World J. Gastroenterol. 11: 407-411 (2005). *
Buning C, Ockenga J, Kruger S, Jurga J, Baier P, Dignass A, Vogel A, Strassburg C, Weltrich R, Genschel J, Lochs H, Schmidt H. The C/C(-13910) and G/G(-22018) genotypes for adult-type hypolactasia are not associated with inflammatory bowel disease. Scand. J. Gastroenterol. 38: 538-542 (2003). *
Buning C, Schmidt HH, Molnar T, DE Jong DJ, Fiedler T, Buhner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Drenth JP, Landt O, Nickel R, Buttner J, Lochs H, Witt H. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment. Pharmacol. Ther. 26: 1025-1033 (2007). *
Buning C, Schmidt HH, Molnar T, Drenth JP, Fiedler T, Gentz E, Todorov T, Baumgart DC, Sturm A, Nagy F, Lonovics J, de Jong DJ, Landt O, Kage A, Nickel R, Buttner J, Lochs H, Witt H. No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with Crohn's disease: a study in 3 independent European cohorts. Inflamm. Bowel Dis. 14: 332-337 (2008). *
Buning J, Homann N, von Smolinski D, Borcherding F, Noack F, Stolte M, Kohl M, Lehnert H, Ludwig D. Helminths as governors of inflammatory bowel disease. Gut 57: 1182-1183 (2008).
Buning J, Hundorfean G, Schmitz M, Zimmer KP, Strobel S, Gebert A, Ludwig D. Antigen targeting to MHC class II-enriched late endosomes in colonic epithelial cells: trafficking of luminal antigens studied in vivo in Crohn's colitis patients. FASEB J. 20: 359-361 (2006). *
Buning J, von Smolinski D, Tafazzoli K, Zimmer KP, Strobel S, Apostolaki M, Kollias G, Heath JK, Ludwig D, Gebert A. Multivesicular bodies in intestinal epithelial cells: responsible for MHC class II-restricted antigen processing and origin of exosomes. Immunology 125: 510-521 (2008). *
Bunni J, Monkhouse SJ, Armstrong CP. Colonic perforation following mild abdominal trauma in a patient with Crohn's disease: a case report. World J. Emerg. Surg. 3: 13 (2008). *
Burakoff R. Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis? Inflamm. Bowel Dis. 14: S202-S203 (2008).
Burakoff R. Indeterminate colitis: clinical spectrum of disease. J. Clin. Gastroenterol. 38: S41-S43 (2004).
Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm. Bowel Dis. 12: 558-565 (2006). *
Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, Casciotti L, Maganti V, Reddy PS, Strahs A, Immermann F, Spinelli W, Schwertschlag U, Slager AM, Cotreau MM, Dorner AJ. Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J. Mol. Diagn. 8: 51-61 (2006). *
Burgdorf F, Schreyogg J, Keller W, von Wietersheim J, Deter HC; und the German Study Group on Psychosocial Intervention in Crohn's Disease. Predictors of health-care utilization of patients with Crohn's disease. Results of a prospective randomized multicenter trial. Med. Klin. (Munich) 102: 881-887 (2007).
Burger DC, Florin TH. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. Med. J. Aust. 190: 341-342 (2009).
Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, McPhail C, Rogala L, Miller N, Bernstein CN. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis - how much is irritable bowel syndrome? Clin. Gastroenterol. Hepatol. 4: 614-620 (2006).
Burgos-Vargas R. Spondyloarthropathies and psoriatic arthritis in children. Curr. Opin. Rheumatol. 5: 634-643 (1993).
Burgoyne CH, Field SL, Brown AK, Hensor EM, English A, Bingham SL, Verburg R, Fearon U, Lawson CA, Hamlin JP, Straszynski L, Veale D, Conaghan P, Hull MA, van Laar JM, Tennant A, Emery P, Isaacs JD, Ponchel F. Abnormal T-cell differentiation persists in rheumatoid arthritis patients in clinical remission and predicts relapse. Ann. Rheum. Dis. 67: 750-757 (2008).
Burke AP, Tavora F, Narula N, Tomaszewski JE, Virmani R. Aortitis and ascending aortic aneurysm: description of 52 cases and proposal of a histologic classification. Hum. Pathol. 39: 514-526 (2008).
Burke DA, Axon AT. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 297: 102-104 (1988). *
Burke JP, Ferrante M, Dejaegher K, Watson RW, Docherty NG, De Hertogh G, Vermeire S, Rutgeerts P, D'Hoore A, Penninckx F, Geboes K, Van Assche G, O'Connell PR. Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm. Bowel Dis. 14: 1197-1204 (2008). *
Burke JP, Kelleher B, Ramadan S, Quinlan M, Sugrue D, O'Donovan MA. Pericarditis as a complication of infliximab therapy in Crohn's disease. Inflamm. Bowel Dis. 14: 428-429 (2008). *
Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am. J. Gastroenterol. 102: 439-448 (2007). *
Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. Parasite Immunol. 31: 163-176 (2009). *
Burke P, Meyer V, Kocoshis S, Orenstein D, Chandra R, Sauer J. Obsessive-compulsive symptoms in childhood inflammatory bowel disease and cystic fibrosis. J. Am. Acad. Child. Adolesc. Psychiatry 28: 525-527 (1989).
Burke P, Meyer V, Kocoshis S, Orenstein DM, Chandra R, Nord DJ, Sauer J, Cohen E. Depression and anxiety in pediatric inflammatory bowel disease and cystic fibrosis. J. Am. Acad. Child. Adolesc. Psychiatry 28: 948-951 (1989).
Burleson GR, Burleson FG. Testing human biologicals in animal host resistance models. J. Immunotoxicol. 5: 23-31 (2008).
Burmester GR, Mease PJ, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann. Rheum. Dis. Jan 15 [Epub ahead of print] (2009). *
Burnham JM, Shults J, Petit MA, Semeao E, Beck TJ, Zemel BS, Leonard MB. Alterations in proximal femur geometry in children treated with glucocorticoids for Crohn disease or nephrotic syndrome: impact of the underlying disease. J. Bone Miner. Res. 22: 551-559 (2007).
Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, Leonard MB. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J. Bone Miner. Res. 19: 1961-1968 (2004).
Burnham JM, Shults J, Semeao E, Foster BJ, Zemel BS, Stallings VA, Leonard MB. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am. J. Clin. Nutr. 82: 413-420 (2005). *
Burnham WR, Lennard-Jones JE, Stanford JL, Bird RG. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 2: 693-696 (1978).
Burns DG. Smoking in inflammatory bowel disease and the irritable bowel syndrome. S. Afr. Med. J. 69: 232-233 (1986).
Burns KA, Martinon F. Inflammatory diseases: is ubiquitinated NEMO at the hub? Curr. Biol. 14: R1040-R1042 (2004). *
Burt RK, Traynor A, Oyama Y, Craig R. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 101: 2064-2066 (2003). *
Buscaglia JM, Giday SA, Kantsevoy SV, Clarke JO, Magno P, Yong E, Mullin GE. Performance characteristics of the suspected blood indicator feature in capsule endoscopy according to indication for study. Clin. Gastroenterol. Hepatol. 6: 298-301 (2008).
Bush M, Patel S, Lapinski R, Stone J. Perinatal outcomes in inflammatory bowel disease. J. Matern. Fetal. Neonatal. Med. 15: 237-241 (2004).
Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory bowel disease. J. Rheumatol. 26: 1167-1171 (1999).
Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 3: e2267 (2008). *
Bustamante M, Devesa F, Pareja V, Ferrando MJ, Ortuno J, Borghol A. Development of inflammatory bowel disease in a husband and wife. Gastroenterol. Hepatol. 25: 244-246 (2002).
Butler M, Boyle JJ, Powell JJ, Playford RJ, Ghosh S. Dietary microparticles implicated in Crohn's disease can impair macrophage phagocytic activity and act as adjuvants in the presence of bacterial stimuli. Inflamm. Res. 56: 353-361 (2007). *
Butt MT, Bener A, Al-Kaabi S, Yakoub R. Clinical characteristics of Crohn s disease in Qatar. Saudi Med. J. 26: 1796-1799 (2005).
Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD006634 (2008). *
Buxton MJ, Lacey LA, Feagan BG, Niecko T, Miller DW, Townsend RJ. Mapping from disease-specific measures to utility: an analysis of the relationships between the inflammatory bowel disease questionnaire and Crohn's disease activity index in Crohn's disease and measures of utility. Value Health 10: 214-220 (2007).
Byrn JC, Wang JL, Divino CM, Nguyen SQ, Warner RR. Management of goblet cell carcinoid. J. Surg. Oncol. 94: 396-402 (2006).
Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn's disease. Dis. Colon Rectum 50: 586-597 (2007). *
Byrne FR, Viney JL. Mouse models of inflammatory bowel disease. Curr. Opin. Drug Discov. Devel. 9: 207-217 (2006).
Byun JR, Cho SH, Yang DH, Kim YK, Ju JK, Choi SK, Chung IJ. Ileovesical fistula caused by hepatocellular carcinoma. Korean J. Intern. Med. 20: 76-79 (2005).
Caballero T, Nogueras F, Medina MT, Caracuel MD, de Sola C, Martinez-Salmeron FJ, Rodrigo M, Garcia del Moral R. Intraepithelial and lamina propria leucocyte subsets in inflammatory bowel disease: an immunohistochemical study of colon and rectal biopsy specimens. J. Clin. Pathol. 48: 743-748 (1995). *
Cabral VL, Miszputen SJ, Catapani WR. Anti-neutrophil cytoplasmic antibodies in Brazilian patients with inflammatory bowel disease. Hepatogastroenterology 50: 412-415 (2003).
Cabre E, Gassull MA. Nutrition in inflammatory bowel disease: impact on disease and therapy. Curr. Opin. Gastroenterol. 17: 342-349 (2001).
Cabre E, Gassull MA. Nutritional and metabolic issues in inflammatory bowel disease. Curr. Opin. Clin. Nutr. Metab. Care 6: 569-576 (2003).
Cabre Gelada E. Nutrition and inflammatory bowel disease. Nutr. Hosp. 22 Suppl. 2: 65-73 (2007).
Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch. Dis. Child. 89: 69-71 (2004). *
Cachia E, Calleja N, Aakeroy R, Degaetano J, Vassallo M. Incidence of inflammatory bowel disease in Malta between 1993 and 2005: a retrospective study. Inflamm. Bowel Dis. 14: 550-553 (2008). *
Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin Iv HW. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456: 259-263 (2008). *
Cadwell K, Patel KK, Komatsu M, Virgin HW 4th, Stappenbeck TS. A common role for Atg16L1, Atg5 and Atg7 in small intestinal Paneth cells and Crohn disease. Autophagy 5: 250-252 (2009).
Cagnard B, Tosoni-Verlingue D, Tribut O, Moizard C, Bridoux-Henno L, Delaperriere N, Bentue-Ferrer D, Dabadie A. Advantages of different dosages of active metabolites in the follow-up of azathioprine treatment for Crohn disease. Arch. Pediatr. 13 Suppl. 1: S67-S68 (2007).
Cai J, Li F, Zhou W, Luo HS. Ileocecal ulcer in Central China: case series. Dig. Dis. Sci. 52: 3169-3173 (2007). *
Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig. Dis. Sci. 54: 842-847 (2009). *
Calabrese C, Gionchetti P, Rizzello F, Liguori G, Gabusi V, Tambasco R, Poggioli G, Pierangeli F, Campieri M, Di Febo G. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment. Pharmacol. Ther. 27: 759-764 (2008). *
Calabrese E, La Seta F, Buccellato A, Virdone R, Pallotta N, Corazziari E, Cottone M. Crohn's disease: a comparative prospective study of transabdominal ultrasonography, small intestine contrast ultrasonography, and small bowel enema. Inflamm. Bowel Dis. 11: 139-145 (2005). *
Calabrese E, Petruzziello C, Onali S, Condino G, Zorzi F, Pallone F, Biancone L. Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm. Bowel Dis. Apr 30 [Epub ahead of print] (2009).
Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann. Rheum. Dis. 67 Suppl. 3: iii64-iii65 (2008).
Calder E. Radiological aspects of recoverable regional ileitis and its relationship to Crohn's disease. Glasgow Med. J. 30: 65-81 (1949).
Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm. Bowel Dis. 11: 435-441 (2005). *
Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig. Dis. Sci. 34: 1841-1854 (1989).
Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin. Cutan. Med. Surg. 26: 6-14 (2007).
Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejon A, Vergara M, Campo R, Brullet E. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm. Bowel Dis. 12: 692-696 (2006). *
Calvino J, Romero R, Pintos E, Losada E, Novoa D, Guimil D, Mardaras J, Sanchez-Guisande D. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin. Nephrol. 49: 265-267 (1998).
Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 33: 668-674 (1992). *
Cameron CA, Sawatzky JA. Postoperative pain management: the challenges of the patient with Crohn's disease. Medsurg. Nurs. 17: 85-91 (2008).
Camilleri M. GIH clinical research 2003-2004: the year in review. Clin. Gastroenterol. Hepatol. 2: 1043-1047 (2004). *
Camilleri M. Anti-TNF antibodies for Crohn's disease. N. Engl. J. Med. 357: 1662 (2007).
Camilleri M, Nadeau A, Tremaine WJ, Lamsam J, Burton D, Odunsi S, Sweetser S, Singh R. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol. Motil. Mar 13 [Epub ahead of print] (2009).
Cammarota T, Sarno A, Robotti D, Bonenti G, Debani P, Versace K, Astegiano M, Pera A. US evaluation of patients affected by IBD: how to do it, methods and findings. Eur. J. Radiol. 69: 429-437 (2009).
Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm. Bowel Dis. 4: 285-290 (1998). *
Campbell FC, Maxwell RJ. Rationale for cancer prevention strategies in high-risk ulcerative colitis. Surgeon 7: 96-100 (2009).
Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut 50 Suppl. 3: iii43-iii46 (2002). *
Campos FG, Waitzberg DL, Teixeira MG, Mucerino DR, Kiss DR, Habr-Gama A. Pharmacological nutrition in inflammatory bowel diseases. Nutr. Hosp. 18: 57-64 (2003).
Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore) 72: 151-183 (1993).
Canani RB, Romano MT, Greco L, Terrin G, Sferlazzas C, Barabino A, Fontana M, Roggero P, Guariso G, De Angelis G, Fecarotta S, Polito G, Cucchiara S. Effects of disease activity on anti-Saccharomyces cerevisiae antibodies - Implications for diagnosis and follow-up of children with Crohn's disease. Inflamm. Bowel Dis. 10: 234-239 (2004). *
Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment. Pharmacol. Ther. 23: 377-385 (2006). *
Canavan C, Abrams KR, Hawthorne B, Mayberry JF. Long-term prognosis in Crohn's disease: an epidemiological study of patients diagnosed more than 20 years ago in Cardiff. Aliment. Pharmacol. Ther. 25: 59-65 (2007). *
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment. Pharmacol. Ther. 23: 1097-1104 (2006). *
Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment. Pharmacol. Ther. 25: 861-870 (2007). *
Canbay A, Bechmann LP, Best J, Jochum C, Treichel U, Gerken G. Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z. Gastroenterol. 44: 245-248 (2006).
Candela G, Di Libero L, Varriale S, Manetta F, Giordano M, Lanza M, Nunziata A, Santini L. Anastomotic configuration as a risk factor in the recurring onset after intestinal resection for Crohn's disease: our point of view. Minerva Chir. 62: 61-67 (2007).
Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin. Immunol. 118: 11-19 (2006). *
Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37: 674-678 (1995). *
Cane G, Moal VL, Pages G, Servin AL, Hofman P, Vouret-Craviari V. Up-regulation of intestinal vascular endothelial growth factor by Afa/Dr diffusely adhering Escherichia coli. PLoS ONE 2: e1359 (2007). *
Cannioto Z, Berti I, Martelossi S, Bruno I, Giurici N, Crovella S, Ventura A. IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur. J. Pediatr. 168: 149-155 (2009).
Canto E, Ricart E, Busquets D, Monfort D, Garcia-Planella E, Gonzalez D, Balanzo J, Rodriguez-Sanchez JL, Vidal S. Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype. World J. Gastroenterol. 13: 5446-5453 (2007). *
Canto E, Ricart E, Monfort D, Gonzalez-Juan D, Balanzo J, Rodriguez-Sanchez JL, Vidal S. TNFalpha production to TLR2 ligands in active IBD patients. Clin. Immunol. 119: 156-165 (2006). *
Cantor MJ, Nickerson P, Bernstein CN. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am. J. Gastroenterol. 100: 1134-1142 (2005). *
Cao Q, Si JM, Gao M, Zhou G, Hu WL, Li JH. Clinical presentation of inflammatory bowel disease: a hospital based retrospective study of 379 patients in eastern China. Chin. Med. J. (Engl.) 118: 747-752 (2005).
Cao Q, Zhu Q, Shang Y, Gao M, Si J. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion 79: 58-63 (2009).
Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell Physiol. 213: 341-347 (2007). *
Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gutin A, Abkevic V, Burden AD, Lanchbury J, Barker JN, Trembath RC, Nestle FO. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122: 201-206 (2007). *
Caprilli R, Angelucci E, Clemente V. Recent advances in the management of Crohn's disease. Dig. Liver Dis. 40: 709-716 (2008).
Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn's disease? Dig. Liver Dis. 37: 973-979 (2005).
Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Dig. Liver Dis. 37: 407-417 (2005).
Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, Papi C, Viscido A, Camma C, Corrao G, Latella G. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment. Pharmacol. Ther. 17: 517-523 (2003). *
Caprilli R, Frieri G. The dyspeptic macrophage 30 years later: and update in the pathogenesis of Crohn's disease. Dig. Liver Dis. 41: 166-168 (2009).
Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'morain C, Anwar MM, Freitas JL, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55 Suppl. 1: i36-i58 (2006). *
Caprilli R, Guagnozzi D. CARD 15 and Toll-like receptors: the link with Crohn's disease. Dig. Liver Dis. 35: 753-757 (2003).
Caprilli R, Viscido A, Guagnozzi D. Review article: biological agents in the treatment of Crohn's disease. Aliment. Pharmacol. Ther. 16: 1579-1590 (2002). *
Caprioli F, Losco A, Vigano C, Conte D, Biondetti P, Forzenigo LV, Basilisco G. Computer-assisted evaluation of perianal fistula activity by means of anal ultrasound in patients with Crohn's disease. Am. J. Gastroenterol. 101: 1551-1558 (2006). *
Caprioli F, Pallone F, Monteleone G. Th17 immune response in IBD: a new pathogenic mechanism. Journal of Crohn's and Colitis 2: 291-295 (2008).
Caprioli F, Sarra M, Caruso R, Stolfi C, Fina D, Sica G, Macdonald TT, Pallone F, Monteleone G. Autocrine regulation of IL-21 production in human T lymphocytes. J. Immunol. 180: 1800-1807 (2008). *
Caprioli F, Stolfi C, Caruso R, Fina D, Sica G, Biancone L, Pallone F, Monteleone G. Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation. Gut 57: 1674-1680 (2008).
Capristo E, Valentini G, Scarfone A, Addolorato G, Giancaterini A, Ghittoni G, Mingrone G, Greco AV, Gasbarrini G. Alterations of nutrional status in the main gastro-intestinal pathologies. Minerva Gastroenterol. Dietol. 45: 137-151 (1999).
Cara Terribas CJ, Gonzalez Guijarro L. Hypomethylation and multiple sclerosis, the susceptibility factor? Neurologia 17: 132-135 (2002).
Caradonna L, Amati L, Lella P, Jirillo E, Caccavo D. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease. Am. J. Gastroenterol. 95: 1495-1502 (2000). *
Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J. Endotoxin Res. 6: 205-214 (2000). *
Caramoy A, Lappas A, Fauser S, Kirchhof B. Central scotoma and blurred vision in a patient with Crohn's disease. Ophthalmologe May 15 [Epub ahead of print] (2009).
Carbone J, Gonzalez-Lara V, Sarmiento E, Chean C, Perez JL, Marin I, Rodriguez-Molina JJ, Gil J, Fernandez-Cruz E. Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab. Ann. N. Y. Acad. Sci. 1107: 346-355 (2007). *
Carbone J, Perez-Rojas J, Sarmiento E. Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor. Curr. Infect. Dis. Rep. 11: 229-236 (2009).
Carbonnel F. Which place for methotrexate in treatment of luminal Crohn's disease? Gastroenterol. Clin. Biol. 33: 18-20 (2009).
Carbonnel F, Macaigne G, Beaugerie L, Gendre JP, Cosnes J. Crohn's disease severity in familial and sporadic cases. Gut 44: 91-95 (1999). *
Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 125: 1583-1590 (2003). *
Card T, Logan RF, Rodrigues LC, Wheeler JG. Antibiotic use and the development of Crohn's disease. Gut 53: 246-250 (2004). *
Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 53: 251-255 (2004). *
Cardon LR. Genetics. Delivering new disease genes. Science 314: 1403-1405 (2006). *
Cardoso H, Nunes AC, Carneiro F, Veloso FT. Successful infliximab therapy for oral Crohn's disease. Inflamm. Bowel Dis. 12: 337-338 (2006). *
Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H, Denson LA. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm. Bowel Dis. 14: 446-457 (2008). *
Cariappa A, Sands B, Forcione D, Finkelstein D, Podolsky DK, Pillai S. Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease. Gut 43: 210-215 (1998). *
Caricato M, Ausania F, Borzomati D, Valeri S, Coppola R, Verzi A, Tonini G. Large abdominal mass in Crohn's disease. Gut 53: 1493 (2004). *
Cario E, Golenbock DT, Visintin A, Runzi M, Gerken G, Podolsky DK. Trypsin-sensitive modulation of intestinal epithelial MD-2 as mechanism of lipopolysaccharide tolerance. J. Immunol. 176: 4258-4266 (2006). *
Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68: 7010-7017 (2000). *
Carlo JT, Demarco D, Smith BA, Livingston S, Wiser K, Kuhn JA, Lamont JP. The utility of capsule endoscopy and its role for diagnosing pathology in the gastrointestinal tract. Am. J. Surg. 190: 886-890 (2006). *
Carlsen HS, Yamanaka T, Scott H, Rugtveit J, Brandtzaeg P. The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria. Inflamm. Bowel Dis. 12: 1013-1024 (2006). *
Carlson GL. Surgical management of intestinal failure. Proc. Nutr. Soc. 62: 711-718 (2003). *
Carlson JA, Chen KR. Cutaneous vasculitis update: neutrophilic muscular vessel and eosinophilic, granulomatous, and lymphocytic vasculitis syndromes. Am. J. Dermatopathol. 29: 32-43 (2007).
Carlsson E, Bosaeus I, Nordgren S. What concerns subjects with inflammatory bowel disease and an ileostomy? Scand. J. Gastroenterol. 38: 978-984 (2003). *
Carneiro LA, Travassos LH, Girardin SE. Nod-like receptors in innate immunity and inflammatory diseases. Ann. Med. 39: 581-593 (2007).
Carol M, Borruel N, Antolin M, Llopis M, Casellas F, Guarner F, Malagelada JR. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J. Leukoc. Biol. 79: 917-922 (2006). *
Carpenter E, Jackson MA, Friesen CA, Scarbrough M, Roberts CC. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. J. Pediatr. 144: 541-544 (2004). *
Carranza DC, Young L. Successful treatment of metastatic Crohn's disease with cyclosporine. J. Drugs Dermatol. 7: 789-791 (2008).
Carrat Ugrave P, Dragonieri S, Nocerino MC, Trabucco SM, Lacedonia D, Parisi G, Resta O. A case of cryptogenic organizing pneumonia occurring in Crohn's disease. Can. Respir. J. 12: 437-439 (2005).
Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U.S.A. 104: 282-287 (2007). *
Carrigan SO, Pink DB, Stadnyk AW. Neutrophil transepithelial migration in response to the chemoattractant fMLP but not C5a is phospholipase D-dependent and related to the use of CD11b/CD18. J. Leukoc. Biol. 82: 1575-1584 (2007). *
Carroccio A, Di Prima L, Pirrone G, Ambrosiano G, Noto D, Cefalu AB. Anti-TNF (infliximab) treatment in Crohn disease: safety profile. Recenti Prog. Med. 97: 108-112 (2006).
Carter AB, Misyak SA, Hontecillas R, Bassaganya-Riera J. Dietary modulation of inflammation-induced colorectal cancer through PPARgamma. PPAR Res. 2009: 498352 (2009). *
Carter JD, Valeriano J, Vasey FB. Crohn disease worsened by anakinra administration. J. Clin. Rheumatol. 9: 276-277 (2003).
Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 53 Suppl. 5: V1-V16 (2004). *
Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment. Pharmacol. Ther. 14: 1169-1179 (2000). *
Caruso R, Sarra M, Stolfi C, Rizzo A, Fina D, Fantini MC, Pallone F, Macdonald TT, Monteleone G. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 136: 2270-2279 (2009). *
Carvalho AT, Elia CC, de Souza HS, Elias PR, Pontes EL, Lukashok HP, de Freitas FC, Lapa e Silva JR. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J. Clin. Gastroenterol. 36: 120-125 (2003).
Carvalho FA, Barnich N, Sauvanet P, Darcha C, Gelot A, Darfeuille-Michaud A. Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm. Bowel Dis. 14: 1051-1060 (2008).
Carvalho R, Dilworth P, Docimo S, Cuffari C. Crohn disease of the neovagina and augmented bladder in a child born with cloacal exstrophy. J. Pediatr. Gastroenterol. Nutr. 48: 106-109 (2009).
Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin. Pediatr. Surg. 16: 164-171 (2007).
Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflamm. Bowel Dis. 12: 258-262 (2006). *
Casanelli JM, Keli E, N'Dri J, Bohoussou PE, Blegole C, Moussa B, N'guessan HA. Crohn's disease: first report in Cote-d'Ivoire. Med. Trop. (Mars.) 64: 384-386 (2004).
Casati J, Toner BB, de Rooy EC, Drossman DA, Maunder RG. Concerns of patients with inflammatory bowel disease: a review of emerging themes. Dig. Dis. Sci. 45: 26-31 (2000). *
Casella G, De Marco E, Monti C, Baldini V. The therapeutic role of thalidomide in inflammatory bowel disease. Minerva Gastroenterol. Dietol. 52: 293-301 (2006).
Casellas F, Alcala MJ, Prieto L, Miro JR, Malagelada JR. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am. J. Gastroenterol. 99: 457-461 (2004). *
Casellas F, Arenas JI, Baudet JS, Fabregas S, Garcia N, Gelabert J, Medina C, Ochotorena I, Papo M, Rodrigo L, Malagelada JR. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm. Bowel Dis. 11: 488-496 (2005). *
Casellas F, Borruel N, Antolin M, Varela E, Torrejon A, Armadans L, Guarner F, Malagelada JR. Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis. Inflamm. Bowel Dis. 13: 386-390 (2007). *
Casellas F, Borruel N, Torrejon A, Varela E, Antolin M, Guarner F, Malagelada JR. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment. Pharmacol. Ther. 25: 1061-1067 (2007). *
Casellas F, Fontanet G, Borruel N, Malagelada J. The opinion of patients with inflammatory bowel disease on healthcare received. Rev. Esp. Enferm. Dig. 96: 174-184 (2004). *
Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Impact of surgery for Crohn's disease on health-related quality of life. Am. J. Gastroenterol. 95: 177-182 (2000). *
Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm. Bowel Dis. 13: 1395-1400 (2007). *
Casellas F, Vivancos JL, Sampedro M, Malagelada JR. Relevance of the phenotypic characteristics of Crohn's disease in patient perception of health-related quality of life. Am. J. Gastroenterol. 100: 2737-2742 (2005). *
Casellas Jorda F. TNF-alpha inhibitors in inflamatory bowel disease. Med. Clin. (Barc.) 123: 627-634 (2004).
Casellas Jorda F, Lopez Vivancos J. Evaluation of quality of life in digestive diseases. Gastroenterol. Hepatol. 27: 58-68 (2004).
Casillas S, Delaney CP. Laparoscopic surgery for inflammatory bowel disease. Dig. Surg. 22: 135-142 (2005).
Casillas S, Delaney CP, Senagore AJ, Brady K, Fazio VW. Does conversion of a laparoscopic colectomy adversely affect patient outcome? Dis. Colon Rectum 47: 1680-1685 (2004).
Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 154: 2434-2440 (1995).
Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F, Moesgaard F, Munkholm P; on behalf of the Danish Crohn Colitis Database. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin. Gastroenterol. Hepatol. 6: 1212-1217 (2008).
Caspi O, Polliack A, Klar R, Ben-Yehuda D. The association of inflammatory bowel disease and leukemia - coincidence or not? Leuk. Lymphoma 17: 255-262 (1995).
Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int. J. Immunopathol. Pharmacol. 19: 237-240 (2006).
Cassater D, Gambaro G, Fabris A, Cena C, Calabria S, Capelluto S, Lupo A. Henoch-Schonlein purpura and Crohn's disease in a family. J. Nephrol. 19: 387-390 (2006).
Cassinotti A, Annaloro C, Ardizzone S, Onida F, Volpe AD, Clerici M, Usardi P, Greco S, Maconi G, Porro GB, Deliliers GL. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 57: 211-217 (2008).
Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm. Bowel Dis. Feb 23 [Epub ahead of print] (2009).
Castellaneta SP, Afzal NA, Greenberg M, Deere H, Davies S, Murch SH, Walker-Smith JA, Thomson M. Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 39: 257-261 (2004). *
Castellanos E, Aranaz A, Gould KA, Linedale R, Stevenson K, Alvarez J, Dominguez L, de Juan L, Hinds J, Bull TJ. Discovery of stable and variable differences in the Mycobacterium avium subspecies paratuberculosis Types I, II and III genomes by pan-genome microarray analysis. Appl. Environ. Microbiol. 75: 676-686 (2009). *
Castellino F, Rosina F, Bansi DS, Bauducci M, Touscoz GA, Giorda L, Borghesio E, Bessone MP, Astegiano M, Musso A, et al. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease? Eur. J. Gastroenterol. Hepatol. 7: 859-864 (1995).
Castiglione F, Bucci L, Pesce G, De Palma GD, Camera L, Cipolletta F, Testa A, Diaferia M, Rispo A. Oral contrast-enhanced sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. Inflamm. Bowel Dis. 14: 1240-1245 (2008).
Castiglione F, De Sio I, Cozzolino A, Rispo A, Manguso F, Del Vecchio Blanco G, Di Girolamo E, Castellano L, Ciacci C, Mazzacca G. Bowel wall thickness at abdominal ultrasound and the one-year-risk of surgery in patients with Crohn's disease. Am. J. Gastroenterol. 99: 1977-1983 (2004). *
Castiglione F, Rispo A, Di Girolamo E, Cozzolino A, Manguso F, Grassia R, Mazzacca G. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment. Pharmacol. Ther. 18: 1107-1112 (2003). *
Castillo E, Thomassie LM, Whitlow CB, Margolin DA, Malcolm J, Beck DE. Continent ileostomy: current experience. Dis. Colon Rectum 48: 1263-1268 (2005). *
Castro M, Knafelz D, Rossi L, Ambrosini MI, Papadatou B, Mambrini G, Magnani M. Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn's disease: case report. J. Pediatr. Gastroenterol. Nutr. 42: 313-315 (2006). *
Castro M, Papadatou B, Baldassare M, Balli F, Barabino A, Barbera C, Barca S, Barera G, Bascietto F, Berni Canani R, Calacoci M, Campanozzi A, Castellucci G, Catassi C, Colombo M, Covoni MR, Cucchiara S, D'Altilia MR, De Angelis GL, De Virgilis S, et al. Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996-2003). Inflamm. Bowel Dis. 14: 1246-1252 (2008).
Castro M, Rossi L, Papadatou B, Bracci F, Knafelz D, Ambrosini M, Calce A, Serafini S, Isacchi G, D'orio F, Mambrini G, Magnani M. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J. Pediatr. Gastroenterol. Nutr. 44: 423-426 (2007). *
Castro-Santos P, Mozo L, Gutierrez C, Suarez A. TNFalpha genotype influences development of IgA-ASCA antibodies in Crohn's disease patients with CARD15 wild type. Clin. Immunol. 121: 305-313 (2006). *
Castro-Santos P, Suarez A, Lopez-Rivas L, Mozo L, Gutierrez C. TNFalpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency. Am. J. Gastroenterol. 101: 1039-1047 (2006). *
Cat H, Sophani I, Lemann M, Modiglani R, Solue JC. Cyclosporin treatment of anal and perianal lesions associated with Crohn's disease. Turk. J. Gastroenterol. 14: 121-127 (2003). *
Catarzi S, Marcucci T, Papucci L, Favilli F, Donnini M, Tonelli F, Vincenzini MT, Iantomasi T. Apoptosis and Bax, Bcl-2, Mcl-1 expression in neutrophils of Crohn's disease patients. Inflamm. Bowel Dis. 14: 819-825 (2008). *
Catenacci MH, King KK. Images in emergency medicine. Crohn's disease. Ann. Emerg. Med. 46: 559, 564 (2005).
Caturelli E, Ghittoni G, Roselli P. Ultrasound assessment of vascularization of bowel wall in Crohn's disease. Eur. J. Radiol. 65: 242-243 (2008).
Caunedo Alvarez A, Herrerias Gutierrez JM. Role of endoscopic capsule in the diagnosis of digestive diseases. Med. Clin. (Barc.) 124: 427-433 (2005).
Cavaglieri CR, Nishiyama A, Fernandes LC, Curi R, Miles EA, Calder PC. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sci. 73: 1683-1690 (2003). *
Cavanaugh J. NOD2: ethnic and geographic differences. World J. Gastroenterol. 12: 3673-3677 (2006). *
Cavanaugh J; IBD International Genetics Consortium. International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. Am. J. Hum. Genet. 68: 1165-1171 (2001). *
Cavanaugh JA, Adams KE, Quak EJ, Bryce ME, O'Callaghan NJ, Rodgers HJ, Magarry GR, Butler WJ, Eaden JA, Roberts-Thomson IC, Pavli P, Wilson SR, Callen DF. CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population. Ann. Hum. Genet. 67: 35-41 (2003). *
Cavanaugh JA, Callen DF, Wilson SR, Stanford PM, Sraml ME, Gorska M, Crawford J, Whitmore SA, Shlegel C, Foote S, Kohonen-Corish M, Pavli P. Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. Ann. Hum. Genet. 62: 291-298 (1998). *
Cavanaugh JA, Pavli P. Ulcerative colitis: a genetic disease? Baillieres Clin. Gastroenterol. 11: 1-15 (1997).
Cave D. Capsule endoscopy and Crohn's disease. Gastrointest. Endosc. 61: 262-263 (2005). *
Cave NJ. Chronic inflammatory disorders of the gastrointestinal tract of companion animals. N. Z. Vet. J. 51: 262-274 (2003).
Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin. Drug Saf. 7: 617-632 (2008).
Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J. Gastroenterol. 13: 5238-5244 (2007). *
Caye-Thomasen P, Nielsen TR, Petri NE. Primary oral manifestation of Crohn disease. Ugeskr. Laeger. 164: 3363-3364 (2002).
Cazzato IA, Cammarota G, Nista EC, Cesaro P, Sparano L, Bonomo V, Gasbarrini GB, Gasbarrini A. Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. Dig. Liver Dis. 39: 483-487 (2007).
Ceballos C. Growth and early onset inflammatory bowel disease. Gastroenterol. Nurs. 31: 101-104 (2008).
Celik Y, Dagli U, Yalin Kilic M, Toruner M, Ceren Ozen S, Ozkan M, Soykan I, Cetinkaya H, Ulker A, Ozden A, Mithat Bozdayi A. Cytokine gene polymorphisms in Turkish patients with inflammatory bowel disease. Scand. J. Gastroenterol. 41: 559-565 (2006). *
Cellier C, De Beenhouwer H, Berger A, Penna C, Carbonnel F, Parc R, Cugnenc PH, Le Quintrec Y, Gendre JP, Barbier JP, Portaels F. Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum DNA cannot be detected by PCR in Crohn's disease tissue. Gastroenterol. Clin. Biol. 22: 675-678 (1998).
Cerezo Ruiz A, Gomez Camacho F, Garcia Sanchez V, Iglesias Flores E, Gallardo Valverde JM, DE Dios Vega JF. A young woman with Crohn's disease and portal gas. Gastroenterol. Hepatol. 31: 550-551 (2008).
Cerveny P, Bortl�k M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm. Bowel Dis. 13: 1244-1249 (2007). *
Cesarini M, Angelucci E, Fiorino G, Crudeli A, Vernia P, Caprilli R. Postoperative recurrence of Crohn's disease and videocapsule endoscopy: it is necessary to leave no stone unturned. Inflamm. Bowel Dis. 14: 1165-1166 (2008).
Cesaro A, Abakar-Mahamat A, Brest P, Lassalle S, Selva E, Filippi J, Hebuterne X, Hugot JP, Doglio A, Galland F, Naquet P, Vouret-Craviari V, Mograbi B, Hofman PM. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G1332-G1343 (2009). *
Ceyhan B. Pulmonary involvement in inflammatory bowel disease. Tuberk. Toraks. 54: 292-298 (2006).
Cezard JP, Munck A, Mouterde O, Morali A, Lenaerts C, Lachaux A, Turck D, Schmitz J, Maurage C, Girardet JP, Belli D, Lamireau T, Sarles J, Chouraqui JP, Descos B, Dabadi A, Meyer M, Olives JP, Mary JY. Prevention of relapse by mesalazine (pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol. Clin. Biol. 33: 31-40 (2009).
Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, Mougenot JF, Alberti C, Goulet O. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 36: 632-636 (2003). *
Cezard JP, Touati G, Alberti C, Hugot JP, Brinon C, Czernichow P. Growth in paediatric Crohn's disease. Horm. Res. 58 Suppl. 1: 11-15 (2002).
Chacon O, Bermudez LE, Barletta RG. Johne's disease, inflammatory bowel disease, and Mycobacterium paratuberculosis. Annu. Rev. Microbiol. 58: 329-363 (2004). *
Chakraborty A, Bremner AR, Moore I, Beattie RM. Coeliac disease and Crohn's disease: an association not to be forgotten. Hosp. Med. 64: 684-655 (2003).
Challis S, Surgenor S. Helping patients with Crohn's disease to stop smoking. Prof. Nurse 19: 386-389 (2004).
Chamaillard M, Girardin SE, Viala J, Philpott DJ. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell. Microbiol. 5: 581-592 (2003). *
Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S, Chareyre F, Bui TH, Giovannini M, Zaehringer U, Penard-Lacronique V, Sansonetti PJ, Hugot JP, Thomas G. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 100: 3455-3460 (2003). *
Chamberlin W. Importance of the Australian Crohn's disease antibiotic study. Gastroenterology 133: 1744-1745 (2007). *
Chamberlin W, Borody T, Naser S. MAP-associated Crohn's disease MAP, Koch's postulates, causality and Crohn's disease. Dig. Liver Dis. 39: 792-794 (2007).
Chamberlin W, Ghobrial G, Chehtane M, Naser SA. Successful treatment of a Crohn's disease patient infected with bacteremic Mycobacterium paratuberculosis. Am. J. Gastroenterol. 102: 689-691 (2007). *
Chamberlin W, Graham DY, Hulten K, El-Zimaity HM, Schwartz MR, Naser S, Shafran I, El-Zaatari FA. Review article: Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease. Aliment. Pharmacol. Ther. 15: 337-346 (2001). *
Chamberlin W, Hulten K, Graham DY. Antibiotics as primary therapy for Crohn's disease. Drugs Today (Barc.) 36: 667-678 (2000).
Chamberlin W, Naser SA. Blood cultures of 19 Crohn's disease patients. Am. J. Gastroenterol. 103: 802-803 (2008).
Chamberlin WM, Naser SA. Integrating theories of the etiology of Crohn's disease on the etiology of Crohn's disease: questioning the hypotheses. Med. Sci. Monit. 12: RA27-RA33 (2006). *
Chamberlin WM, Shafran I. Anti-mycobacterials and Crohn's disease. Aliment. Pharmacol. Ther. 28: 373-374 (2008). *
Chamberlin WM, Shafran I. Anti-mycobacterials and Crohn's disease. Aliment. Pharmacol. Ther. 28: 373-374 (2008). *
Chami G, Raza M, Bernstein CN. Usefulness and impact on management of positive and negative capsule endoscopy. Can. J. Gastroenterol. 21: 577-581 (2007).
Chamouard P, Desprez D, Hugel B, Kunzelmann C, Gidon-Jeangirard C, Lessard M, Baumann R, Freyssinet JM, Grunebaum L. Circulating cell-derived microparticles in Crohn's disease. Dig. Dis. Sci. 50: 574-580 (2005). *
Chamouard P, Monneaux F, Richert Z, Voegeli AC, Lavaux T, Gaub MP, Baumann R, Oudet P, Muller S. Diminution of circulating CD4(+)CD25 (high) T cells in naive Crohn's disease. Dig. Dis. Sci. Dec 3 [Epub ahead of print] (2008). *
Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin. Gastroenterol. Hepatol. 4: 882-887 (2006).
Champault A, Benoist S, Alves A, Panis Y. Surgical therapy for Crohn's disease of the colon and rectum. Gastroenterol. Clin. Biol. 28: 882-892 (2004).
Chan CY, Browning JC, Larsen F, Hsu S. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis. Dermatol. Online J. 14: 12 (2008).
Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J. Drugs Dermatol. 3: 315-318 (2004).
Chan RC, Katelaris PH, Stewart P, Lin BP. Small bowel adenocarcinoma with high levels of microsatellite instability in Crohn's disease. Hum. Pathol. 37: 631-634 (2006).
Chanda P, Sucheston L, Zhang A, Brazeau D, Freudenheim JL, Ambrosone C, Ramanathan M. AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environment interactions associated with complex phenotypes. Genetics 180: 1191-1210 (2008). *
Chanda P, Sucheston L, Zhang A, Ramanathan M. The interaction index, a novel information-theoretic metric for prioritizing interacting genetic variations and environmental factors. Eur. J. Hum. Genet. Mar 18 [Epub ahead of print] (2009).
Chanda P, Zhang A, Brazeau D, Sucheston L, Freudenheim JL, Ambrosone C, Ramanathan M. Information-theoretic metrics for visualizing gene-environment interactions. Am. J. Hum. Genet. 81: 939-963 (2007). *
Chande N, Macdonald J, McDonald J. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 4: CD006618 (2007). *
Chande N, Ponich T, Gregor J. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can. J. Gastroenterol. 19: 553-558 (2005).
Chandran P, Satthaporn S, Robins A, Eremin O. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (I). Surgeon 1: 63-75 (2003).
Chandran P, Satthaporn S, Robins A, Eremin O. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (II). Surgeon 1: 125-136 (2003).
Chang DK, Kim JJ, Choi H, Eun CS, Han DS, Byeon JS, Kim JO. Double balloon endoscopy in small intestinal Crohn's disease and other inflammatory diseases such as cryptogenic multifocal ulcerous stenosing enteritis (CMUSE). Gastrointest. Endosc. 66: S96-S98 (2007).
Chang H, Qin W, Li Y, Zhang J, Lin Z, Lv M, Sun Y, Feng J, Shen B. A novel human scFv fragment against TNF-alpha from de novo design method. Mol. Immunol. 44: 3789-3796 (2007). *
Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents - a guide for GPs. Aust. Fam. Physician 36: 1035-1038 (2007). *
Chang PK, Holt EG, De Villiers WJ, Boulanger BR. A new complication from a new technology: what a general surgeon should know about wireless capsule endoscopy. Am. Surg. 71: 455-458 (2005).
Chao CC, Ng Jao YT, Mo LR. Capsule endoscopy for gastrointestinal bleeding with an obscure etiology. J. Formos. Med. Assoc. 104: 659-665 (2005).
Chao JC, Lucha PA Jr. Enteritis cystica profunda: is trauma the etiology? Interval development in the previously normal ileum: a case report and literature review. Mil. Med. 173: 513-514 (2008).
Chaoui Z, Bernoussi A, Belmekki M, Berraho A. Uveitis and chronic intestinal inflammatory diseases: three case studies. J. Fr. Ophtalmol. 28: 854-856 (2005).
Chapman JM, Onnie CM, Prescott NJ, Fisher SA, Mansfield JC, Mathew CG, Lewis CM, Verzilli CJ, Whittaker JC. Searching for genotype-phenotype structure: using hierarchical log-linear models in Crohn disease. Am. J. Hum. Genet. 84: 178-187 (2009). *
Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 21: 870-877 (1980). *
Chapman RW, Cottone M, Selby WS, Shepherd HA, Sherlock S, Jewell DP. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut 27: 86-91 (1986). *
Chapman-Kiddell CA, Davies PS, Gillen L, Radford-Smith GL. Role of diet in the development of inflammatory bowel disease. Inflamm. Bowel Dis. May 21 [Epub ahead of print] (2009).
Charach G, Grosskopf I, Weintraub M. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone. Digestion 77: 198-200 (2008). *
Charagundla SR, Levine MS, Torigian DA, Campbell MS, Furth EE, Rombeau J. Diffuse intestinal ganglioneuromatosis mimicking Crohn's disease. AJR Am. J. Roentgenol. 182: 1166-1168 (2004). *
Charpignon C, Beau P. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Gastroenterol. Clin. Biol. 32: 153-157 (2008). *
Charron M. Inflammatory bowel disease activity assessment with biologic markers and (99m)Tc-WBC scintigraphy: are there different trends in ileitis versus colitis? J. Nucl. Med. 44: 1586-1591 (2003). *
Charron M. Temporal correlation of the erythrocyte sedimentation rate with Tc-99m WBC uptake on children with inflammatory bowel diseases. Clin. Nucl. Med. 28: 905-907 (2003).
Charron M, Fernando del Rosario J, Kocoshis S. Distribution of acute bowel inflammation determined by technetium-labeled white blood cells in children with inflammatory bowel disease. Inflamm. Bowel Dis. 4: 84-88 (1998). *
Chatzicostas C, Koutroubakis IE, Tzardi M, Roussomoustakaki M, Prassopoulos P, Kouroumalis EA. Colonic tuberculosis mimicking Crohn's disease: case report. BMC Gastroenterol. 2: 10 (2002). *
Chatzicostas C, Roussomoustakaki M, Potamianos S, Paspatis G, Mouzas I, Romanos J, Mavrogeni H, Kouroumalis EA. Factors associated with disease evolution in Greek patients with inflammatory bowel disease. BMC Gastroenterol. 6: 21 (2006). *
Chaudhary R, Ghosh S. Prediction of response to infliximab in Crohn's disease. Dig. Liver Dis. 37: 559-563 (2005).
Chauveau E, Terrier F, Casassus-Buihle D, Moncoucy X, Oddes B. Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease. Presse. Med. 34: 583-584 (2005).
Chavez-Lopez M, Delgado-Villafana J, Gallaga A, Huerta-Yanez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol. Immunopathol. (Madr.) 33: 291-292 (2005).
Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J. Gastroenterol. Hepatol. 22: 268-274 (2007). *
Cheema AA, McNeill AJ. Images in cardiology. Left main coronary artery stenosis associated with aortitis in a patient with Crohn's disease. Heart 92: 618 (2006). *
Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J. Clin. Gastroenterol. 38: S44-S50 (2004).
Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 98: 1315-1324 (2003). *
Cheifetz AS, Kornbluth AA, Legnani P, Schmelkin I, Brown A, Lichtiger S, Lewis BS. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am. J. Gastroenterol. 101: 2218-2222 (2006). *
Cheifetz AS, Lewis BS. Capsule endoscopy retention: is it a complication? J. Clin. Gastroenterol. 40: 688-691 (2006).
Cheikh I, Maamouri N, Chouaib S, Chaabouni H, Ouerghi H, Ben Ammar A. Association of celiac disease and Crohn's disease. A case report. Tunis. Med. 81: 969-971 (2003).
Chen B, Zeng Z, Hou J, Chen M, Gao X, Hu P. Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population. Scand. J. Gastroenterol. 44: 720-726 (2009). *
Chen CC, Isomoto H, Narumi Y, Sato K, Oishi Y, Kobayashi T, Yanagihara K, Mizuta Y, Kohno S, Tsukamoto K. Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population. Clin. Immunol. 126: 165-171 (2008). *
Chen CM, Gong Y, Zhang M, Chen JJ. Reciprocal cross talk between Nod2 and TAK1 signaling pathways. J. Biol. Chem. 279: 25876-25882 (2004). *
Chen CS, Sullivan S, Anderson T, Tan AC, Alex PJ, Brant SR, Cuffari C, Bayless TM, Talor MV, Burek CL, Wang H, Li R, Datta LW, Wu Y, Winslow RL, Zhu H, Li X. Identification of novel serological biomarkers for inflammatory bowel disease using E. coli proteome chip. Mol. Cell. Proteomics Apr 7 [Epub ahead of print] (2009). *
Chen DP, Weber SC, Constantinou PS, Ferris TA, Lowe HJ, Butte AJ. Clinical arrays of laboratory measures, or "clinarrays", built from an electronic health record enable disease subtyping by severity. AMIA Annu. Symp. Proc. 2007: 115-119 (2007).
Chen M, Peyrin-Biroulet L, Xia B, Rodriguez-Gueant RM, Bronowicki JP, Bigard MA, Gueant JL. Methionine synthase A2756G polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase C677T pancolitis, in Central China. BMC Med. Genet. 9: 78 (2008). *
Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, Hu Z. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can. J. Gastroenterol. 21: 155-158 (2007).
Chen MC, Mudge CS, Klumpp D. Urothelial lesion formation is mediated by TNFR1 during neurogenic cystitis. Am. J. Physiol. Renal Physiol. 291: F741-F749 (2006). *
Chen S, Harisinghani MG, Wittenberg J. Small bowel CT fat density target sign in chronic radiation enteritis. Australas. Radiol. 47: 450-452 (2003).
Chen SC, Cummings OW, Hartley MP, Filomena CA, Cho WK. Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. Dig. Dis. Sci. 51: 952-955 (2006). *
Chen W, Li D, Paulus B, Wilson I, Chadwick VS. High prevalence of Mycoplasma pneumoniae in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. Dig. Dis. Sci. 46: 2529-2535 (2001). *
Chen Y, Noble EG. Is exercise beneficial to the inflammatory bowel diseases? An implication of heat shock proteins. Med. Hypotheses 72: 84-86 (2009).
Cheng Y, Desreumaux P. 5-Aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J. Gastroenterol. 11: 309-314 (2005). *
Cheon JH, Kim YS, Lee IS, Chang DK, Ryu JK, Lee KJ, Moon JS, Park CH, Kim JO, Shim KN, Choi CH, Cheung DY, Jang BI, Seo GS, Chun HJ, Choi MG; Korean Gut Image Study Group. Can we predict spontaneous capsule passage after retention? A nationwide study to evaluate the incidence and clinical outcomes of capsule retention. Endoscopy 39: 1046-1052 (2007).
Cheow HK, Voutnis DD, Evans JW, Szczepura KR, Swift EA, Bird NJ, Ruparelia P, Solanki CK, Ballinger JR, Chilvers ER, Middleton SJ, Peters AM. Quantification of disease activity in patients undergoing leucocyte scintigraphy for suspected inflammatory bowel disease. Eur. J. Nucl. Med. Mol. Imaging 32: 329-337 (2005). *
Cherian S, Singh P. Is routine ileoscopy useful? An observational study of procedure times, diagnostic yield, and learning curve. Am. J. Gastroenterol. 99: 2324-2329 (2004). *
Cherian V, Machnicki S. Posterior mediastinal masses in a patient with exacerbation of Crohn disease. Chest 131: 1963-1966 (2007). *
Chermesh I, Azriel A, Alter-Koltunoff M, Eliakim R, Karban A, Levi BZ. Crohn's disease and SLC11A1 promoter polymorphism. Dig. Dis. Sci. 52: 1632-1635 (2007). *
Chermesh I, Tamir A, Lachter J, Eliakim R. Intravenous cyclosporine for inflammatory bowel disease - safe and effective. Hepatogastroenterology 54: 2003-2006 (2007).
Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, Gelber M, Halpern Z, Bengmark S, Eliakim R. Failure of synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig. Dis. Sci. 52: 385-389 (2007). *
Chermesh I, Tamir A, Suissa A, Eliakim R. Ferrus calcium citrate is absorbed better than iron bisglycinate in patients with Crohn's disease, but not in healthy controls. Dig. Dis. Sci. 51: 942-945 (2006). *
Cherry K. NOD2/CARD15 variants and Crohn's disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 11 (2006). *
Chetty R, Hafezi S, Montgomery E. An incidental enterocolic lymphocytic phlebitis pattern is seen commonly in the rectal stump of patients with diversion colitis superimposed on inflammatory bowel disease. J. Clin. Pathol. 62: 464-467 (2009).
Cheung O, Regueiro MD. Inflammatory bowel disease emergencies. Gastroenterol. Clin. North Am. 32: 1269-1288 (2003).
Chew MH, Goh MH, Ooi BS, Eu KW. Giant pseudopolyposis in Crohn's disease mimicking malignancy. Int. J. Colorectal Dis. 23: 823-824 (2008). *
Chew SS, Ngo TQ, Douglas PR, Newstead GL, Selby W, Solomon MJ. Cholecystectomy in patients with Crohn's ileitis. Dis. Colon Rectum 46: 1484-1488 (2003).
Chiarello PG, Penaforte FR, Japur CC, Souza CD, Vannucchi H, Troncon LE. Increased folate Intake with no changes in serum homocysteine and decreased levels of C-reactive protein in patients with inflammatory bowel diseases. Dig. Dis. Sci. 54: 627-633 (2009). *
Chiarenza L, Pignataro A, Lanza V. Refeeding syndrome in early pregnancy. Case report. Minerva Anestesiol. 71: 803-808 (2005).
Chiba M, Fukushima T, Horie Y, Iizuka M, Masamune O. No Mycobacterium paratuberculosis detected in intestinal tissue, including Peyer's patches and lymph follicles, of Crohn's disease. J. Gastroenterol. 33: 482-487 (1998).
Chiba M, Iizuka M, Horie Y, Igarashi K, Masamune O. HLA-DR antigen expression in macroscopically uninvolved areas of intestinal epithelia in Crohn's disease. Gastroenterol. Jpn. 24: 365-372 (1989).
Chiba M, Kono M, Hoshina S, Komatsu M, Kitagawa Y, Iizuka M, Watanabe S. Presence of bacterial 16S ribosomal RNA gene segments in human intestinal lymph follicles. Scand. J. Gastroenterol. 35: 824-831 (2000). *
Chiba M, Sugawara T, Tsuda H, Abe T, Tokairin T, Kashima Y. Esophageal ulcer of Crohn's disease: disappearance in 1 week with infliximab. Inflamm. Bowel Dis. Oct 22 [Epub ahead of print] (2008).
Chicharro M, Guarner L, Vilaseca J, Planas M, Malagelada J. Does cyclosporin A worsen liver function in patients with inflammatory bowel disease and total parenteral nutrition? Rev. Esp. Enferm. Dig. 92: 68-77 (2000).
Chiche L. A complicated case of Crohn's disease. J. Chir. (Paris) 142: 49-53 (2005).
Chin AC, Lee WY, Nusrat A, Vergnolle N, Parkos CA. Neutrophil-mediated activation of epithelial protease-activated receptors-1 and -2 regulates barrier function and transepithelial migration. J. Immunol. 181: 5702-5710 (2008). *
Chin AC, Parkos CA. Neutrophil transepithelial migration and epithelial barrier function in IBD: potential targets for inhibiting neutrophil trafficking. Ann. N. Y. Acad. Sci. 1072: 276-287 (2006). *
Chinen H, Matsuoka K, Sato T, Kamada N, Okamoto S, Hisamatsu T, Kobayashi T, Hasegawa H, Sugita A, Kinjo F, Fujita J, Hibi T. Lamina propria c-kit(+) immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 133: 559-573 (2007). *
Chiodini RJ. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin. Microbiol. Rev. 2: 90-117 (1989). *
Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer WR Jr, Coutu JA. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease. J. Clin. Microbiol. 20: 966-971 (1984). *
Chiodini RJ, Van Kruiningen HJ, Thayer WR, Coutu JA. Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease. J. Clin. Microbiol. 24: 357-363 (1986). *
Chiodini RJ, Van Kruiningen HJ, Thayer WR, Coutu JA, Merkal RS. In vitro antimicrobial susceptibility of a Mycobacterium sp. isolated from patients with Crohn's disease. Antimicrob. Agents Chemother. 26: 930-932 (1984). *
Chiodini RJ, Van Kruiningen HJ, Thayer WR, Merkal RS, Coutu JA. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig. Dis. Sci. 29: 1073-1079 (1984).
Chiorean MV, Sandrasegaran K, Saxena R, Maglinte DD, Nakeeb A, Johnson CS. Correlation of CT enteroclysis with surgical pathology in Crohn's disease. Am. J. Gastroenterol. 102: 2541-2550 (2007). *
Cho HS, Byun TJ, Ahn SB, Kim TY, Eun CS, Jeon YC, Kim YS, Han DS. A case of familial Crohn's disease observed in a parent and his offspring. Korean J. Gastroenterol. 52: 247-250 (2008).
Cho J. Genetic aspects of inflammatory bowel disease: how far have we come, and where are we heading? Curr. Gastroenterol. Rep. 1: 491-495 (1999).
Cho J. Genetic advances in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 9: 191-200 (2006).
Cho J. Update on inflammatory bowel disease genetics. Curr. Gastroenterol. Rep. 2: 434-439 (2000).
Cho JH. Advances in the genetics of inflammatory bowel disease. Curr. Gastroenterol. Rep. 6: 467-473 (2004).
Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8: 458-466 (2008). *
Cho JH. Inflammatory bowel disease: genetic and epidemiologic considerations. World J. Gastroenterol. 14: 338-347 (2008). *
Cho JH. Significant role of genetics in IBD: the NOD2 gene. Rev. Gastroenterol. Disord. 3 Suppl. 1: S18-S22 (2003). *
Cho JH. Update on the genetics of inflammatory bowel disease. Curr. Gastroenterol. Rep. 3: 458-463 (2001).
Cho JH. The Nod2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease. Inflamm. Bowel Dis. 7: 271-275 (2001). *
Cho JH, Abraham C. Inflammatory bowel disease genetics: Nod2. Annu. Rev. Med. 58: 401-416 (2007). *
Cho JH, Nicolae DL, Gold LH, Fields CT, LaBuda MC, Rohal PM, Pickles MR, Qin L, Fu Y, Mann JS, Kirschner BS, Jabs EW, Weber J, Hanauer SB, Bayless TM, Brant SR. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc. Natl. Acad. Sci. U.S.A. 95: 7502-7507 (1998). *
Cho JH, Nicolae DL, Ramos R, Fields CT, Rabenau K, Corradino S, Brant SR, Espinosa R, LeBeau M, Hanauer SB, Bodzin J, Bonen DK. Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum. Mol. Genet. 9: 1425-1432 (2000). *
Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology 133: 1327-1339 (2007). *
Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment with infliximab in Crohn's disease - the experience of single center in Korea. Korean J. Gastroenterol. 46: 48-55 (2005).
Choi PM, Kim WH. Colon cancer surveillance. Gastroenterol. Clin. North Am. 24: 671-687 (1995).
Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. Dig. Dis. Sci. 39: 1885-1892 (1994).
Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35: 950-954 (1994). *
Chon H, Choi B, Lee E, Lee S, Jeong G. Immunomodulatory effects of specific bacterial components of Lactobacillus plantarum KFCC11389P on the murine macrophage cell line RAW 264.7. J. Appl. Microbiol. Apr 15 [Epub ahead of print] (2009). *
Chong AK, Taylor A, Miller A, Hennessy O, Connell W, Desmond P. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. Gastrointest. Endosc. 61: 255-261 (2005). *
Chong SK, Grossman A, Walker-Smith JA, Rees LH. Endocrine dysfunction in children with Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 3: 529-534 (1984).
Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm. Bowel Dis. 12: 29-32 (2006). *
Chopra P, Kanoje V, Semwal A, Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin. Investig. Drugs 17: 1411-1425 (2008).
Chorny A, Gonzalez-Rey E, Varela N, Robledo G, Delgado M. Signaling mechanisms of vasoactive intestinal peptide on inflammatory conditions. Regul. Pept. 137: 67-74 (2006).
Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin. Drug Saf. 6: 479-485 (2007).
Chow DK, Leong RW, Lai LH, Wong GL, Leung WK, Chan FK, Sung JJ. Changes in Crohn's disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm. Bowel Dis. 14: 536-541 (2008). *
Chow DK, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Inflamm. Bowel Dis. 15: 551-557 (2009).
Chow JY, Carlstrom K, Barrett KE. Growth hormone reduces chloride secretion in human colonic epithelial cells via EGF receptor and extracellular regulated kinase. Gastroenterology 125: 1114-1124 (2003). *
Chowers Y, Odes S, Bujanover Y, Eliakim R, Bar Meir S, Avidan B. The month of birth is linked to the risk of Crohn's disease in the Israeli population. Am. J. Gastroenterol. 99: 1974-1976 (2004). *
Chowers Y, Sela BA, Holland R, Fidder H, Simoni FB, Bar-Meir S. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am. J. Gastroenterol. 95: 3498-3502 (2000). *
Choy MY, Walker-Smith JA, Williams CB, MacDonald TT. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 31: 1365-1370 (1990). *
Choy P, Bissett I, Docherty J, Parry B, Merrie A. Stapled versus handsewn methods for ileocolic anastomoses. Cochrane Database Syst. Rev. 3: CD004320 (2007). *
Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease. Z. Gastroenterol. 45: 605-608 (2007).
Christ AD, Stevens AC, Koeppen H, Walsh S, Omata F, Devergne O, Birkenbach M, Blumberg RS. An interleukin 12-related cytokine is up-regulated in ulcerative colitis but not in Crohn's disease. Gastroenterology 115: 307-313 (1998). *
Christianakis E, Pashalidis N, Kokkinou S, Pitiakoudis M, Mplevrakis E, Chorti M, Rizos S, Filippou D. Acute jejunoileal obstruction due to a pseudopolyp in a child with undiagnosed Crohn disease: a case report. J. Med. Case Reports 2: 54 (2008). *
Christodoulou DK, Katsanos KH, Kitsanou M, Stergiopoulou C, Hatzis J, Tsianos EV. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig. Liver Dis. 34: 781-786 (2002).
Christophers E. Comorbidities in psoriasis. J. Eur. Acad. Dermatol. Venereol. 20 Suppl. 2: 52-55 (2006). *
Christophers E. Comorbidities in psoriasis. Clin. Dermatol. 25: 529-534 (2007).
Chua KH, Hilmi I, Ng CC, Eng TL, Palaniappan S, Lee WS, Goh KL. Identification of NOD2/CARD15 mutations in Malaysian patients with Crohn's disease. J. Dig. Dis. 10: 124-130 (2009). *
Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, Morgenstern EH, Rubin SD, Sacknoff AG, Gleim GM. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up. Inflamm. Bowel Dis. 4: 177-181 (1998). *
Chung CC, Tsang WW, Kwok SY, Li MK. Laparoscopy and its current role in the management of colorectal disease. Colorectal Dis. 5: 528-543 (2003). *
Chung KM, Kim HS, Park SY, Lim SR, Ryang DY, Jeong HK, Lee WS, Park CH, Lee JH, Choi SK, Rew JS. The changes in incidence of Crohn's disease and intestinal tuberculosis in Korea. Korean J. Gastroenterol. 52: 351-358 (2008).
Chung WJ, Sontheimer H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J. Neurochem. Apr 29 [Epub ahead of print] (2009).
Chung Y, Dong C. Don�t leave home without it: the IL-23 visa to TH-17 cells. Nat. Immunol. 10: 236-238 (2009). *
Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm. Bowel Dis. 13: 1374-1378 (2007). *
Chutkan R. Video capsule endoscopy in IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 54. May 7-8 (2004). *
Chutkan R, Sternthal M, Janowitz HD. A family with collagenous colitis, ulcerative colitis, and Crohn's disease. Am. J. Gastroenterol. 95: 3640-3641 (2000). *
Ciantar M, Adlam DM. Treatment with infliximab: implications in oral surgery? A case report. Br. J. Oral Maxillofac. Surg. 45: 507-510 (2007).
Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, Peralta S, Franco V, Giardina E, Craxi A, Pitzalis C, Triolo G. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 60: 955-965 (2009). *
Cichoz-Lach H. Esophageal Crohn disease. South. Med. J. 101: 886 (2008).
Cichoz-Lach H, Celinnski K. Modern methods of endoscopic diagnosis of gastrointestinal tract. J. Physiol. Pharmacol. 58 Suppl. 3: 21-31 (2007). *
Ciclitira PJ, Ellis HJ, Evans DJ. A solid-phase radioimmunoassay for measurement of circulating antibody titres to wheat gliadin and its subfractions in patients with adult coeliac disease. J. Immunol. Methods 62: 231-239 (1983).
Ciga M, Oteiza F, Marzo J, Armendariz P, De Miguel M, Ortiz H. Treatment of perianal Crohn's disease. An. Sist. Sanit. Navar. 29: 367-386 (2006).
Cima RR, Anderson KJ, Larson DW, Dozois EJ, Hassan I, Sandborn WJ, Loftus EV, Pemberton JH. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm. Bowel Dis. 13: 1266-1270 (2007). *
Cinemre H, Bilir C, Gokosmanoglu F, Kadakal F. Anti-Saccharomyces cerevisiae antibodies in acute myocardial infarction. J. Investig. Med. 55: 444-449 (2007).
Cioffi U, De Simone M, Ferrero S, Ciulla MM, Lemos A, Contessini Avesani E. Synchronous adenocarcinoma and carcinoid tumor of the terminal ileum in a Crohn's disease patient. BMC Cancer 5: 157 (2005). *
Ciorba MA, Prakash C. Wireless capsule endoscopy in the diagnosis of small bowel Crohn's disease. Inflamm. Bowel Dis. 9: 276 (2003). *
Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol. Res. 46: 1-6 (2002). *
Cirone K, Morsella C, Romano M, Paolicchi F. Mycobacterium avium subsp. paratuberculosis in food and its relationship with Crohn's disease. Rev. Argent Microbiol. 39: 57-68 (2007).
Ciulla A, Tomasello G, Urso G, Sanzo A, Maiorana A, Castronovo G, Damiani S. Abrikossoff's tumour: report of a rare case in anal perianal region. Ann. Ital. Chir. 75: 87-89 (2004).
Civitavecchia G, Renda MC, Ruggeri RF, Maggio A, Renna S, Orlando A, Cottone M. IL-23R determines susceptibility in Crohn's disease in a Mediterranean area. Inflamm. Bowel Dis. 15: 317-318 (2009). *
Claise C, Johanet C, Bouhnik Y, Kapel N, Homberg JC, Poupon R. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases. Liver 16: 28-34 (1996).
Clancy R, Ren Z, Turton J, Pang G, Wettstein A. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion. Dig. Liver Dis. 39: 445-451 (2007).
Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN. The Manitoba IBD index: evidence for a new and simple indicator of IBD activity. Am. J. Gastroenterol. May 19 [Epub ahead of print] (2009). *
Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 21: 71-75 (2009).
Claret L, Miquel S, Vieille N, Ryjenkov DA, Gomelsky M, Darfeuille Michaud A. The flagellar sigma factor Flia regulates adhesion and invasion of Crohn's disease-associated Escherichia coli via a c-di-GMP-dependent pathway. J. Biol. Chem. 282: 33275-33283 (2007). *
Clark CA, Mehta BH, Pruchnicki MC, Rodis JL. The pharmacist's role in teaching methotrexate injection for patients with Crohn's disease. Am. J. Health Syst. Pharm. 63: 1792-1794 (2006). *
Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 18: 335-343 (2007).
Clark MP, Benjamin E, Alusi G. A rare case of Crohn's disease in head and neck surgery. J. Laryngol. Otol. 117: 146-147 (2003).
Clark NM, Marinis JM, Cobb BA, Abbott DW. MEKK4 sequesters RIP2 to dictate NOD2 signal specificity. Curr. Biol. 18: 1402-1408 (2008).
Clarke AR, Meniel V. The intestinal stem cell niche studied through conditional transgenesis. Ernst Schering Found. Symp. Proc. 5: 99-108 (2006).
Clarke JO, Giday SA, Magno P, Shin EJ, Buscaglia JM, Jagannath SB, Mullin GE. How good is capsule endoscopy for detection of periampullary lesions? Results of a tertiary-referral center. Gastrointest. Endosc. 68: 267-272 (2008).
Clarke K, Sagunarthy R, Kansal S. RDW as an additional marker in inflammatory bowel disease/undifferentiated colitis. Dig. Dis. Sci. 53: 2521-2523 (2008). *
Clarkston WK, Presti ME, Petersen PF, Zachary PE Jr, Fan WX, Leonardi CL, Vernava AM 3rd, Longo WE, Kreeger JM. Role of Mycobacterium paratuberculosis in Crohn's disease: a prospective, controlled study using polymerase chain reaction. Dis. Colon Rectum 41: 195-199 (1998).
Claus J, Pringot J, Ghijselings L, Landen S. Small bowel obstruction by abricot pit in Crohn's disease. JBR-BTR 89: 329 (2006).
Clavel T, Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm. Bowel Dis. 13: 1153-1164 (2007). *
Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, Ross RP. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am. J. Gastroenterol. 104: 1162-1169 (2009).
Clemente G, Sarno G, De Rose AM, Mele C, Ranucci G, Nuzzo G. Unexpected diagnosis of Crohn's disease after the ingestion of a dental bridge. Inflamm. Bowel Dis. 15: 812-813 (2009).
Cloney DL, Sutphen JL, Borowitz SM, Frierson H Jr. Crohn's disease complicating cystic fibrosis. South. Med. J. 87: 81-83 (1994).
Coban S, Ensari A, Kuzu MA, Yalcin S, Palabiyikoglu M, Ormeci N. Cytomegalovirus infection in a patient with Crohn's ileocolitis. Can. J. Gastroenterol. 19: 109-111 (2005).
Cobden I, Rothwell J, Axon AT. Intestinal permeability and screening tests for coeliac disease. Gut 21: 512-518 (1980). *
Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol. Rev. 206: 277-295 (2005). *
Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig. Dis. Sci. 51: 2045-2047 (2006). *
Coccia EM, Remoli ME, Di Giacinto C, Del Zotto B, Giacomini E, Monteleone G, Boirivant M. Cholera toxin subunit B inhibits IL-12 and IFN-gamma production and signalling in experimental colitis and Crohn's disease. Gut 54: 1558-1564 (2005). *
Cohavy O, Harth G, Horwitz M, Eggena M, Landers C, Sutton C, Targan SR, Braun J. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect. Immun. 67: 6510-6517 (1999). *
Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J. Eur. Acad. Dermatol. Venereol. 23: 561-565 (2009). *
Cohen HD, Das KM. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. J. Clin. Gastroenterol. 40 Suppl. 3: S150-S154 (2006).
Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J. Rheumatol. 34: 380-385 (2007).
Cohen LB. Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. Can. J. Gastroenterol. 18: 419 (2004).
Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm. Bowel Dis. 14: 738-743 (2008). *
Cohen RD. Mycobacterium in Crohn's: something to ruminate about? Gastroenterology 128: 2167-2168 (2005). *
Cohen RD. Infliximab as first-line therapy for severe Crohn's disease? Inflamm. Bowel Dis. 8: 58-59 (2002). *
Cohen RD. The cost of Crohn's disease: drugs or surgery? BioDrugs 14: 331-344 (2000).
Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm. Bowel Dis. 7 Suppl. 1: S17-S22 (2001). *
Cohen RD. Evolving medical therapies for ulcerative colitis. Curr. Gastroenterol. Rep. 4: 497-505 (2002).
Cohen RD, Bowie WR, Enns R, Flint J, Fitzgerald JM. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax 62: 1013-1014 (2007).
Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn's disease. Am. J. Gastroenterol. 95: 524-530 (2000). *
Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am. J. Gastroenterol. 95: 3469-3477 (2000). *
Cohen RD, Waters HC, Tang B, Rahman MI. Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm. Bowel Dis. 14: 1707-1714 (2008).
Cohen SA, Gralnek IM, Ephrath H, Saripkin L, Meyers W, Sherrod O, Napier A, Gobin T. Capsule endoscopy may reclassify pediatric inflammatory bowel disease: a historical analysis. J. Pediatr. Gastroenterol. Nutr. 47: 31-36 (2008).
Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm. Bowel Dis. 13: 1453-1454 (2007). *
Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum. 61: 813-821 (2009). *
Coll P, Guttormsen AB, Berstad A. Gastrointestinal disease with elevated plasma homocysteine level. Tidsskr. Nor. Laegeforen. 119: 3577-3579 (1999).
Colli MV, Amaro TA, Pinto AL, Gaburri PD, Chebli JM. Azathioprine toxicity in Crohn's disease: incidence, approach and course. Rev. Assoc. Med. Bras. 54: 415-421 (2008).
Collingwood S, Witherington J. Therapeutic approaches towards the treatment of gastroinstestinal disorders. Drug News Perspect. 20: 139-144 (2007).
Collins CB, Ho J, Wilson TE, Wermers JD, Tlaxca JL, Lawrence MB, Solga M, Lannigan J, Rivera-Nieves J. CD44 deficiency attenuates chronic murine ileitis. Gastroenterology 135: 1993-2002 (2008). *
Collins MT, Lisby G, Moser C, Chicks D, Christensen S, Reichelderfer M, Hoiby N, Harms BA, Thomsen OO, Skibsted U, Binder V. Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J. Clin. Microbiol. 38: 4373-4381 (2000). *
Collins P, Mpofu C, Watson A, Rhodes J. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst. Rev. 2: CD000279 (2006). *
Colman RW. Regulation of angiogenesis by the kallikrein-kinin system. Curr. Pharm. Des. 12: 2599-2607 (2006).
Colombel JF. Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults. Expert Rev. Gastroenterol. Hepatol. 2: 163-176 (2008).
Colombel JF. The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice? Clin. Gastroenterol. Hepatol. 1: 5-9 (2003). *
Colombel JF, Gower-Rousseau C. Etiology of Crohn disease. Current data. Presse. Med. 23: 558-560 (1994).
Colombel JF, Guillemot F, Van Gossum A, Dufosse F, Cortot A, Dupont E, Paris JC. Familial Crohn's disease in multiple siblings: no linkage to the HLA system. Gastroenterol. Clin. Biol. 13: 676-678 (1989).
Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126: 19-31 (2004). *
Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am. J. Gastroenterol. 99: 878-883 (2004). *
Colombel JF, Reumaux D, Duthilleul P, Noel LH, Gower-Rousseau C, Paris JC, Cortot A. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. Gastroenterol. Clin. Biol. 16: 656-660 (1992).
Colombel JF, Ricart E, Loftus EV, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. Management of Crohn's disease of the ileoanal pouch with infliximab. Am. J. Gastroenterol. 98: 2239-2244 (2003). *
Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, Van Deventer S, Ferguson A, Desreumaux P, Forbes A, Geboes K, Melani L, Cohard M. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49: 42-46 (2001). *
Colombel JF, Sandborn WJ. Development of fistulae in ileo-anal pouch does not necessarily indicate Crohn's disease: response. Am. J. Gastroenterol. 99: 2067 (2004). *
Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. May 11 [Epub ahead of print] (2009).
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52-65 (2007). *
Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am. J. Gastroenterol. 104: 1170-1179 (2009).
Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts PJ, Enns RA, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 58: 940-948 (2009). *
Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. Quantitative measurement and visual assessment of ileal Crohn's disease activity by CT enterography: correlation with endoscopic severity and C-reactive protein. Gut 55: 1561-1567 (2006). *
Colombel JF, Watson AJ, Neurath MF. The 10 remaining mysteries of inflammatory bowel disease. Gut 57: 429-433 (2008). *
Colombo PL, Benedetti M, Tinozzi FP, Ticozzelli E, Maroni N, Di Sabatino A, Tinozzi S. Different approaches for medical or surgical management of Crohn's disease: the importance of the classification of Vienna. Ann. Ital. Chir. 77: 485-496 (2006).
Colpaert S, Vanstraelen K, Liu Z, Penninckx F, Geboes K, Rutgeerts P, Ceuppens J. Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease. Clin. Immunol. 102: 68-76 (2002). *
Colpaert S, Vastraelen K, Liu Z, Maerten P, Shen C, Penninckx F, Geboes K, Rutgeerts P, Ceuppens JL. In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease. Eur. Cytokine Netw. 13: 431-437 (2002).
Comabella M, Altet L, Peris F, Villoslada P, Sanchez A, Montalban X. Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. Mult. Scler. 10: 618-620 (2004). *
Comalada M, Peppelenbosch MP. Impaired innate immunity in Crohn's disease. Trends Mol. Med. 12: 397-399 (2006). *
Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol. Clin. North Am. 33: 387-406 (2004).
Comes MC, Gower-Rousseau C, Colombel JF, Belaiche J, Van Kruiningen HJ, Nuttens MC, Cortot A. Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liege county of Belgium. Gut 35: 1316-1318 (1994). *
Cominelli F. Cytokine-based therapies for Crohn's disease - new paradigms. N. Engl. J. Med. 351: 2045-2048 (2004). *
Cominelli F, Pizarro TT. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment. Pharmacol. Ther. 10 Suppl. 2: 49-53 (1996).
Comite de nutrition de la Societe francaise de pediatrie. Nutritional treatment in childhood Crohn's disease. Arch. Pediatr. 12: 1255-1266 (2005).
Condino AA, Fidanza S, Hoffenberg EJ. A home infliximab infusion program. J. Pediatr. Gastroenterol. Nutr. 40: 67-69 (2005). *
Condino AA, Hoffenberg EJ, Accurso F, Penvari C, Anthony M, Gralla J, O'connor JA. Frequency of ASCA seropositivity in children with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 41: 23-26 (2005). *
Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf. 21: 311-323 (1999).
Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34: 1081-1085 (1993). *
Connor SJ, Paraskevopoulos N, Newman R, Cuan N, Hampartzoumian T, Lloyd AR, Grimm MC. CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 53: 1287-1294 (2004). *
Conrad K, Schmechta H, Klafki A, Lobeck G, Uhlig HH, Gerdi S, Henker J. Serological differentiation of inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 14: 129-135 (2002).
Conscience I, Perceau G, Durlach A, Bernard P. Vulvar involvement in Crohn's disease: efficacy of metronidazole. Ann. Dermatol. Venereol. 133: 585-587 (2006).
Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lemann M, Mary JY; Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm. Bowel Dis. 12: 551-557 (2006). *
Consolo P, Strangio G, Luigiano C, Giacobbe G, Pallio S, Familiari L. Optical coherence tomography in inflammatory bowel disease: prospective evaluation of 35 patients. Dis. Colon Rectum 51: 1374-1380 (2008). *
Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 55: 1760-1767 (2006). *
Contessini Avesani E, Vicentini L, Carrara A, Botti F, Reduzzi R, Dallera P. Surgical treatment of Crohn's disease. Indication and management in 20 patients. Minerva Gastroenterol. Dietol. 44: 17-21 (1998).
Conti F, Borrelli O, Anania C, Marocchi E, Romeo EF, Paganelli M, Valesini G, Cucchiara S. Chronic intestinal inflammation and seronegative spondyloarthropathy in children. Dig. Liver Dis. 37: 761-767 (2005).
Coogan PF, Rosenberg L. The use of folic acid antagonists and the risk of colorectal cancer. Pharmacoepidemiol. Drug Saf. 16: 1111-1119 (2007).
Cook LS. A causal role for Mycobacterium avium subspecies paratuberculosis in Crohn's disease? Can. J. Gastroenterol. 14: 479-480 (2000).
Cooke DM. Inflammatory bowel disease: primary health care management of ulcerative colitis and Crohn's disease. Nurse Pract. 16: 27-30, 35-36, 38-39 (1991).
Cooney R, Cummings JR, Pathan S, Beckly J, Geremia A, Hancock L, Guo C, Morris A, Jewell DP. Association between genetic variants in myosin IXB and Crohn's disease. Inflamm. Bowel Dis. 15: 1014-1021 (2009). *
Cooper JG, Purcell GP. Data mining for correlations between diet and Crohn's disease activity. AMIA Annu. Symp. Proc. 2006: 897 (2006).
Cooper T, Savige J, Nassis L, Paspaliaris B, Neeson P, Neil J, Knight KR, Daskalakis M, Doery JC. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin. Rheumatol. Int. 19: 129-136 (2000). *
Coppi LC, Thomazzi SM, Ayrizono MD, Coy CS, Fagundes JJ, Goes JR, Franchi GC Jr, Nowill AE, Montes CG, Antunes E, Ferraz JG. Comparative study of eosinophil chemotaxis, adhesion, and degranulation in vitro in ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 13: 211-218 (2007). *
Corbaz A, ten Hove T, Herren S, Graber P, Schwartsburd B, Belzer I, Harrison J, Plitz T, Kosco-Vilbois MH, Kim SH, Dinarello CA, Novick D, van Deventer S, Chvatchko Y. IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J. Immunol. 168: 3608-3616 (2002). *
Coremans G, Dockx S, Wyndaele J, Hendrickx A. Do anal fistulas in Crohn's disease behave differently and defy Goodsall's rule more frequently than fistulas that are cryptoglandular in origin? Am. J. Gastroenterol. 98: 2732-2735 (2003). *
Cormier K, Mager D, Bannister L, Fortin M, Richards H, Jackson C, Pencharz P. Resting energy expenditure in the parenterally fed pediatric population with Crohn's disease. JPEN J. Parenter. Enteral Nutr. 29: 102-107 (2005).
Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P. Inflammatory caspases: targets for novel therapies. Curr. Pharm. Des. 13: 367-385 (2007).
Cornes JS, Stecher M. Primary Crohn's disease of the colon and rectum. Gut 2: 189-201 (1961). *
Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment. Pharmacol. Ther. 15: 463-473 (2001). *
Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am. J. Gastroenterol. 103: 2394-2400 (2008). *
Cornish JA, Tan EK, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56: 830-837 (2007). *
Corporaal S, Karrenbeld A, van der Linde K, Voskuil JH, Kleibeuker JH, Dijkstra G. Diffuse enteritis after colectomy for ulcerative colitis: two case reports and review of the literature. Eur. J. Gastroenterol. Hepatol. 21: 710-715 (2009).
Corrao G, Tragnone A, Caprilli R, Trallori G, Papi C, Andreoli A, Di Paolo M, Riegler G, Rigo GP, Ferrau O, Mansi C, Ingrosso M, Valpiani D. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int. J. Epidemiol. 27: 397-404 (1998). *
Correa I, Veny M, Esteller M, Pique JM, Yague J, Panes J, Salas A. Defective IL-10 production in severe phenotypes of Crohn's disease. J. Leukoc. Biol. 85: 896-903 (2009). *
Corti S, Stephan R. Detection of Mycobacterium avium subspecies paratuberculosis specific IS900 insertion sequences in bulk-tank milk samples obtained from different regions throughout Switzerland. BMC Microbiol. 2: 15 (2002). *
Coruzzi P, Castiglioni P, Parati G, Brambilla V, Brambilla L, Gualerzi M, Cademartiri F, Franze A, De Angelis G, Di Rienzo M, Di Mario F. Autonomic cardiovascular regulation in quiescent ulcerative colitis and Crohn's disease. Eur. J. Clin. Invest. 37: 964-970 (2007). *
Cosnes J. Understanding the opposite effects of smoking in IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 48. May 7-8 (2004). *
Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract. Res. Clin. Gastroenterol. 18: 481-496 (2004).
Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut 45: 218-222 (1999). *
Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8: 244-250 (2002). *
Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. Gender differences in the response of colitis to smoking. Clin. Gastroenterol. Hepatol. 2: 41-48 (2004). *
Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54: 237-241 (2005). *
Cosnes J, Seksik P, Nion-Larmurier I, Beaugerie L, Gendre JP. Prior appendectomy and the phenotype and course of Crohn's disease. World J. Gastroenterol. 12: 1235-1242 (2006). *
Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10: 149-166 (2007). *
Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis. 35: 642-647 (2003).
Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54: 364-368 (2005). *
Costa-Romero M, Coto-Segura P, Suarez-Saavedra S, Ramos-Polo E, Santos-Juanes J. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm. Bowel Dis. 14: 1462-1463 (2008).
Coste A, Dubuquoy L, Barnouin R, Annicotte JS, Magnier B, Notti M, Corazza N, Antal MC, Metzger D, Desreumaux P, Brunner T, Auwerx J, Schoonjans K. LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proc. Natl. Acad. Sci. U.S.A. 104: 13098-13103 (2007). *
Costello CM, Mah N, Hasler R, Rosenstiel P, Waetzig GH, Hahn A, Lu T, Gurbuz Y, Nikolaus S, Albrecht M, Hampe J, Lucius R, Kloppel G, Eickhoff H, Lehrach H, Lengauer T, Schreiber S. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med. 2: e199 (2005). *
Coteur G, Feagan B, Keininger DL, Kosinski M. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Aliment. Pharmacol. Ther. 29: 1032-1041 (2009). *
Cottier H, Hassig A. Immunoglobulin in chronic inflammatory diseases. Vox. Sang. 51 Suppl. 2: 39-43 (1986).
Cottone M. Recurrent disease after resection for Crohn's disease: is it preventable? Inflamm. Bowel Dis. 12 Suppl. 3: S13-S14 (2006).
Cottone M, Cipolla C, Rosselli M. Epidemiology and pathogenesis of Crohn's disease. Chir. Ital. 47: 1-7 (1995).
Cottone M, Marrone C, Casa A, Oliva L, Orlando A, Calabrese E, Martorana G, Pagliaro L. Familial occurrence of inflammatory bowel disease in celiac disease. Inflamm. Bowel Dis. 9: 321-323 (2003). *
Cottone M, Martorana G, Di Mitri R, Camma C, Caprilli R. Epidemiology of inflammatory bowel disease in Italy. Ital. J. Gastroenterol. Hepatol. 31: 503-507 (1999).
Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opin. Biol. Ther. 6: 401-408 (2006).
Cottone M, Mocciaro F, Orlando A. Infliximab prevents Crohn's disease recurrence after ileal resection. Expert Rev. Gastroenterol. Hepatol. 3: 231-234 (2009).
Cottone M, Mocciaro F, Scimeca D. Adalimumab induction for Crohn's disease. Gastroenterology 130: 1929 (2006). *
Cottone M, Orlando A, Modesto I. Postoperative maintenance therapy for inflammatory bowel disease. Curr. Opin. Gastroenterol. 22: 377-381 (2006).
Cottone M, Orlando A, Viscido A, Calabrese E, Camma C, Casa A. Review article: prevention of postsurgical relapse and recurrence in Crohn's disease. Aliment. Pharmacol. Ther. 17 Suppl. 2: 38-42 (2003).
Cottone M, Renda MC, Mattaliano A, Oliva L, Fries W, Criscuoli V, Modesto I, Scimeca D, Maggio A, Casa A, Maisano S, Mocciaro F, Sferrazza A, Orlando A. Incidence of Crohn's disease and CARD15 mutation in a small township in Sicily. Eur. J. Epidemiol. 21: 887-892 (2006). *
Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J, Brytting M, Egeler RM, Rabourdin-Combe C, Henter JI, Arico M, Delprat C. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat. Med. 14: 81-87 (2008). *
Coussens PM. Mycobacterium paratuberculosis and the bovine immune system. Anim. Health Res. Rev. 2: 141-161 (2001).
Cox DG, Crusius JB, Peeters PH, Bueno-de-Mesquita HB, Pena AS, Canzian F. Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease. World J. Gastroenterol. 11: 6003-6008 (2005). *
Cox J. Inflammatory bowel disease: implications for the medical-surgical nurse. Medsurg. Nurs. 4: 427-434 (1995).
Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27: 580-583 (1998). *
Coyne JD. Crohn's disease with inflammatory splenic granuloma. J. Clin. Pathol. 59: 889 (2006). *
Coyne K, Joshua-Gotlib S, Kimel M, Thompson C, Lewis A, Danilewitz M. Validation of the treatment satisfaction questionnaire for Crohn's disease (TSQ-C). Dig. Dis. Sci. 50: 252-258 (2005). *
Cozzi F, Podswiadek M, Cardinale G, Oliviero F, Dani L, Sfriso P, Punzi L. Mud-bath treatment in spondylitis associated with inflammatory bowel disease - a pilot randomised clinical trial. Joint Bone Spine 74: 436-439 (2007). *
Craggs A, Welfare M, Donaldson PT, Mansfield JC. The CC chemokine receptor 5 delta32 mutation is not associated with inflammatory bowel disease (IBD) in NE England. Genes Immun. 2: 114-116 (2001). *
Craggs A, West S, Curtis A, Welfare M, Hudson M, Donaldson P, Mansfield J. Absence of a genetic association between IL-1RN and IL-1B gene polymorphisms in ulcerative colitis and Crohn disease in multiple populations from northeast England. Scand. J. Gastroenterol. 36: 1173-1178 (2001). *
Craig D, Robins G, Howdle PD. Advances in celiac disease. Curr. Opin. Gastroenterol. 23: 142-148 (2007).
Craig RM, Traynor A, Oyama Y, Burt RK. Hematopoietic stem cell transplantation for severe Crohn's disease. Bone Marrow Transplant. 32 Suppl. 1: S57-S59 (2003). *
Crane AM, Bradbury L, van Heel DA, McGovern DP, Brophy S, Rubin L, Siminovitch KA, Wordsworth BP, Calin A, Brown MA. Role of NOD2 variants in spondylarthritis. Arthritis Rheum. 46: 1629-1633 (2002). *
Cravo ML, Albuquerque CM, Salazar de Sousa L, Gloria LM, Chaves P, Dias Pereira A, Nobre Leitao C, Quina MG, Costa Mira F. Microsatellite instability in non-neoplastic mucosa of patients with ulcerative colitis: effect of folate supplementation. Am. J. Gastroenterol. 93: 2060-2064 (1998). *
Crawford NP, Colliver DW, Eichenberger MR, Funke AA, Kolodko V, Cobbs GA, Petras RE, Galandiuk S. CARD15 genotype-phenotype relationships in a small inflammatory bowel disease population with severe disease affection status. Dig. Dis. Sci. 52: 2716-2724 (2007). *
Crawford NP, Colliver DW, Funke AA, Young MN, Kelley S, Cobbs GA, Petras RE, Galandiuk S. Characterization of genotype-phenotype relationships and stratification by the CARD15 variant genotype for inflammatory bowel disease susceptibility loci using multiple short tandem repeat genetic markers. Hum. Mutat. 25: 156-166 (2005). *
Crawford NP, Eichenberger MR, Colliver DW, Lewis RK, Cobbs GA, Petras RE, Galandiuk S. Evaluation of Slc11a1 as an inflammatory bowel disease candidate gene. BMC Med. Genet. 6: 10 (2005). *
Crema MD, Richarme D, Azizi L, Hoeffel CC, Tubiana JM, Arrive L. Pouchography, CT, and MRI features of ileal J pouch-anal anastomosis. AJR Am. J. Roentgenol. 187: W594-W603 (2006). *
Cremon C, Pallotti F, Bacchilega M, Stanghellini V, Corinaldesi R, Barbara G. Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. Expert Rev. Gastroenterol. Hepatol. 2: 735-740 (2008).
Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin. Nutr. 27: 328-339 (2008).
Cresti S, Ouaissi M, Sielezneff I, Chaix JB, Pirro N, Berthet B, Consentino B, Sastre B. Advantage of vacuum assisted closure on healing of wound associated with omentoplasty after abdominoperineal excision: a case report. World J. Surg. Oncol. 6: 136 (2008). *
Criscuoli V, Casa A, Orlando A, Pecoraro G, Oliva L, Traina M, Rizzo A, Cottone M. Severe acute colitis associated with CMV: a prevalence study. Dig. Liver Dis. 36: 818-820 (2004).
Crispino P, Pica R, Angelucci E, Consolazio A, Rivera M, Cassieri C, Paoluzi P. Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature. Int. J. Colorectal Dis. 22: 553-558 (2007). *
Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VE, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK. Analysis of families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 76: 561-571 (2005). *
Croese J, Wood MJ, Melrose W, Speare R. Allergy controls the population density of Necator americanus in the small intestine. Gastroenterology 131: 402-409 (2006). *
Crohn BB. Psychic factors affecting the course of chronic ulcerative colitis. Gastroenterology 12: 325-327 (1949).
Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. 1932. Mt. Sinai J. Med. 67: 263-268 (2000).
Croitoru K, Zhou P. T-cell-induced mucosal damage in the intestine. Curr. Opin. Gastroenterol. 20: 581-586 (2004).
Crook DW, Knuesel PR, Froehlich JM, Eigenmann F, Unterweger M, Beer HJ, Kubik-Huch RA. Comparison of magnetic resonance enterography and video capsule endoscopy in evaluating small bowel disease. Eur. J. Gastroenterol. Hepatol. 21: 54-65 (2009).
Cross R. Another anti-TNF therapy for patients with Crohn's disease. Inflamm. Bowel Dis. 14: 425-427 (2008). *
Cross RK, Binion DG. Narcotic use in patients with Crohn's disease: reply from Drs. Cross and Binion. Am. J. Gastroenterol. 101: 1397-1398 (2006). *
Cross RK, Jung C, Wasan S, Joshi G, Sawyer R, Roghmann MC. Racial differences in disease phenotypes in patients with Crohn's disease. Inflamm. Bowel Dis. 12: 192-198 (2006). *
Cross RK, Lapshin O, Finkelstein J. Patient subjective assessment of drug side effects in inflammatory bowel disease. J. Clin. Gastroenterol. 42: 244-251 (2008).
Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 9: 179-189 (2003). *
Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn's disease. Aliment. Pharmacol. Ther. 21: 1211-1216 (2005). *
Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am. J. Gastroenterol. 100: 2225-2259 (2005). *
Croucher PJ, Mascheretti S, Hampe J, Huse K, Frenzel H, Stoll M, Lu T, Nikolaus S, Yang SK, Krawczak M, Kim WH, Schreiber S. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur. J. Hum. Genet. 11: 6-16 (2003). *
Crowson AN, Nuovo GJ, Mihm MC Jr, Magro C. Cutaneous manifestations of Crohn's disease, its spectrum, and its pathogenesis: intracellular consensus bacterial 16S rRNA is associated with the gastrointestinal but not the cutaneous manifestations of Crohn's disease. Hum. Pathol. 34: 1185-1192 (2003). *
Crumbock SC, Loeb SJ, Fick DM. Physical activity, stress, disease activity, and quality of life in adults with Crohn disease. Gastroenterol. Nurs. 32: 188-195 (2009).
Cruyssen BV, Peeters H, Hoffman IE, Laukens D, Coucke P, Marichal D, Cuvelier C, Remaut E, Veys EM, Mielants H, De Vos M, De Keyser F. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clin. Exp. Immunol. 140: 354-359 (2005). *
Cserni T, Szekeres JP, Furka I, Nemeth N, Jozsa T, Miko I. Hydrostatic characteristics of the ileocolic valve and intussuscepted nipple valves: an animal model. J. Invest. Surg. 18: 185-191 (2005). *
Csernok E, Ai M, Gross WL, Wicklein D, Petersen A, Lindner B, Lamprecht P, Holle JU, Hellmich B. Wegener's autoantigen induces maturation of dendritic cells and licences them for TH1 priming via the protease-activated receptor-2 pathway. Blood 107: 4440-4448 (2006). *
Csillag C, Borup R, Olsen J, Nielsen FC, Nielsen OH. Treatment response and colonic gene expression in patients with Crohn's disease. Scand. J. Gastroenterol. 42: 834-840 (2007). *
Csillag C, Nielsen OH, Borup R, Nielsen FC. Microarrays and Crohn's disease: collecting reliable information. Scand. J. Gastroenterol. 40: 369-377 (2005). *
Csillag C, Nielsen OH, Borup R, Nielsen FC, Olsen J. Clinical phenotype and gene expression profile in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G298-G304 (2007). *
Csillag C, Nielsen OH, Borup R, Olsen J, Bjerrum JT, Nielsen FC. CARD15 status and familial predisposition for Crohn's disease and colonic gene expression. Dig. Dis. Sci. 52: 1783-1789 (2007). *
Csillag C, Nielsen OH, Vainer B, Olsen J, Dieckgraefe BK, Hendel J, Vind I, Dupuy C, Nielsen FC, Borup R. Expression of the genes dual oxidase 2, lipocalin 2 and regenerating islet-derived 1 alpha in Crohn's disease. Scand. J. Gastroenterol. 42: 454-463 (2007). *
Cuadrado E, Alonso M, de Juan MD, Echaniz P, Arenas JI. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis. World J. Gastroenterol. 14: 1521-1527 (2008). *
Cucchiara S, Escher JC, Hildebrand H, Amil-Dias J, Stronati L, Ruemmele FM. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J. Pediatr. Gastroenterol. Nutr. 48: 257-267 (2009).
Cucchiara S, Latiano A, Palmieri O, Canani RB, D'Inca R, Guariso G, Vieni G, De Venuto D, Riegler G, De'Angelis GL, Guagnozzi D, Bascietto C, Miele E, Valvano MR, Bossa F, Annese V; Italian Society of Pediatric Gastroenterology and Nutrition. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44: 171-179 (2007). *
Cucchiara S, Latiano A, Palmieri O, Staiano AM, D'Inca R, Guariso G, Vieni G, Rutigliano V, Borrelli O, Valvano MR, Annese V. Role of CARD15, DLG5 and OCTN genes polymorphisms in children with inflammatory bowel diseases. World J. Gastroenterol. 13: 1221-1229 (2007). *
Cucchiara S, Morley-Fletcher A. "New drugs: kids come first": children should be included in trials of new biological treatments. Inflamm. Bowel Dis. 13: 1165-1169 (2007). *
Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V, De'Angelis GL, Federici T. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig. Liver Dis. 40 Suppl. 2: S260-S264 (2008).
Cucino C, Sonnenberg A. The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn's disease. Am. J. Gastroenterol. 96: 2107-2112 (2001). *
Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 7: 250-255 (2001). *
Cuenca F, Garcia Paredes J, Mendoza J, Cruz D, Herrero A, Diaz-Rubio M. Experience with granulocytapheresis in Crohn's disease. Rev. Esp. Enferm. Dig. 96: 501-506 (2004).
Cuffari C. Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr. 58: 139-157 (2006).
Cuffari C. Anti-TNF therapy in Crohn's disease: a balance between a targeted therapeutic approach and drug-induced immunogenicity. Expert Rev. Gastroenterol. Hepatol. 1: 233-237 (2008).
Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2: 410-417 (2004). *
Cuffari C, Dubinsky M, Darbari A, Sena L, Baldassano R. Crohn's jejunoileitis: the pediatrician's perspective on diagnosis and management. Inflamm. Bowel Dis. 11: 696-704 (2005). *
Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48: 642-646 (2001). *
Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment. Pharmacol. Ther. 14: 1009-1014 (2000). *
Cuffari C, Li DY, Mahoney J, Barnes Y, Bayless TM. Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy. Dig. Dis. Sci. 49: 133-137 (2004). *
Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand. J. Clin. Lab. Invest. 66: 249-259 (2006). *
Cukovic-Cavka S. Diffuse jejunoileitis in an adolescent. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 69. May 7-8 (2004). *
Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B. Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. Digestion 73: 107-110 (2006). *
Cukovic-Cavka S, Vermeire S, Hrstic I, Claessens G, Kolacek S, Jakic-Razumovic J, Krznaric Z, Grubelic K, Radic D, Misak Z, Jadresin O, Rutgeerts P, Vucelic B. NOD2/CARD15 mutations in Croatian patients with Crohn's disease: prevalence and genotype-phenotype relationship. Eur. J. Gastroenterol. Hepatol. 18: 895-899 (2006).
Cullen G, O'Toole A, Keegan D, Sheahan K, Hyland JM, O'Donoghue DP. Long-term clinical results of ileocecal resection for Crohn's disease. Inflamm. Bowel Dis. 13: 1369-1373 (2007). *
Cullen S, Chapman R. Chapter 19. Sclerosing cholangitis: primary and secondary. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 249-261 (2007). *
Culliford A, Markowitz D, Rotterdam H, Green PHR. Scalloping of duodenal mucosa in Crohn's disease. Inflamm. Bowel Dis. 10: 270-273 (2004). *
Culligan B. Orbital myositis following streptococcal pharyngitis in a pediatric patient. Optometry 76: 250-258 (2005).
Cummings JH, Kong SC. Probiotics, prebiotics and antibiotics in inflammatory bowel disease. Novartis Found. Symp. 263: 99-111 (2004).
Cummings JR, Cooney R, Pathan S, Anderson CA, Barrett JC, Beckly J, Geremia A, Hancock L, Guo C, Ahmad T, Cardon LR, Jewell DP. Confirmation of the role of ATG16l1 as a Crohn's disease susceptibility gene. Inflamm. Bowel Dis. 13: 941-946 (2007). *
Cummings JR, Jewell DP. Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm. Bowel Dis. 11: 56-61 (2005). *
Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ 336: 1062-1066 (2008).
Cummings SA, Rubin DT. The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J. Genet. Couns. 15: 465-476 (2006). *
Cummins RE, Mullins D, Smith LJ, Ford MJ. Metastatic Crohn's disease: a case report. Pediatr. Dermatol. 13: 25-28 (1996).
Cunliffe RN. alpha-Defensins in the gastrointestinal tract. Mol. Immunol. 40: 463-467 (2003). *
Cunliffe RN, Kamal M, Rose FR, James PD, Mahida YR. Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa. J. Clin. Pathol. 55: 298-304 (2002). *
Cunliffe RN, Rose FR, Keyte J, Abberley L, Chan WC, Mahida YR. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 48: 176-185 (2001). *
Cunnane SC, Manku MS, Horrobin DF. The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. Med. Hypotheses 5: 403-414 (1979).
Cuoco L, Vescovo G, Castaman R, Ravara B, Cammarota G, Angelini A, Salvagnini M, Dalla Libera L. Skeletal muscle wastage in Crohn's disease: a pathway shared with heart failure? Int. J. Cardiol. 127: 219-227 (2008).
Curova K, Kmetova M, Sabol M, Gombosova L, Lazurova I, Siegfried L. Enterovirulent E. coli in inflammatory and noninflammatory bowel diseases. Folia Microbiol. (Praha.) 54: 81-86 (2009).
Curran ME, Lau KF, Hampe J, Schreiber S, Bridger S, Macpherson AJ, Cardon LR, Sakul H, Harris TJ, Stokkers P, Van Deventer SJ, Mirza M, Raedler A, Kruis W, Meckler U, Theuer D, Herrmann T, Gionchetti P, Lee J, Mathew C, Lennard-Jones J. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 115: 1066-1071 (1998). *
Currie CG, McCallum K, Poxton IR. Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease. J. Med. Microbiol. 50: 345-354 (2001). *
Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 46: 1688-1693 (2007). *
Cury DH, Costa JE, Irika K, Mijji L, Garcez A, Buchiguel C, Silva I, Sipahi A. Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease. Dig. Dis. Sci. 53: 2516-2520 (2008). *
Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br. J. Dermatol. 154: 726-729 (2006). *
Cuthbert AP, Fisher SA, Lewis CM, Mathew CG, Sanderson J, Forbes A. Genetic association between EPHX1 and Crohn's disease: population stratification, genotyping error, or random chance? Gut 53: 1386 (2004). *
Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122: 867-874 (2002). *
Cuvelier C, Mielants H, De Vos M, Quatacker J, Veys E. Idiopathic inflammatory bowel diseases: immunological hypothesis. Acta Gastroenterol. Belg. 57: 292-299 (1994).
Cuzzocrea S. Emerging biotherapies for inflammatory bowel disease. Expert Opin. Emerg. Drugs 8: 339-347 (2003).
Czaja AJ, Shums Z, Donaldson PT, Norman GL. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. Dig. Dis. Sci. 49: 611-618 (2004). *
Czub E, Herzig KH, Szaflarska-Poplawska A, Kiehne K, Socha P, Wos H, Kaminska B, Blaszczynski M, Cichy W, Bala G, Brodzicki J, Grzybowska-Chlebowczyk U, Walkowiak J. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand. J. Gastroenterol. 42: 1147-1150 (2007). *
Czymek R, Limmer S, Kleemann M, Hildebrand P, Schmidt A, Jungbluth T, Roblick U, Kujath P, Bruch HP. Crohn's disease - a chameleon during pregnancy. Langenbecks Arch. Surg. 394: 517-527 (2009). *
D'Addabbo A, Latiano A, Palmieri O, Creanza MT, Maglietta R, Annese V, Ancona N. Association of genetic profiles to Crohn's disease by linear combinations of single nucleotide polymorphisms. Artif. Intell. Med. 46: 131-138 (2009).
D'Addabbo A, Latiano A, Palmieri O, Maglietta R, Annese V, Ancona N. Regularized least squares classifiers may predict Crohn's disease from profiles of single nucleotide polymorphisms. Ann. Hum. Genet. 71: 537-549 (2007). *
D'Alessandria C, Malviya G, Viscido A, Aratari A, Maccioni F, Amato A, Scopinaro F, Caprilli R, Signore A. Use of a (99m)Tc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies. Q. J. Nucl. Med. Mol. Imaging 51: 334-342 (2007).
D'Amato M, Bruce S, Bresso F, Zucchelli M, Ezer S, Pulkkinen V, Lindgren C, Astegiano M, Rizzetto M, Gionchetti P, Riegler G, Sostegni R, Daperno M, D'Alfonso S, Momigliano-Richiardi P, Torkvist L, Puolakkainen P, Lappalainen M, Paavola-Sakki P, et al. Neuropeptide S receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. Gastroenterology 133: 808-817 (2007). *
D'Argenio G, Biancone L, Cosenza V, Della Valle N, D'Armiento FP, Boirivant M, Pallone F, Mazzacca G. Transglutaminases in Crohn's disease. Gut 37: 690-695 (1995). *
D'Eredita G, Ferrarese F, Cecere V, Fabiano G. Factors affecting prognosis in patients with short bowel syndrome. G. Chir. 24: 302-304 (2003).
D'Haens G. Mucosal healing in pediatric Crohn's disease: the goal of medical treatment. Inflamm. Bowel Dis. 10: 479-480 (2004). *
D�Haens G. Pratical use of steroids in IBD. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 30 (2005). *
D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56: 725-732 (2007). *
D'Haens G. Medical management of major internal fistulae in Crohn's disease. Inflamm. Bowel Dis. 6: 244-245 (2000). *
D'Haens G. Anti-TNF therapy for Crohn's disease. Curr. Pharm. Des. 9: 289-294 (2003).
D'Haens G. Optimizing the use of current drugs in IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 65. May 7-8 (2004). *
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660-667 (2008). *
D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 8: 506-512 (2006).
D'Haens G, Daperno M. Advances in medical therapy for Crohn's disease. Curr. Gastroenterol. Rep. 4: 506-512 (2002).
D'Haens G, Feagan B, Stitt L. Early combined immunosuppression in Crohn's disease - authors' reply. Lancet 371: 1996-1997 (2008). *
D'Haens G, Hiele M, Rutgeerts P, Geboes K, Ceuppens JL. Depressed T cell reactivity to recall antigens in Crohn's disease before and after surgical resection. Gut 35: 1728-1733 (1994). *
D'Haens G, Hlavaty T. Advances in medical therapy for Crohn's disease. Curr. Gastroenterol. Rep. 6: 496-505 (2004).
D'Haens G, Rutgeerts P. Postoperative recurrence of Crohn's disease: pathophysiology and prevention. Inflamm. Bowel Dis. 5: 295-303 (1999). *
D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116: 1029-1034 (1999). *
D'Haens GR. Infliximab (Remicade), a new biological treatment for Crohn's disease. Ital. J. Gastroenterol. Hepatol. 31: 519-520 (1999).
D'Haens GR. Infliximab as disease-modifying therapy. Eur. J. Gastroenterol. Hepatol. 15: 233-237 (2003). *
D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135: 1123-1129 (2008). *
D'halluin PN, Tribut O, Branger B, Lebreton C, Bretagne JF, Bentue-Ferrer D, Heresbach D. RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine. Gastroenterol. Clin. Biol. 29: 1264-1269 (2005).
D'Inca R, Annese V, di Leo V, Latiano A, Quaino V, Abazia C, Vettorato MG, Sturniolo GC. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment. Pharmacol. Ther. 23: 1455-1461 (2006). *
D'Inca R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC. Can calprotectin predict relapse risk in inflammatory bowel disease? Am. J. Gastroenterol. 103: 2007-2014 (2008).
D'Inca R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int. J. Colorectal Dis. 22: 429-437 (2007). *
D'Inca R, Podswiadek M, Ferronato A, Punzi L, Salvagnini M, Sturniolo GC. Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig. Liver Dis. Mar 9 [Epub ahead of print] (2009).
D'Odorico A, Bortolan S, Cardin R, D'Inca' R, Martines D, Ferronato A, Sturniolo GC. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand. J. Gastroenterol. 36: 1289-1294 (2001).
D'Ovidio V, Aratari A, Viscido A, Pimpo MT, Caprilli R, Torchio P. Infliximab and quality of life in steroid-dependent Crohn's disease. Dig. Liver Dis. 36: 557-558 (2004).
D'Souza S, Levy E, Mack D, Israel D, Lambrette P, Ghadirian P, Deslandres C, Morgan K, Seidman EG, Amre DK. Dietary patterns and risk for Crohn's disease in children. Inflamm. Bowel Dis. 14: 367-373 (2008). *
da Fonseca LM, Castro FV, Celani MF, da Silva RG, Lacerda-Filho A. Ileo-uterine fistula during pregnancy in a patient with Crohn disease: an uncommon complication. ANZ J. Surg. 78: 1142-1143 (2008).
da Luz Moreira A, Stocchi L, Remzi FH, Geisler D, Hammel J, Fazio VW. Laparoscopic surgery for patients with Crohn's colitis: a case-matched study. J. Gastrointest. Surg. 11: 1529-1533 (2007). *
da Rosa Utiyama SR, da Silva Kotze LM, Nisihara RM, Carvalho RF, de Carvalho EG, de Sena MG, de Messias Reason IJ. Spectrum of autoantibodies in celiac patients and relatives. Dig. Dis. Sci. 46: 2624-2630 (2001). *
da Silva JG, De Brito T, Cintra Damiao AO, Laudanna AA, Sipahi AM. Histologic study of colonic mucosa in patients with chronic diarrhea and normal colonoscopic findings. J. Clin. Gastroenterol. 40: 44-48 (2006).
Dabrowska-Ufniarz E, Jarosz M, Jarosz O, Nekanda-Trepka A. A case of Lesniowski-Crohn disease preceded by Yersinia pseudotuberculosis infection. Wiad. Lek. 47: 784-787 (1994).
Dafnis G. Repeated coaxial colonic stenting in the palliative management of benign colonic obstruction. Eur. J. Gastroenterol. Hepatol. 19: 83-86 (2007).
Dager WE, White RH. Low-molecular-weight heparin-induced thrombocytopenia in a child. Ann. Pharmacother. 38: 247-250 (2004).
Dagia C, Ditchfield M, Kean M, Catto-Smith T. Imaging for Crohn disease: use of 3-T MRI in a paediatric setting. J. Med. Imaging Radiat. Oncol. 52: 480-488 (2008).
Dahan S, Roda G, Pinn D, Roth-Walter F, Kamalu O, Martin AP, Mayer L. Epithelial:lamina propria lymphocyte interactions promote epithelial cell differentiation. Gastroenterology 134: 192-203 (2008). *
Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand. J. Gastroenterol. 42: 1440-1444 (2007). *
Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM, Spies T, Groh V. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J. Exp. Med. 206: 793-805 (2009). *
Daig R, Andus T, Aschenbrenner E, Falk W, Scholmerich J, Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 38: 216-222 (1996). *
Daig R, Rogler G, Aschenbrenner E, Vogl D, Falk W, Gross V, Scholmerich J, Andus T. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 46: 350-358 (2000). *
Daiss W, Scheurlen M, Malchow H. Epidemiology of inflammatory bowel disease in the county of Tubingen (West Germany). Scand. J. Gastroenterol. Suppl. 170: 39-43 (1989).
Dajotoy T, Andersson P, Bjartell A, Lofdahl CG, Tapper H, Egesten A. Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-gamma. J. Leukoc. Biol. 76: 685-691 (2004). *
Dalal I, Karban A, Wine E, Eliakim R, Shirin H, Fridlender M, Shaoul R, Leshinsky-Silver E, Levine A. Polymorphisms in the TNF-alpha promoter and variability in the granulomatous response in patients with Crohn's disease. Pediatr. Res. 59: 825-828 (2006). *
Daley TD, Armstrong JE. Oral manifestations of gastrointestinal diseases. Can. J. Gastroenterol. 21: 241-244 (2007).
Dalle IJ, Maes BD, Geboes KP, Lemahieu W, Geboes K. Crohn's-like changes in the colon due to mycophenolate? Colorectal Dis. 7: 27-34 (2005). *
Dalwadi H, Wei B, Kronenberg M, Sutton CL, Braun J. The Crohn's disease-associated bacterial protein I2 is a novel enteric T cell superantigen. Immunity 15: 149-158 (2001). *
Daly MJ, Pearce AV, Farwell L, Fisher SA, Latiano A, Prescott NJ, Forbes A, Mansfield J, Sanderson J, Langelier D, Cohen A, Bitton A, Wild G, Lewis CM, Annese V, Mathew CG, Rioux JD. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur. J. Hum. Genet. 13: 835-839 (2005). *
Daly MJ, Rioux JD. New approaches to gene hunting in IBD. Inflamm. Bowel Dis. 10: 312-317 (2004). *
Dalzell AM, Heaf DP, Carty H. Pathology mimicking distal intestinal obstruction syndrome in cystic fibrosis. Arch. Dis. Child. 65: 540-541 (1990).
Dambacher J, Beigel F, Seiderer J, Haller D, Goke B, Auernhammer CJ, Brand S. Interleukin-31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is up-regulated in inflammatory bowel disease. Gut 56: 1257-1265 (2007). *
Dambacher J, Beigel F, Zitzmann K, de Toni E, Goke B, Diepolder HM, Auernhammer CJ, Brand S. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut May 15 [Epub ahead of print] (2008).
Dambacher J, Staudinger T, Seiderer J, Sisic Z, Schnitzler F, Pfennig S, Hofbauer K, Konrad A, Tillack C, Otte JM, Diebold J, Goke B, Ochsenkuhn T, Lohse P, Brand S. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm. Bowel Dis. 13: 71-82 (2007). *
Damen GM, Hol J, de Ruiter L, Bouquet J, Sinaasappel M, van der Woude J, Laman JD, Hop WC, Buller HA, Escher JC, Nieuwenhuis EE. Chemokine production by buccal epithelium as a distinctive feature of pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 42: 142-149 (2006). *
Damergis JA, Chee K, Amitai A. Otogenic pneumococcal meningitis with pneumocephalus. J. Emerg. Med. Jun 30 [Epub ahead of print] (2008).
Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int. J. Biochem. Cell Biol. 30: 909-922 (1998). *
Danda D, Kurian G, Chacko A, Chandy G, Patra S, Mathew A, Thomas K. Crohn's disease in rheumatology clinic - an Indian experience. J. Postgrad. Med. 51: 269-272 (2005). *
Danelius M, Ost A, Lapidus AB. Inflammatory bowel disease-related lesions in the duodenal and gastric mucosa. Scand. J. Gastroenterol. 44: 441-445 (2009). *
Danelli P, Bartolucci C, Sampietro GM, Panizzo V, Sartani A, Maconi G, Parente E, Taschieri AM. Surgical options in the treatment of perianal Crohn's disease. Ann. Ital. Chir. 74: 635-640 (2003).
Danese S. Negative regulators of angiogenesis in inflammatory bowel disease: thrombospondin in the spotlight. Pathobiology 75: 22-24 (2008).
Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig. Liver Dis. 40 Suppl. 2: S225-S228 (2008).
Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion 77: 96-107 (2008). *
Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 12: 4807-4812 (2006). *
Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52: 1435-1441 (2003). *
Danese S, Mocciaro F, Guidi L, Scribano ML, Comberlato M, Vito A, Elisabetta C, Tommaso S, Marzo M, Vangeli M, Pulitano' R, Manca A, Armuzzi A, Malesci A, Prantera C, Cottone M. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. Inflamm. Bowel Dis. 14: 1168-1170 (2008).
Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 99: 938-945 (2004). *
Danese S, Pagano N, Angelucci E, Stefanelli T, Repici A, Omodei P, Daperno M, Malesci A. Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance. Curr. Med. Chem. 14: 1489-1497 (2007).
Danese S, Papa A. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. Eur. J. Gastroenterol. Hepatol. 20: 826-828 (2008).
Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am. J. Gastroenterol. 102: 174-186 (2007). *
Danese S, Papa A, Scaldaferri F, Graziani C, Bonizzi M, Armuzzi A, Fedeli G, Gasbarrini G, Gasbarrini A. A novel pathogenic role for microvasculature in inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 10: 3-5 (2006).
Danese S, Peyrin-Biroulet L. Early combined immunosuppression in Crohn's disease. Lancet 371: 1996 (2008).
Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, Fiocchi C. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 130: 2060-2073 (2006). *
Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun. Rev. 3: 394-400 (2004).
Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J. Immunol. 176: 2617-2624 (2006). *
Danese S, Sans M, Spencer D, Beck I, Donate F, Plunkett M, de la Motte C, Redline R, Shaw D, Levine A, Mazar A, Fiocchi C. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 56: 855-862 (2007). *
Danese S, Scaldaferri F, Papa A, Pola R, Sans M, Gasbarrini G, Pola P, Gasbarrini A. Platelets: new players in the mucosal scenario of inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 8: 193-198 (2004).
Danese S, Semeraro S, Armuzzi A, Papa A, Gasbarrini A. Biological therapies for inflammatory bowel disease: research drives clinics. Mini. Rev. Med. Chem. 6: 771-784 (2006).
Danese S, Semeraro S, Marini M, Roberto I, Armuzzi A, Papa A, Gasbarrini A. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig. Liver Dis. 37: 811-818 (2005).
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A. Extraintestinal manifestations in inflammatory bowel disease. World J. Gastroenterol. 11: 7227-7236 (2005). *
Danese S, Sgambato A, Papa A, Scaldaferri F, Pola R, Sans M, Lovecchio M, Gasbarrini G, Cittadini A, Gasbarrini A. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am. J. Gastroenterol. 100: 886-895 (2005). *
Danese S, Stefanelli T, Omodei P, Zatelli S, Bonifacio C, Balzarini L, Repici A, Malesci A. Successful treatment of fistulizing Crohn's disease with certolizumab pegol. Inflamm. Bowel Dis. 14: 292-293 (2008). *
Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am. J. Surg. Pathol. 31: 1800-1812 (2007).
Danik JS, Pare G, Chasman DI, Zee RY, Kwiatkowski DJ, Parker A, Miletich JP, Ridker PM. Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17,686 women: the Women�s Genome Health Study. Circ. Cardiovasc. Genet. 2: 134-141 (2009).
Dann SM, Eckmann L. Innate immune defenses in the intestinal tract. Curr. Opin. Gastroenterol. 23: 115-120 (2007).
Danze PM, Colombel JF, Jacquot S, Loste MN, Heresbach D, Ategbo S, Khamassi S, Perichon B, Semana G, Charron D, Cezard JP. Association of HLA class II genes with susceptibility to Crohn's disease. Gut 39: 69-72 (1996). *
Danzi JT. Extraintestinal manifestations of idiopathic inflammatory bowel disease. Arch. Intern. Med. 148: 297-302 (1988).
Daoud L, El Euch D, Ben Tekaya N, Cherif F, Mokni M, Ben Osman A. Erythema nodosum: profile in a Tunisian teaching hospital. Tunis. Med. 85: 1020-1024 (2007).
Dapena Diaz JL, Diaz de Heredia Rubio C, Bastida Vila P, Llort Sales A, Elorza Alvarez I, Olive Oliveras T, Sanchez de Toledo Codina J. Haemophagocytic syndrome: a common pathogenic mechanism of various aetiologies. An. Pediatr. (Barc.) May 28 [Epub ahead of print] (2009).
Daperno M, D'haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest. Endosc. 60: 505-512 (2004). *
Daperno M, Sostegni R, Lavagna A, Crocella L, Ercole E, Rigazio C, Rocca R, Pera A. The role of endoscopy in inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 8: 209-214 (2004).
Darbari A, Kalloo AN, Cuffari C. Diagnostic yield, safety, and efficacy of push enteroscopy in pediatrics. Gastrointest. Endosc. 64: 224-228 (2006).
Darbari A, Sena L, Argani P, Oliva-Hemker JM, Thompson R, Cuffari C. Gadolinium-enhanced magnetic resonance imaging: a useful radiological tool in diagnosing pediatric IBD. Inflamm. Bowel Dis. 10: 67-72 (2004). *
Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127: 412-421 (2004). *
Darling A. Caring for the patient with Crohn's disease: practical do's and don'ts to improve patients' quality of life. Gastroenterol. Nurs. 31: S2-S4 (2008).
Daryani NE, Nayer Habibi A, Bashashati M, Keramati MR, Rafiee MJ, Ajdarkosh H, Azmi M. Takayasu's arteritis associated with Crohn's disease: a case report. J. Med. Case Reports 2: 87 (2008). *
Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK. Crohn's disease in India: a multicenter study from a country where tuberculosis is endemic. Dig. Dis. Sci. 54: 1099-1107 (2009). *
Das KM. "Is foe your friend?" Inflamm. Bowel Dis. 10: 693 (2004). *
Das KM. Immunopathogenesis of primary sclerosing cholangitis: possible role of a shared colonic and biliary epithelial antigen. J. Gastroenterol. Hepatol. 19: S290-S294 (2004). *
Das KM. Response: double blind trial in Crohn's disease of autologous colon extracted proteins (Am J Gastroenterol 2006;101:561-8). Am. J. Gastroenterol. 101: 2889-2890 (2006). *
Das KM. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine. Postgrad. Med. 74: 141-148, 150-151 (1983).
Das KM, Bajpai M. Tropomyosins in human diseases: ulcerative colitis. Adv. Exp. Med. Biol. 644: 158-167 (2008).
Das KM, Dubi